<SEC-DOCUMENT>0001493152-26-027201.txt : 20260604
<SEC-HEADER>0001493152-26-027201.hdr.sgml : 20260604
<ACCEPTANCE-DATETIME>20260604080040
ACCESSION NUMBER:		0001493152-26-027201
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20260601
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260604
DATE AS OF CHANGE:		20260604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Imunon, Inc.
		CENTRAL INDEX KEY:			0000749647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				521256615
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15911
		FILM NUMBER:		261063246

	BUSINESS ADDRESS:	
		STREET 1:		997 LENOX DRIVE
		STREET 2:		SUITE 100
		CITY:			LAWRENCEVILLE
		STATE:			NJ
		ZIP:			08648
		BUSINESS PHONE:		(609) 896-9100

	MAIL ADDRESS:	
		STREET 1:		997 LENOX DRIVE
		STREET 2:		SUITE 100
		CITY:			LAWRENCEVILLE
		STATE:			NJ
		ZIP:			08648

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celsion CORP
		DATE OF NAME CHANGE:	20071121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CELSION CORP
		DATE OF NAME CHANGE:	19980515

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEUNG LABORATORIES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:IMNN="http://imunon.com/20260601">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_IMNN_imunon.com_20260601 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20260601_20260601 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0000749647 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000005" name="dei:EntityCentralIndexKey">0000749647</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="imnn-20260601.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-06-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000749647</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-06-01</xbrli:startDate>
        <xbrli:endDate>2026-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20260601__20260601_zybXP5JrOa07"><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_905_edei--DocumentPeriodEndDate_c20260601__20260601_z23ZtSIB6wo5"><ix:nonNumeric contextRef="AsOf2026-06-01" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">June 1,
2026</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_909_edei--EntityRegistrantName_c20260601__20260601_zhZ43t4yiQ7k" style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000012" name="dei:EntityRegistrantName">Imunon,
Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20260601__20260601_zzolyfg04cqk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-06-01" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><span id="xdx_908_edei--EntityFileNumber_c20260601__20260601_zvOwDHgokDm1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000014" name="dei:EntityFileNumber">001-15911</ix:nonNumeric></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 32%"><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20260601__20260601_zlNkLWzAmLJ5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000015" name="dei:EntityTaxIdentificationNumber">52-1256615</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 66%"><span id="xdx_907_edei--EntityAddressAddressLine1_c20260601__20260601_zsTdydyyTOk9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000016" name="dei:EntityAddressAddressLine1">997
    Lenox Drive</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20260601__20260601_zDDPqRcQb9Sk"><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite
    100</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20260601__20260601_zgzj6LsfofBj"><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000018" name="dei:EntityAddressCityOrTown">Lawrenceville</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20260601__20260601_zihywMdPaIka"><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000019" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span id="xdx_903_edei--EntityAddressPostalZipCode_c20260601__20260601_z0uqKRkNjyjb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000020" name="dei:EntityAddressPostalZipCode">08648-2311</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_907_edei--CityAreaCode_c20260601__20260601_zkOZ5CwkcHQc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000021" name="dei:CityAreaCode">(609)</ix:nonNumeric></b></span><b>
<span id="xdx_905_edei--LocalPhoneNumber_c20260601__20260601_zmu1zHbCmeR7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000022" name="dei:LocalPhoneNumber">896-9100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_900_edei--WrittenCommunications_c20260601__20260601_zejfXlf7Ndpb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-06-01" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--SolicitingMaterial_c20260601__20260601_zgh34oCabV" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-06-01" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--PreCommencementTenderOffer_c20260601__20260601_zcUVrp7J0RZb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-06-01" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20260601__20260601_z5oP8lHMzlX9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-06-01" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_edei--Security12bTitle_c20260601__20260601_zlRc9hKzTiV4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000027" name="dei:Security12bTitle">Common
    stock, par value $0.01 per share</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_edei--TradingSymbol_c20260601__20260601_zCzSIDSa5qO4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-06-01" id="Fact000028" name="dei:TradingSymbol">IMNN</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_edei--SecurityExchangeName_c20260601__20260601_zLDyGntfSWT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-06-01" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20260601__20260601_zA94oaRyo3Yg"><ix:nonNumeric contextRef="AsOf2026-06-01" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item</b></span><b>
<span style="font-family: Times New Roman, Times, Serif">1.01</span></b></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into
                a Material Definitive Agreement.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026,
Imunon, Inc. (the &#8220;<b><i>Company</i></b>&#8221;) entered into a securities purchase agreement (the &#8220;<b><i>Securities Purchase
Agreement</i></b>&#8221;) with Streeterville Capital, LLC (the &#8220;<b><i>Investor</i></b>&#8221;), providing for the issuance and
sale by the Company, and the purchase by the Investor, of (i) 250 shares (the &#8220;<b><i>Preferred Shares</i></b>&#8221;) of the Company&#8217;s
Series A Preferred Stock, par value $0.01 per share (the &#8220;<b><i>Series A Preferred Stock</i></b>&#8221;), at a price of $10,000
per share, for aggregate proceeds of $2,500,000; (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the
&#8220;<b><i>A-1 Note</i></b>&#8221;); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the &#8220;<b><i>B
Note</i></b>&#8221; and together with the A-1 Note, the &#8220;<b><i>Notes</i></b>&#8221;). The transactions contemplated by the Securities
Purchase Agreement (collectively, the &#8220;<b><i>Transaction</i></b>&#8221;) closed on June 3, 2026 (the &#8220;<b><i>Closing Date</i></b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
closing, the Company received $10,000,000 from the Investor, $5,000,000 of which was deposited into a bank account owned by a wholly-owned
subsidiary of the Company as cash collateral for the Notes (the &#8220;<b><i>Cash Collateral Account</i></b>&#8221;). The obligations
under the Notes are secured by substantially all of the assets of the Company, other than its intellectual property assets, and are guaranteed
by certain of the Company&#8217;s subsidiaries. The Company intends to utilize the other $5,000,000 of proceeds from the closing of the
Transaction, along with any proceeds later released from the Cash Collateral Account, for general corporate purposes, including research
and development activities, capital expenditures and working capital. The Company agreed to pay the placement agents for the financing
a fee of 7.0% of the gross proceeds received by the Company in connection with the Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the aggregate outstanding balance of the A-1 Note or the aggregate number of outstanding Preferred Shares is reduced by $2,000,000 (or,
if less than $2,000,000, the entire remaining outstanding balance of the A-1 Note), the Company will have the right to exchange up to
$1,000,000, plus interest (or, if less than $1,000,000, the entire remaining amount of the B Note, or such other amount as the parties
mutually agree), of the B Note for a new secured note in the same form and having the same terms as the A-1 Note (each, a &#8220;<b><i>Note
Exchange</i></b>&#8221;). Upon the completion of each Note Exchange, an amount of cash equal to the amount of the B Note exchanged in
such Note Exchange will be released from the Cash Collateral Account to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
A-1 Note will bear interest at 8% per annum and will mature 18 months following the Closing Date. The B Note will bear interest at 5%
per annum and will mature 18 months following the Closing Date. The Notes can be prepaid by the Company in whole or in part at any time,
subject to a 10% prepayment premium on any principal amounts prepaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
six months after the Closing Date, the Investor may redeem up to $250,000 of the principal amount of the A-1 Note each calendar month.
In addition, on any trading day when the Company&#8217;s common stock trades at a price that is at least 15% greater than the &#8220;Minimum
Price&#8221; as defined under Nasdaq Stock Market LLC Rule 5635(d), the Investor may redeem an additional principal amount of the Notes
equal to 5% of the trading volume of the Company&#8217;s common stock on such trading day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be subject to customary covenants while the Notes remain outstanding. The Notes also contain customary events of default,
the occurrence of which would permit the Investor to accelerate the obligations under the Notes and exercise remedies against any collateral
(including amounts on deposit in the Cash Collateral Account) or guarantees in respect of the Notes. In addition, following the occurrence
of an event of default, the interest rate of each Note would increase to the lesser of 15% per year or the maximum rate permitted by
applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Securities Purchase Agreement, A-1 Note and B Note do not purport to be complete and are qualified in their
entirety by reference to the full text of such documents, copies of which are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to
this Current Report on Form 8-K and are incorporated herein by reference. Each of the Securities Purchase Agreement, A-1 Note and B Note
contains representations, warranties and other provisions that were made only for purposes of the applicable agreement and as of specific
dates, are solely for the benefit of the parties thereto, and may be subject to limitations agreed upon by such parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 2.03</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Creation
                                            of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
                                            of Registrant.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in Item 1.01 is incorporated into this Item 2.03 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 3.02</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
                    Sales of Equity Securities.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in the first two paragraphs of Item 1.01 is incorporated into this Item 3.02 by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 5.03 </b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amendments
                                            to Articles of Incorporation or Bylaws; Change in Fiscal Year</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2026, the Company filed a certificate of designation of preferences and rights (the &#8220;<b><i>Certificate of Designation</i></b>&#8221;)
of the Series A Preferred Stock with the Secretary of State of the State of Delaware, designating 400 shares of Series A Preferred Stock,
which became effective upon filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series A Preferred Stock has a stated value of $12,000 (the &#8220;<b><i>Stated Value</i></b>&#8221;) and accrues from the date
of issuance a return of 8% per year, payable in cash or via the issuance of additional shares of Series A Preferred Stock (the &#8220;<b><i>Preferred
Return</i></b>&#8221;). The Series A Preferred Stock is not convertible into shares of common stock or any other class or series of stock
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms and conditions set forth in the Certificate of Designation, at any time the Company may elect to redeem all or any portion
of the Series A Preferred Stock then issued and outstanding from all of the holders of Series A Preferred Stock (a &#8220;<b><i>Corporation
Optional Redemption</i></b>&#8221;) by paying to such holders an amount in cash equal to the Series A Preferred Liquidation Amount (as
defined in the Certificate of Designation) then applicable to the shares of Series A Preferred Stock being redeemed, multiplied by 110%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will be subject to customary covenants while any shares of Series A Preferred Stock remain outstanding. The Certificate of Designation
also contains certain events of default, the occurrence of which would permit holders of Series A Preferred Stock, by action of at least
a majority of such holders, to redeem all of the issued and outstanding shares of Series A Preferred Stock then held by such holders.
In addition, following the occurrence of an event of default, the Preferred Return would increase by 15% per year, which may be applied
in respect of up to three separate events of default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock confers no voting rights on holders, except with respect to matters that materially and adversely affect the
voting powers, rights or preferences of the Series A Preferred Stock or as otherwise required by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Series A Preferred Stock does not purport to be complete and is qualified in its entirety by reference to
the full text of the Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.01</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
                    FD Disclosure.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026,
the Company issued a press release announcing the closing of the Transaction. A copy of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections
11 and 12(a)(2) of the Securities Act. Such information shall not be incorporated by reference into any filing with the Securities and
Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            Statements and Exhibits.</b></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-1.htm">Certificate of Designation of Preferences and Rights of Series A Preferred Stock.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Securities
    Purchase Agreement dated June 2, 2026, by and between the Company and Streeterville Capital, LLC.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-2.htm">Secured
    Promissory Note A-1 dated June 2, 2026, made by the Company in favor of Streeterville Capital, LLC.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-3.htm">Secured
    Promissory Note B dated June 2, 2026, made by the Company in favor of Streeterville Capital, LLC.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated June 4,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded with the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Certain schedules and exhibits to this Exhibit have been omitted. The Company agrees to furnish a copy of the omitted schedules and exhibits
to the Securities and Exchange Commission on a supplemental basis upon its request.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMUNON,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jeffrey Church</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey
    Church</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    June 4,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OlIXMvAyMYksQiS6XXKMJd2R2e3vkXrLNiUaBoaZc745QsxEQWvdIcNpVZVQYz90yiFU2CKjOaN3ZJttCn5WeNHWsTJuXH9gRp5BzyTzhfL30XnXFpsUoiSMZCgTiGUql3DYieCrZ2Ra3aBxWnWgTAMHpoE1OsWv6UOtnmSof41JR2SryaQQz6NJfoOMYgl7uqsH8dVCWWYimI0ViILpNnhX/nRoviTkHfY+zk70v4MPzgFKYA== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
3.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">CERTIFICATE
OF DESIGNATION OF PREFERENCES AND RIGHTS OF</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">SERIES
A PREFERRED STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Imunon,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
Delaware corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 151 of the Delaware General Corporation Law</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, <FONT STYLE="background-color: white">Stacy R. Lindborg</FONT>, hereby certifies that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">She
                                            is the duly elected Chief Executive Officer of Imunon, Inc., a Delaware corporation (&ldquo;Corporation&rdquo;).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            resolution was adopted and approved by the Board of Directors of the Corporation by unanimous
                                            written consent on May 29, 2026 authorizing and approving the Certificate of Designation
                                            of Preferences and Rights of Series A Preferred Stock of the Corporation set forth below.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            shares of Series A Preferred Stock have been issued as of the date hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned does hereby execute this Certificate, and does hereby acknowledge that this instrument constitutes her
act and deed and that the facts stated herein are true.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imunon,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Stacy R. Lindborg</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stacy
    R. Lindborg</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    1, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">CERTIFICATE
OF DESIGNATION OF PREFERENCES AND RIGHTS OF</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">SERIES
A PREFERRED STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Imunon,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
Delaware corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned Chief Executive Officer of Imunon, Inc. (&ldquo;Corporation&rdquo;), a corporation organized and existing under the laws
of the State of Delaware, does hereby certify that, pursuant to the authority contained in the Corporation&rsquo;s Certificate of Incorporation
(&ldquo;Certificate&rdquo;) and pursuant to Section 151 of the Delaware General Corporation Law, and in accordance with the provisions
of the resolution creating a series of the class of the Corporation&rsquo;s authorized preferred stock designated as the Series A Preferred
Stock as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIRST:
The Certificate, as amended, authorizes the issuance by the Corporation of 350,000,000 shares of common stock, par value of $0.01 per
share (&ldquo;Common Stock&rdquo;) and 100,000 shares of preferred stock, par value of $0.01 per share (&ldquo;Preferred Stock&rdquo;),
and further, authorizes the Board of Directors (&ldquo;Board&rdquo;) of the Corporation, by resolution or resolutions, at any time and
from time to time, to divide and establish any or all of the unissued shares of Preferred Stock not then allocated to any series into
one or more series and to designate the rights, preferences and limitations of each series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECOND:
By unanimous written consent of the Board dated May 29, 2026, the Board designated four hundred (400) shares of the Preferred Stock as
Series A Preferred Stock, par value $0.01 per share, pursuant to a resolution providing that a series of Preferred Stock of the Corporation
be and hereby is created and that the designation and number of shares thereof and the voting and other powers, preferences and relative,
participating, optional or other rights of the shares of such Series A Preferred Stock, and the qualifications, limitations and restrictions
thereof, are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SERIES
A PREFERRED STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1. <U>Definitions</U>. Capitalized terms used but not otherwise defined herein shall have meanings set forth in Section 13 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2. <U>Powers and Rights of Series A Preferred Stock</U>. There is hereby designated a class of Preferred Stock of the Corporation
as the Series A Preferred Stock, par value $0.01 per share, of the Corporation (the &ldquo;Series A Stock&rdquo;). The number of shares,
powers, terms, conditions, designations, preferences and privileges, relative, participating, optional and other special rights, and
qualifications, limitations and restrictions of the Series A Stock shall be as set forth in this Certificate of Designation of Preferences
and Rights of Series A Stock (this &ldquo;Certificate of Designation&rdquo;). For purposes hereof, a holder of a share or shares of Series
A Stock, with respect to their rights as related to the Series A Stock, shall be referred to as a &ldquo;Series A Holder.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3. <U>Number and Stated Value</U>. The number of authorized shares of the Series A Stock is four hundred (400) shares. Each share
of Series A Stock shall have a stated value of $12,000.00 (the &ldquo;Stated Value&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4. <U>Ranking</U>. Except to the extent that the holders of at least a majority of the outstanding Series A Stock (the &ldquo;Required
Holders&rdquo;) expressly consent to the creation of Parity Stock (as defined below) or Senior Preferred Stock (as defined below), all
shares of capital stock of the Corporation shall be junior in rank to all Series A Stock with respect to the preferences as to dividends,
distributions and payments upon the liquidation, dissolution and winding up of the Corporation (such junior stock is referred to herein
collectively as &ldquo;Junior Stock&rdquo;). The rights of all such shares of capital stock of the Corporation shall be qualified by
the rights, powers, preferences and privileges of the Series A Stock. Without limiting any other provision of this Certificate of Designation,
without the prior written consent of the Required Holders, voting separately as a single class, the Corporation shall not hereafter authorize
or issue any additional or other shares of capital stock that is (i) of senior rank to the Series A Stock in respect of the preferences
as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation (collectively, the &ldquo;Senior
Preferred Stock&rdquo;), or (ii) of pari passu rank to the Series A Stock in respect of the preferences as to dividends, distributions
and payments upon the liquidation, dissolution and winding up of the Corporation (collectively, the &ldquo;Parity Stock&rdquo;). In the
event of the merger or consolidation of the Corporation with or into another corporation wherein the Corporation is the surviving entity,
the shares of Series A Stock shall maintain their relative rights, powers, designations, privileges and preferences provided for herein
and no such merger or consolidation shall provide for a result inconsistent therewith, subject to the other terms and conditions herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5. <U>Preferred Return</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    share of Series A Stock shall accrue a rate of return on the Stated Value at the rate of eight percent (8%) per annum, to be determined
    pro rata for any fractional year periods (the &ldquo;Preferred Return&rdquo;). The Preferred Return shall accrue on each share of
    Series A Stock from the Issuance Date of such share, and shall be payable or otherwise settled as set forth herein. Following the
    occurrence of an Event of Default (as defined below), the Preferred Return will increase to the lesser of fifteen percent (15%) per
    annum or the maximum rate permitted under applicable law.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Preferred Return shall compound daily and be payable on a quarterly basis, within five (5) Business Days following the end of each
    calendar quarter, either in cash or via the issuance to the applicable Series A Holder of an additional number of shares of Series
    A Stock equal to (i) the Preferred Return then accrued and unpaid, divided by (ii) the $10,000 per share purchase price for the Series
    A Stock, with the election as to payment in cash or via the issuance of additional shares of Series A Stock to be determined in the
    discretion of the Corporation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the event that the Corporation elects to pay any Preferred Return via the issuance of shares of Series A Stock, no fractional shares
    of Series A Stock shall be issued, and the Corporation shall pay in cash the portion of such Preferred Return that would otherwise
    be payable via the issuance of a fractional share of Series A Stock. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6. <U>Liquidation, Dissolution or Winding Up</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding
up of the Corporation, each share of Series A Stock shall be entitled to be paid out of the assets of the Corporation available for distribution
to its stockholders, before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount
per share of Series A Stock equal to the Stated Value at such time plus any accrued but unpaid Preferred Return (as applicable, the &ldquo;Series
A Preferred Liquidation Amount&rdquo;). If upon any such liquidation, dissolution or winding up of the Corporation, the assets of the
Corporation available for distribution to its stockholders shall be insufficient to pay the Series A Preferred Liquidation Amount, the
Series A Holders with respect to their shares of Series A Stock shall share ratably in any distribution of the assets available for distribution
in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution
if all amounts payable on or with respect to such shares were paid in full. Following the payment of the Series A Preferred Liquidation
Amount, if there are any remaining assets of the Corporation available for distribution to its stockholders, the Series A Stock shall
not participate in such distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7. <U>No Conversions.</U> The Series A Stock shall not be convertible into shares of Common Stock or into any other class or series
of stock of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
8. <U>Corporation Optional Redemption</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the terms and conditions herein, at any time the Corporation may elect, in the sole discretion of the Board, to redeem all or
    any portion of the Series A Stock then issued and outstanding from all of the Series A Holders (a &ldquo;Corporation Optional Redemption&rdquo;)
    by paying to the applicable Series A Holders an amount in cash equal to the Series A Preferred Liquidation Amount then applicable
    to such shares of Series A Stock being redeemed in the Corporation Optional Redemption multiplied by one hundred ten percent (110%)
    (the &ldquo;Redemption Price&rdquo;). For the avoidance of doubt, any redemption made in connection with a Fundamental Transaction
    will be made at the Redemption Price. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation shall provide written notice of any Corporation Optional Redemption to the Series A Holder(s) within five (5) Business
    Days following the determination of the Board to consummate the applicable Corporation Optional Redemption, and thereafter such Corporation
    Optional Redemption shall be completed within five (5) Business Days following the delivery of such notice, and at such time the
    Corporation shall deliver to the Series A Holder(s) the Redemption Price in valid funds. Each Series A Holder agrees to execute and
    deliver to the Corporation such instruments and documents, and to take such actions, as reasonably required to consummate the Corporation
    Optional Redemption.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9. <U>Dividends and Distributions</U>. The Series A Stock shall not participate in any dividends, distributions or payments to the
holders of the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10. <U>Vote; Amendment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    than as set forth in Section 10(b), the Series A Stock shall not have any voting rights and shall not vote on any matter submitted
    to the holders of the Common Stock, or any class thereof, for a vote.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation may not, and shall not, amend or repeal this Certificate of Designation without the prior written consent of Series A
    Holders holding a majority of the Series A Stock then issued and outstanding, in which vote each share of Series A Stock then issued
    and outstanding shall have one vote, voting separately as a single class, in person or by proxy, either in writing without a meeting
    or at an annual or a special meeting of such Series A Holders, and any such act or transaction entered into without such vote or
    consent shall be null and void <I>ab initio</I>, and of no force or effect. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
11. <U>Covenants</U>. Until such time as no shares of Series A Stock remain outstanding, the Corporation and any subsidiary (to the
extent applicable) will at all times comply with the following covenants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will timely file on the applicable deadline all reports required to be filed with the SEC pursuant to Sections 13 or
    15(d) of the Exchange Act, and will take all reasonable action under its control to ensure that adequate current public information
    with respect to the Corporation, as required in accordance with Rule 144 of the Securities Act, is publicly available, and will not
    terminate its status as an issuer required to file reports under the Exchange Act even if the Exchange Act or the rules and regulations
    thereunder would permit such termination.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will cause the Common Stock to be listed or quoted for trading on any of NYSE, NYSE American or Nasdaq. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will not issue any new shares of Series A Stock to anyone other than the initial holder of Series A Stock without the
    prior written consent of the Required Holders, which consent may be granted or withheld in the Required Holders&rsquo; sole and absolute
    discretion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will not increase the authorized shares of Common Stock or Preferred Stock without the prior written consent of the Required
    Holders, which consent may be granted or withheld in the Required Holders&rsquo; sole and absolute discretion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will ensure that trading in the Common Stock will not be suspended, halted, chilled, frozen, reach zero bid or otherwise
    cease trading on the Corporation&rsquo;s principal trading market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will not make any Restricted Issuance without the Required Holders&rsquo; prior written consent, which consent may be
    granted or withheld in the Required Holders&rsquo; sole and absolute discretion. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation shall not enter into any agreement or otherwise agree to any covenant, condition, or obligation that locks up, restricts
    in any way or otherwise prohibits the Corporation (i) from entering into a variable rate transaction with any Series A Holder or
    any Affiliate of any Series A Holder, or (ii) from issuing Common Stock, Preferred Stock, warrants, convertible notes, other debt
    securities, or any other of the Corporation&rsquo;s securities to any Series A Holder or any Affiliate of any Series A Holder.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    the exception of Permitted Liens, the Corporation will not pledge or grant a security interest in any of its assets without the Required
    Holders&rsquo; prior written consent, which consent may be granted or withheld in the Required Holders&rsquo; sole and absolute discretion.
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will not, and will not enter into any agreement or commitment to, dispose of any assets or operations that are material
    to the Corporation&rsquo;s operations without the Required Holders&rsquo; prior written consent, which consent may be granted or
    withheld in the Required Holders&rsquo; sole and absolute discretion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will not, and will not enter into any agreement or commitment to, undertake or complete any reverse split of the Common
    Stock or any class of Preferred Stock without the Required Holders&rsquo; prior written consent, which consent may be granted or
    withheld in the Required Holders&rsquo; sole and absolute discretion. Such consent may not be unreasonably withheld.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will not, and will not enter into any agreement or commitment to, create, authorize, or issue any class of Preferred
    Stock (including additional issuances of Series A Stock) without the Required Holders&rsquo; prior written consent, which consent
    may be granted or withheld in the Required Holders&rsquo; sole and absolute discretion.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation will not consummate a Fundamental Transaction or enter into an agreement to consummate a Fundamental Transaction without
    the Required Holders&rsquo; prior written consent, which consent may be granted or withheld in the Required Holders&rsquo; sole and
    absolute discretion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
12. <U>Covenant Default</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Event of Default</U>.
The Required Holders may elect to declare an &ldquo;Event of Default&rdquo; if any of the following conditions or events shall occur
and be continuing:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation fails to fully comply with any covenant, obligation or agreement of the Corporation in this Certificate of Designation
    (other than payment or issuance defaults which are addressed in subparagraph (ii) below), or a breach of any covenant owed to any
    Series A Holder in any other agreement between the Corporation and such Series A Holder,) and such failure, if known to the Required
    Holders and reasonably possible of cure, is not cured within five (5) Business Days following receipt of notice to cure from the
    Required Holders; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation fails to pay any amount due and payable to the Series A Holders pursuant to and as required by this Certificate of Designation,
    or fails to issue any additional shares of Series A Stock to the Series A Holders pursuant to and as required by this Certificate
    of Designation, and such failure, if known to the Series A Holders and reasonably possible of cure, is not cured within five (5)
    Business Days following receipt of notice to cure from the Required Holders; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Corporation shall (1) apply for or consent to the appointment of, or the taking of possession by, a receiver, custodian, trustee
    or liquidator; (2) make a general assignment for the benefit of the Corporation&rsquo;s creditors; or (3) commence a voluntary case
    under the U.S. Bankruptcy Code as now and hereafter in effect, or any successor statute; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a proceeding or
case shall be commenced, without the application or consent of the Corporation, in any court of competent jurisdiction, seeking (1) liquidation,
reorganization or other relief with respect to it or its assets or the composition or readjustment of its debts, or (2) the appointment
of a trustee, receiver, custodian, liquidator or the like of any substantial part of its assets, and, in each case, such proceedings
or case shall continue undismissed, or an order, judgment or decree approving or ordering any of the foregoing shall be entered and continue
unstayed and in effect, for a period of sixty (60) days, if in the United States, or ninety (90) days, if outside of the United States;
or an order for relief against the Corporation shall be entered in an involuntary case under any bankruptcy, insolvency, composition,
readjustment of debt, liquidation of assets or similar law of any jurisdiction.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Consequences
                                            of Events of Default</U>. Upon the occurrence of an Event of Default, the Stated Value will
                                            automatically increase by fifteen percent (15%) (the &ldquo;Default Effect&rdquo;). The Default
                                            Effect may be applied up to three (3) times for three (3) separate Events of Default. If
                                            an Event of Default has occurred (i) the Required Holders may, by notice to the Corporation,
                                            force the Corporation to redeem all of the issued and outstanding shares of Series A Stock
                                            then held by the Series A Holders for a price equal to (1) the Stated Value of all such shares
                                            of Series A Stock; plus (2) any accrued and unpaid Preferred Return with respect to all such
                                            shares of Series A Stock, with such Preferred Return to be paid in cash and not via the issuance
                                            of additional shares of Series A Stock; plus (3) any and all other amounts due and payable
                                            to the Series A Holders pursuant to this Certificate of Designation; (ii) the Series A Holders
                                            shall have the right to pursue any other remedies that the Required Holders may have under
                                            applicable law and/or in equity; and (iii) the Series A Holders shall have the right to seek
                                            and receive injunctive relief from a court or an arbitrator prohibiting the Corporation from
                                            issuing any of its Common Stock or Preferred Stock to any party unless all the shares of
                                            Series A Stock owned by the Series A Holders are redeemed in full simultaneously with such
                                            issuance.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses</U>.
                                            In the event that any Series A Holder incurs expenses in the enforcement of its rights hereunder,
                                            including but not limited to reasonable attorneys&rsquo; fees, then the Corporation shall
                                            immediately reimburse such Series A Holder the reasonable and documented costs thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
13. <U>Definitions</U>. In addition to the terms defined elsewhere in this Certificate of Designation, the following terms, as used
herein, have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Affiliate&rdquo;
    means, with respect to a specified Person, any other Person that directly or indirectly Controls, is Controlled by or is under common
    Control with, the specified Person. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Business
    Day&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in New York City are authorized or required
    by law to remain closed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Control&rdquo;
    means (i) the possession, directly or indirectly, of the power to vote ten percent (10%) or more of the securities or other equity
    interests of a Person having ordinary voting power, (ii) the possession, directly or indirectly, of the power to direct or cause
    the direction of the management and policies of a Person, by contract or otherwise, or (iii) being a director, officer, executor,
    trustee or fiduciary (or their equivalents) of a Person or a Person that controls such Person. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Equity
                                            Securities&rdquo; means Common Stock of the Corporation, Preferred Stock of the Corporation
                                            and any option, warrant, or right to subscribe for, acquire or purchase Common Stock or Preferred
                                            Stock.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Exchange
                                            Act&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
                                            promulgated thereunder.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Fundamental
                                            Transaction&rdquo; means that (i) (A) the Corporation or any of its subsidiaries shall, directly
                                            or indirectly, in one or more related transactions, consolidate or merge with or into (whether
                                            or not the Corporation or any of its subsidiaries is the surviving corporation) any other
                                            person or entity, (B) the Corporation or any of its subsidiaries shall, directly or indirectly,
                                            in one or more related transactions, sell, lease, license, assign, transfer, convey or otherwise
                                            dispose of all or substantially all of its respective properties or assets to any other person
                                            or entity, (C) the Corporation or any of its subsidiaries shall, directly or indirectly,
                                            in one or more related transactions, allow any other person or entity to make a purchase,
                                            tender or exchange offer that is accepted by the holders of more than fifty percent (50%)
                                            of the outstanding shares of voting stock of the Corporation (not including any shares of
                                            voting stock of the Corporation held by the person or persons making or party to, or associated
                                            or affiliated with the persons or entities making or party to, such purchase, tender or exchange
                                            offer), (D) the Corporation or any of its subsidiaries shall, directly or indirectly, in
                                            one or more related transactions, consummate a stock or share purchase agreement or other
                                            business combination (including, without limitation, a reorganization, recapitalization,
                                            spin-off or scheme of arrangement) with any other person or entity whereby such other person
                                            or entity acquires more than fifty percent (50%) of the outstanding shares of voting stock
                                            of the Corporation (not including any shares of voting stock of the Corporation held by the
                                            other persons or entities making or party to, or associated or affiliated with the other
                                            persons or entities making or party to, such stock or share purchase agreement or other business
                                            combination), (E) the Corporation or any of its subsidiaries shall, directly or indirectly,
                                            in one or more related transactions, reorganize, recapitalize or reclassify the Common Stock,
                                            other than an increase in the number of authorized shares of Common Stock, (F) the Corporation
                                            transfers any material asset to any subsidiary, affiliate, person or entity under common
                                            ownership or control with the Corporation, or (G) the Corporation pays or makes any monetary
                                            or non-monetary dividend or distribution to its stockholders; or (ii) any &ldquo;person&rdquo;
                                            or &ldquo;group&rdquo; (as these terms are used for purposes of Sections 13(d) and 14(d)
                                            of the Exchange Act and the rules and regulations promulgated thereunder) is or shall become
                                            the &ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the Exchange Act), directly
                                            or indirectly, of more than fifty percent (50%) of the aggregate ordinary voting power represented
                                            by issued and outstanding voting stock of the Corporation.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Issuance
                                            Date&rdquo; means the date that the applicable shares of Series A Stock are issued to a Series
                                            A Holder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Liabilities&rdquo;
                                            means liabilities, obligations or responsibilities of any nature whatsoever, whether direct
                                            or indirect, matured or un-matured, fixed or unfixed, known or unknown, asserted or unasserted,
                                            choate or inchoate, liquidated or unliquidated, secured or unsecured, absolute, contingent
                                            or otherwise, including any direct or indirect indebtedness, guaranty, endorsement, claim,
                                            loss, damage, deficiency, cost or expense.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Permitted
                                            Liens&rdquo; means (a) Liens for taxes not yet delinquent or Liens for taxes being contested
                                            in good faith and by appropriate proceedings for which adequate reserves have been established;
                                            (b) Liens in favor of Investor under the Security Agreement or arising under the other Transaction
                                            Documents or any prior agreements between Company and Investor; and (c) Liens consented to
                                            in writing by Investor; &ldquo;Lien&rdquo; means, with respect to any property, any security
                                            interest, mortgage, pledge, lien, claim, charge or other encumbrance in, of, or on such property
                                            or the income therefrom, including, without limitation, the interest of a vendor or lessor
                                            under a conditional sale agreement, capital lease or other title retention agreement, or
                                            any agreement to provide any of the foregoing, and the filing of any financing statement
                                            or similar instrument under the UCC or comparable law of any jurisdiction; &ldquo;Investor&rdquo;
                                            means Streeterville Capital, LLC; and &ldquo;Transaction Documents&rdquo; means (i) this
                                            Certificate of Designation, (ii) the following documents by and between the Corporation and
                                            the Investor: (a) Securities Purchase Agreement, (b) Secured Promissory Note A-1, (c) Secured
                                            Promissory Note B, and (d) the Security Agreement (the &ldquo;Security Agreement&rdquo;);
                                            (ii) the Deposit Account Control Agreement by and among Lakeside Bank, the Investor and IMNN
                                            Holdings, LLC; and (iii) the Guaranty by CLSN Laboratories, Inc. and IMNN Holdings, LLC.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Person&rdquo;
                                            means a natural person, a corporation, a limited liability company, a partnership, an association,
                                            a trust or any other entity or organization, including a government or political subdivision
                                            or any agency or instrumentality thereof.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Restricted
                                            Issuance&rdquo; means the (i) the issuance, incurrence or guaranty of any debt or additional
                                            Liabilities other than trade payables incurred in the ordinary course of business, (ii) the
                                            issuance of (a) any Equity Securities of the Corporation, including, without limitation any
                                            Common Stock or any class or series of Preferred Stock; or (b) any securities that are convertible
                                            into or exchangeable for shares of Common Stock or any class or series of Preferred Stock,
                                            other than in each of the foregoing clauses (i) and (ii), for any such issuances or sales
                                            to a Series A Holder as contemplated in this Certificate of Designation or otherwise to a
                                            Series A Holder or any of its Affiliates. For the avoidance of doubt, the issuance of Common
                                            Stock under, pursuant to, in exchange for or in connection with any contract or instrument,
                                            whether convertible or not, is deemed a Restricted Issuance for purposes hereof if the number
                                            of shares of Common Stock to be issued is based upon or related in any way to the market
                                            price of the Common Stock, including, but not limited to, Common Stock issued in connection
                                            with a Section 3(a)(9) exchange, a Section 3(a)(10) settlement, or any other similar settlement
                                            or exchange. Notwithstanding anything to the contrary in the foregoing, &ldquo;Restricted
                                            Issuance&rdquo; shall not include (i) Common Stock issued pursuant to &ldquo;at-the-market&rdquo;
                                            trading (ATM) facilities provided that, the total combined proceeds received by the Corporation
                                            from such ATM facilities may not exceed $10,000,000; and (ii) any issuance of Common Stock,
                                            restricted stock units, options, warrants or other equity awards to Company employees and
                                            non-employee directors for compensatory purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;SEC&rdquo;
                                            means the United States Securities and Exchange Commission.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Securities
                                            Act&rdquo; means the United States Securities Act of 1933, as amended, and the rules and
                                            regulations promulgated thereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
14. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legend</U>.
                                            Any certificates representing the Series A Stock shall bear a restrictive legend in substantially
                                            the following form (and a stop transfer order may be placed against transfer of such stock
                                            certificates):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED NOR
QUALIFIED UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED,
OR HYPOTHECATED UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION IS NOT REQUIRED. ANY TRANSFER OF THE SECURITIES REPRESENTED
BY THIS CERTIFICATE IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE SET FORTH HEREIN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 58.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Uncertificated
                                            Shares Lost or Mutilated Series A Stock Certificate</U>. The Series A Stock shall be issued
                                            to each Series A Holder in uncertificated (book entry) form by the stock transfer agent of
                                            the Corporation unless a Series A Holder requests such Series A Stock be issued to such Series
                                            A Holder in certificated form. If any certificate for the Series A Stock held by the Series
                                            A Holder thereof shall be mutilated, lost, stolen or destroyed, the Corporation shall execute
                                            and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate,
                                            or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate
                                            for the share of Series A Stock so mutilated, lost, stolen or destroyed but only upon receipt
                                            of evidence of such loss, theft or destruction of such certificate, and of the ownership
                                            hereof, and indemnity, if requested, all reasonably satisfactory to the Corporation.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Interpretation</U>.
                                            If the Corporation or any Series A Holder shall commence an action or proceeding to enforce
                                            any provisions of this Certificate of Designation, then the prevailing party in such action
                                            or proceeding shall be reimbursed by the other party for its reasonable and documented attorney&rsquo;s
                                            fees and other reasonable and documented costs and expenses incurred with the investigation,
                                            preparation and prosecution of such action or proceeding.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver</U>.
                                            Any waiver by the Corporation or a Series A Holder of a breach of any provision of this Certificate
                                            of Designation shall not operate as or be construed to be a waiver of any other breach of
                                            such provision or of any breach of any other provision of this Certificate of Designation.
                                            The failure of the Corporation or a Series A Holder to insist upon strict adherence to any
                                            term of this Certificate of Designation on one or more occasions shall not be considered
                                            a waiver or deprive that party of the right thereafter to insist upon strict adherence to
                                            that term or any other term of this Certificate of Designation. Any waiver must be in writing.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>.
                                            If any provision of this Certificate of Designation is invalid, illegal or unenforceable,
                                            the balance of this Certificate of Designation shall remain in effect, and if any provision
                                            is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to
                                            all other Persons and circumstances.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: 1.5pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><B>Exhibit 10.1</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: 1.5pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: 1.5pt; text-align: center"><B>Securities Purchase
Agreement</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: 1.5pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">This
Securities Purchase Agreement</FONT> (this &ldquo;<B>Agreement</B>&rdquo;), dated as of June <R>2,</R> 2026, is entered into by and between
<FONT STYLE="font-variant: small-caps">Imunon, Inc.</FONT>, a Delaware corporation (&ldquo;<B>Company</B>&rdquo;), and <FONT STYLE="font-variant: small-caps">Streeterville
Capital, LLC, </FONT>a Utah limited liability company, its successors and/or assigns (&ldquo;<B>Investor</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A. Company and Investor are executing
and delivering this Agreement in reliance upon Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;<B>1933 Act</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B. Investor desires to purchase
and Company desires to issue and sell, upon the terms and conditions set forth in this Agreement: (i) a Secured Promissory Note A-1 in
the original principal amount of $2,720,000.00 in the form attached hereto as <U>Exhibit A</U> (the &ldquo;<B>A-1 Note</B>&rdquo;, and
together with any notes issued pursuant to Section 1.8 below, the &ldquo;<B>A Notes</B>&rdquo;); (ii) a Secured Promissory Note B in the
original principal amount of $5,000,000.00 in the form attached hereto as <U>Exhibit B</U> (the &ldquo;<B>B Note</B>&rdquo;, and together
with the A Notes, the &ldquo;<B>Notes</B>&rdquo;; each individually, a &ldquo;<B>Note</B>&rdquo;), and (iii) 250 shares of Series A Preferred
Stock, par value $0.01 per share, of Company (the &ldquo;<B>Preferred Shares</B>&rdquo;), the terms of which are set forth in the Certificate
of Designation for such Preferred Shares, in the form attached hereto as <U>Exhibit C</U> (the &ldquo;<B>Certificate of Designation</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C. This Agreement, the Notes,
the Certificate of Designation, the DACA (as defined below), the Collateral Agreements (as defined below), all exhibits and schedules
thereto and all other certificates, documents, agreements, resolutions and instruments delivered to any party under or in connection with
this Agreement, as the same may be amended from time to time, are collectively referred to herein as the &ldquo;<B>Transaction Documents</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D. For purposes of this Agreement,
&ldquo;<B>Securities</B>&rdquo; means the Notes and the Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration
of the above recitals and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company
and Investor hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1. <U>Purchase and Sale of Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.1. <U>Purchase of Notes</U>. On
the Closing Date (as defined below), Company hereby agrees to issue and sell to Investor and Investor hereby agrees to purchase from Company
the A-1 Note and the B Note. In consideration thereof, Investor agrees to pay $7,500,000.00 (the &ldquo;<B>Notes Purchase Price</B>&rdquo;)
to Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.2. <U>Preferred Shares</U>. On
the Closing Date, Company shall also issue and sell to Investor and Investor shall purchase from Company the Preferred Shares. In consideration
thereof, Investor shall pay $2,500,000.00 (together with the Notes Purchase Price, the &ldquo;<B>Purchase Price</B>&rdquo;) to Company.
The purchase price per share for the purchase of all Preferred Shares pursuant to this Agreement will be $10,000.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.3. <U>Form of Payment</U>. On
the Closing Date, Investor shall pay the Purchase Price to Company via wire transfer of immediately available funds against delivery of
the A-1 Note, the B Note, and the Preferred Shares as follows: (i) $2,500,000.00 of the Purchase Price will be sent to Company for the
A-1 Note; (ii) $5,000,000.00 of the Purchase Price will be sent to Lakeside Bank for the B Note to be held in a deposit account in the
name of Company&rsquo;s subsidiary, IMNN Holdings, LLC (&ldquo;<B>IMNN Holdings</B>&rdquo;), that is subject to the DACA; and (iii) $2,500,000.00
of the Purchase Price will be sent to Company for the Preferred Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.4. <U>Closing Date</U>. Subject
to the satisfaction (or written waiver) of the conditions set forth in Section 5 and Section 6 below, the date of the issuance and sale
of the A-1 Note, the B Note, and the Preferred Shares pursuant to this Agreement (the &ldquo;<B>Closing Date</B>&rdquo;) shall be June
<R>2,</R> 2026, or such other mutually agreed upon date. The closing of the transactions contemplated by this Agreement (the &ldquo;<B>Closing</B>&rdquo;)
shall occur on the Closing Date by means of the exchange of electronic signatures but shall be deemed for all purposes to have occurred
at the offices of Hansen Black Anderson Ashcraft PLLC in Lehi, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.5. <U>Original Issue Discount;
Transaction Expense Amount</U>. The A-1 Note carries an original issue discount of $200,000.00 (the &ldquo;<B>OID</B>&rdquo;). In addition,
Company agrees to pay $20,000.00 to Investor to cover Investor&rsquo;s legal, administrative and due diligence expenses incurred in connection
with the purchase and sale of the A-1 Note, the B Note, and the Preferred Shares (the &ldquo;<B>Transaction Expense Amount</B>&rdquo;),
all of which amount is included in the initial principal balance of the A-1 Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.6. <U>DACA</U>. Company&rsquo;s
obligations under the B Note will be secured by cash held in a deposit account (&ldquo;<B>Deposit Account</B>&rdquo;) pursuant to a Deposit
Account Control Agreement in substantially the form attached hereto as <U>Exhibit D</U> (the &ldquo;<B>DACA</B>&rdquo;). Company hereby
grants to Investor a first-position security interest in the Deposit Account and acknowledges and agrees that Investor will have the right
to file a UCC-1 Financing Statement with respect to the Deposit Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.7. <U>Collateral</U>. In addition
to the DACA, Company&rsquo;s obligations under the Notes will be: (a) guaranteed pursuant to a Guaranty substantially in the form attached
hereto as <U>Exhibit E</U> (the &ldquo;<B>Guaranty</B>&rdquo;), to be executed by CLSN Laboratories, Inc. (the &ldquo;<B>CLSN Labs</B>&rdquo;)
and IMNN Holdings (together with CLSN Labs, the &ldquo;<B>Subsidiaries</B>&rdquo;; and each individually, a &ldquo;<B>Subsidiary</B>&rdquo;);
and (b) secured by a Security Agreement executed by Company substantially in the form attached hereto as <U>Exhibit F</U> (the &ldquo;<B>Security
Agreement</B>&rdquo;, and together with the Guaranty, the &ldquo;<B>Collateral Agreements</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.8. <U>B Note Exchanges</U>. If
at any time the aggregate outstanding balance of all A Notes or the aggregate number of outstanding Preferred Shares is reduced by an
amount equal to $2,000,000.00 (calculated as the applicable number of Preferred Share multiplied by the Stated Value (as defined in the
Certificate of Designation)) (or, if less than $2,000,000.00, the entire remaining outstanding balance of the A Notes), then Company will
have the right to exchange up to $1,000,000.00, plus interest (or, if less than $1,000,000.00, the entire remaining amount of the B Note,
or such other amount as the parties mutually agree) of the B Note for an A Note in the same form as the A-1 Note (each, a &ldquo;<B>Note
Exchange</B>&rdquo;). Each Note Exchange will be effected pursuant to Section 3(a)(9) of the 1933 Act. Each additional A Note issued pursuant
to a Note Exchange will have the same maturity date, interest rate, OID percentage, and other economic and other terms as the A-1 Note.
Upon completion of a Note Exchange, an amount equal to the portion of the outstanding balance of the B Note exchanged for the applicable
A Note will be eligible to be released from the Deposit Account. No additional Transaction Expense Amount will be assessed in connection
with the issuance of any A Note pursuant to a Note Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2. <U>Investor&rsquo;s Representations
and Warranties</U>. Investor represents and warrants to Company that as of the Closing Date: (i) each Transaction Document to which it
is a party has been duly executed by Investor, and when delivered by Investor in accordance with the terms hereof or thereof, will constitute
the valid and legally binding obligation of Investor, enforceable against it in accordance with its terms, except (a) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (b) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (c) insofar as indemnification and contribution provisions may be limited by applicable law; (ii)
the execution and delivery of the Transaction Documents and performance by Investor of the transactions contemplated by the Transaction
Documents have been duly authorized by all necessary limited liability company action, as applicable; (iii) Investor is an &ldquo;accredited
investor&rdquo; as that term is defined in Rule 501(a) of Regulation D of the 1933 Act; (iv) Investor, either alone or together with its
representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating
the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment; (v)
Investor is an entity duly formed, validly existing and in good standing under the laws of the jurisdiction of its formation with full
right, limited liability company power, and authority to enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder; (vi) other than to other parties to the Transaction Documents
or to Investor&rsquo;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees,
agents and affiliates, Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction); (vii) Investor has had an opportunity to discuss Company&rsquo;s business, management, financial
affairs and the terms and conditions of the offering of the Securities with Company&rsquo;s management; and (viii) neither Investor, nor
any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker
or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer and sale of the Securities..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3. <U>Company&rsquo;s Representations
and Warranties</U>. Company represents and warrants to Investor that as of the Closing Date: (i) Company is a corporation duly organized,
validly existing and in good standing under the laws of its state of incorporation and has the requisite corporate power to own its properties
and to carry on its business as now being conducted; (ii) Company is duly qualified as a foreign corporation to do business and is in
good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result
in: (a) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (b) a material adverse effect
on the results of operations, assets, business or condition (financial or otherwise) of Company and Subsidiaries, taken as a whole, or
(c) a material adverse effect on Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any
of the Transaction Documents (any of (a), (b) or (c), a &ldquo;<B>Material Adverse Effect</B>&rdquo;); (iii) Company has registered its
shares of common stock, $0.01 par value per share (the &ldquo;<B>Common Shares</B>&rdquo;), under Section 12(b) of the Securities Exchange
Act of 1934, as amended (the &ldquo;<B>1934 Act</B>&rdquo;), and is obligated to file reports pursuant to Section 13(a) or Section 15(d)
of the 1934 Act; (iv) each of the Transaction Documents and the transactions contemplated hereby and thereby, have been duly and validly
authorized by Company and no further action is required by the Company, the Company&rsquo;s board of directors (the &ldquo;<B>Board of
Directors</B>&rdquo;), a committee of the Board of Directors, or the Company&rsquo;s stockholders in connection herewith or therewith
to authorize such matters; (v) the Transaction Documents have been duly executed and delivered by Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligations of Company enforceable in accordance with their terms,
except (a) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting enforcement of creditors&rsquo; rights generally, (b) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (b) insofar as indemnification and contribution provisions
may be limited by applicable law; (vi) the execution and delivery of the Transaction Documents by Company, the issuance of the Securities
in accordance with the terms hereof, and the consummation by Company of the other transactions contemplated by the Transaction Documents
do not and will not conflict with or result in a breach by Company of any of the terms or provisions of, or constitute a default under
(a) Company&rsquo;s incorporation documents or bylaws, each as currently in effect, (b) any indenture, mortgage, deed of trust, or other
material agreement or instrument to which Company is a party or by which it or any of its properties or assets are bound or (c) any existing
applicable law, rule, or regulation or any applicable decree, judgment, or order of any court, United States federal, state or foreign
regulatory body, administrative agency, or other governmental body having jurisdiction over Company or any of Company&rsquo;s properties
or assets; (vii) no further authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization,
or stock exchange or market or the stockholders or any lender of Company is required to be obtained by Company for the issuance of the
Securities to Investor or the entering into of the Transaction Documents; (viii) to the Company&rsquo;s knowledge, none of Company&rsquo;s
filings with the United States Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) contained, at the time they were filed,
any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements
made therein, in light of the circumstances under which they were made, not misleading; (ix) Company has filed all reports, schedules,
forms, statements and other documents required to be filed by Company with the SEC under the 1934 Act on a timely basis or has received
a valid extension of such time of filing and has filed any such report, schedule, form, statement or other document prior to the expiration
of any such extension; (x) there is no action, suit, proceeding, inquiry or investigation before or by any court, public board or body
pending or, to the knowledge of Company, threatened against or affecting Company before or by any governmental or regulatory authority
or administrative agency (federal, state, county local or foreign), wherein an unfavorable decision would have a Material Adverse Effect
on Company or the validity or enforceability of, or the authority or ability of Company to perform its obligations under, any of the Transaction
Documents; (xi) Company has not consummated any financing transaction that has not been disclosed in a periodic filing or current report
with the SEC under the 1934 Act where disclosure was required pursuant to the 1934 Act; (xii) Company is not, nor has it been at any time
in the previous twelve (12) months, an issuer subject to Rule 144(i)(1) under the 1933 Act; (xiii) with respect to any commissions, brokerage
or finder&rsquo;s fees or similar payments that will or would become due and owing by Company to any person or entity as a result of this
Agreement or the transactions contemplated hereby (&ldquo;<B>Broker Fees</B>&rdquo;), any such Broker Fees will be paid in full compliance
with all applicable laws and regulations and only to a person or entity that is a registered investment adviser or registered broker-dealer;
(xiv) Investor shall have no obligation with respect to any Broker Fees or with respect to any claims made by or on behalf of other persons
for fees of a type contemplated in this subsection that may be due in connection with the transactions contemplated hereby and Company
shall indemnify and hold harmless each of Investor, Investor&rsquo;s employees, officers, directors, stockholders, managers, agents, and
partners, and their respective affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and
attorneys&rsquo; fees) and expenses suffered in respect of any such claimed or existing Broker Fees; (xv) neither Investor nor any of
its officers, directors, members, managers, employees, agents or representatives has made any representations or warranties to Company
or any of its officers, directors, employees, agents or representatives except as expressly set forth in the Transaction Documents and,
in making its decision to enter into the transactions contemplated by the Transaction Documents, Company is not relying on any representation,
warranty, covenant or promise of Investor or its officers, directors, members, managers, employees, agents or representatives other than
as set forth in the Transaction Documents; (xvi) Company acknowledges that the State of Utah has a reasonable relationship and sufficient
contacts to the transactions contemplated by the Transaction Documents and any dispute that may arise related thereto such that the laws
and venue of the State of Utah, as set forth more specifically in Section 7.2 below, shall be applicable to the Transaction Documents
and the transactions contemplated therein; (xvii) Company acknowledges that Investor is not registered as a &lsquo;dealer&rsquo; under
the 1934 Act; and (xviii) Company has performed due diligence and background research on Investor and its affiliates and has received
and reviewed the due diligence summary sheet provided by Investor. Company, being aware of the matters and legal issues described in subsections
(xvii) and (xviii) above, acknowledges and agrees that such matters, or any similar matters, have no bearing on the transactions contemplated
by the Transaction Documents and covenants and agrees it will not use any such information or legal theory as a defense to performance
of its obligations under the Transaction Documents or in any attempt to avoid, modify, reduce, rescind or void such obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4. <U>Company Covenants</U>. Until
all of Company&rsquo;s obligations under the Notes are paid and performed in full, or within the timeframes otherwise specifically set
forth below, Company will at all times comply with the following covenants: (i) so long as Investor beneficially owns any Note and for
at least twenty (20) Trading Days (as defined in the Notes) thereafter, Company will timely file on the applicable deadline all reports
required to be filed with the SEC pursuant to Sections 13 or 15(d) of the 1934 Act, and will take all reasonable action under its control
to ensure that adequate current public information with respect to Company, as required in accordance with Rule 144 of the 1933 Act, is
publicly available, and will not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or
the rules and regulations thereunder would permit such termination; (ii) Company will ensure that the Common Shares are listed or quoted
for trading on NYSE, NYSE American, or Nasdaq; (iii) Company will ensure that trading in the Common Shares will not be suspended, halted,
chilled, frozen, reach zero bid or otherwise cease trading on Company&rsquo;s principal trading market; (iv) Company will not make any
Restricted Issuance (as defined below) without Investor&rsquo;s prior written consent, which consent may be granted or withheld in Investor&rsquo;s
sole and absolute discretion; (v) Company will not enter into any agreement or otherwise agree to any covenant, condition, or obligation
that locks up, restricts in any way or otherwise prohibits Company: (a) from entering into a variable rate transaction with Investor or
any affiliate of Investor, or (b) from issuing Common Shares, preferred stock, warrants, convertible notes, other debt securities, or
any other Company securities to Investor or any affiliate of Investor; (vi) other than Permitted Liens, neither Company nor either Subsidiary
will grant any security interest, lien, pledge, guaranty or other encumbrance with respect to any of its assets; (vii) Company will notify
Investor of any action, suit, proceeding, inquiry or investigation filed or initiated against Company or IMNN Holdings within three (3)
Trading Days of the initiation of such; (viii) neither Company nor either Subsidiary will sell, transfer, or issue any equity or grant
any rights to any equity interest or voting rights in the Subsidiaries; (ix) Company will not allow IMNN Holdings to issue, incur, or
guaranty any debt or conduct any business operations; and (x) Company will not allow CLSN Labs to issue, incur or guaranty any debt other
than in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes hereof, the term
&ldquo;<B>Restricted Issuance</B>&rdquo; means the issuance, incurrence or guaranty of any debt obligations (including any merchant cash
advance, account receivable factoring or other similar agreement) other than trade payables in the ordinary course of business, or the
issuance of any securities that: (1) have or may have conversion rights of any kind, contingent, conditional or otherwise, in which the
number of shares that may be issued pursuant to such conversion right varies with the market price of the Common Shares; (2) are or may
become convertible into Common Shares (including without limitation convertible debt, warrants or convertible preferred shares), with
a conversion price that varies with the market price of the Common Shares, even if such security only becomes convertible following an
event of default, the passage of time, or another trigger event or condition; (3) have a fixed conversion price, exercise price or exchange
price that is subject to being reset at some future date at any time after the initial issuance of such debt or equity security (A) due
to a change in the market price of Company&rsquo;s Common Shares since the date of the initial issuance, or (B) upon the occurrence of
specified or contingent events directly or indirectly related to the business of Company (including, without limitation, any &ldquo;full
ratchet&rdquo; or &ldquo;weighted average&rdquo; anti-dilution provisions, but not including any standard anti-dilution protection for
any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction); or (4) are issued in connection with
a Section 3(a)(9) exchange, a Section 3(a)(10) settlement, or any other similar settlement or exchange. For the avoidance of doubt, none
of the following will be considered Restricted Issuances: (i) current or future ATM facilities; (ii) any issuance of Common Shares, restricted
stock units, options, warrants or other equity awards to Company employees and non-employee directors for compensatory purposes; and (iii)
primary offerings of Common Shares or warrants without variable price mechanics or any anti-dilution, &ldquo;alternate cash exercise&rdquo;,
or cashless exercise provisions or other similar mechanics or provisions that would allow for the reduction of the exercise price of the
warrants or increase the number of shares exercisable under the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes hereof, the term
&ldquo;<B>Permitted Liens</B>&rdquo; means (a) Liens for taxes not yet delinquent or Liens for taxes being contested in good faith and
by appropriate proceedings for which adequate reserves have been established; (b) Liens in favor of Investor under the Security Agreement
or arising under the other Transaction Documents or any prior agreements between Company and Investor; and (c) Liens consented to in writing
by Investor; and &ldquo;<B>Lien</B>&rdquo; means, with respect to any property, any security interest, mortgage, pledge, lien, claim,
charge or other encumbrance in, of, or on such property or the income therefrom, including, without limitation, the interest of a vendor
or lessor under a conditional sale agreement, capital lease or other title retention agreement, or any agreement to provide any of the
foregoing, and the filing of any financing statement or similar instrument under the UCC or comparable law of any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5. <U>Conditions to Company&rsquo;s
Obligation to Sell</U>. The obligation of Company hereunder to issue and sell the Securities to Investor at the Closing is subject to
the satisfaction, on or before the Closing Date, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.1. Investor shall have executed
all applicable Transaction Documents and delivered the same to Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.2. Investor shall have delivered
the Purchase Price to Company in accordance with Section 1.3 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6. <U>Conditions to Investor&rsquo;s
Obligation to Purchase</U>. The obligation of Investor hereunder to purchase the Securities at the Closing is subject to the satisfaction,
on or before the Closing Date, of each of the following conditions, provided that these conditions are for Investor&rsquo;s sole benefit
and may be waived by Investor at any time in its sole discretion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.1. Company shall have executed
all applicable Transaction Documents and delivered the same to Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.2. Company shall have issued and
delivered the Preferred Shares to Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.3. Company shall have delivered
to Investor a fully executed Officer&rsquo;s Certificate substantially in the form attached hereto as <U>Exhibit G</U> evidencing Company&rsquo;s
approval of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.4. IMNN Holdings and Lakeside
Bank shall have executed and delivered the DACA to Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.5. Each Subsidiary shall have
executed and delivered the Guaranty to Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">6.6. Company shall have filed the
Certificate of Designation with the State of Delaware and received confirmation from the State of Delaware that such Certificate of Designation
has been accepted and approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7. <U>Miscellaneous</U>. The provisions
set forth in this Section 7 shall apply to this Agreement, as well as all other Transaction Documents as if these terms were fully set
forth therein; provided, however, that in the event there is a conflict between any provision set forth in this Section 7 and any provision
in any other Transaction Document, the provision in such other Transaction Document shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.1. <U>Arbitration of Claims</U>.
The parties shall submit all Claims (as defined in <U>Exhibit H</U>) arising under this Agreement or any other Transaction Document or
any other agreement between the parties and their affiliates or any Claim relating to the relationship of the parties to binding arbitration
pursuant to the arbitration provisions set forth in <U>Exhibit H</U> attached hereto (the &ldquo;<B>Arbitration Provisions</B>&rdquo;).
For the avoidance of doubt, the parties agree that the injunction described in Section 7.3 below may be pursued in an arbitration that
is separate and apart from any other arbitration regarding all other Claims arising under the Transaction Documents. The parties hereby
acknowledge and agree that the Arbitration Provisions are unconditionally binding on the parties hereto and are severable from all other
provisions of this Agreement. By executing this Agreement, Company represents, warrants and covenants that Company has reviewed the Arbitration
Provisions carefully, consulted with legal counsel about such provisions (or waived its right to do so), understands that the Arbitration
Provisions are intended to allow for the expeditious and efficient resolution of any dispute hereunder, agrees to the terms and limitations
set forth in the Arbitration Provisions, and that Company will not take a position contrary to the foregoing representations. Company
acknowledges and agrees that Investor may rely upon the foregoing representations and covenants of Company regarding the Arbitration Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.2. <U>Governing Law; Venue</U>.
This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation
and performance of this Agreement shall be governed by, the internal laws of the State of Utah, without giving effect to any choice of
law or conflict of law provision or rule (whether of the State of Utah or any other jurisdiction) that would cause the application of
the laws of any jurisdiction other than the State of Utah. Each party consents to and expressly agrees that the exclusive venue for arbitration
of any dispute arising out of or relating to any Transaction Document or the relationship of the parties or their affiliates shall be
in Salt Lake County, Utah. Without modifying the parties&rsquo; obligations to resolve disputes hereunder pursuant to the Arbitration
Provisions, for any litigation arising in connection with any of the Transaction Documents, each party hereto hereby (i) consents to and
expressly submits to the exclusive personal jurisdiction of any state or federal court sitting in Salt Lake County, Utah, (ii) expressly
submits to the exclusive venue of any such court for the purposes hereof, and (iii) waives any claim of improper venue and any claim or
objection that such courts are an inconvenient forum or any other claim, defense or objection to the bringing of any such proceeding in
such jurisdiction or to any claim that such venue of the suit, action or proceeding is improper. Company acknowledges that the governing
law and venue provisions set forth in this Section 7.2 are material terms to induce Investor to enter into the Transaction Documents and
that but for Company&rsquo;s agreements set forth in this Section 7.2 Investor would not have entered into the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.3. <U>Specific Performance</U>.
The parties acknowledge and agree that each party may suffer irreparable harm if Company or Investor fail to perform any material provision
of this Agreement or any of the other Transaction Documents in accordance with its specific terms. It is accordingly agreed that Company
and Investor shall be entitled to seek one or more injunctions to prevent or cure breaches of the provisions of this Agreement or such
other Transaction Document and to enforce specifically the terms and provisions hereof or thereof, this being in addition to any other
remedy to which Investor may be entitled under the Transaction Documents, at law or in equity. Company specifically agrees that: (i) following
an Event of Default (as defined in the Notes or the Certificate of Designation) under any Note or the Certificate of Designation, Investor
shall have the right to seek injunctive relief from a court or an arbitrator prohibiting Company from issuing any of its Common Shares
or preferred stock to any party unless fifty percent (50%) of the gross proceeds received by Company in connection with such issuance
are simultaneously used by Company to make a payment under the Notes and/or a redemption of the Preferred Shares under the Certificate
of Designation; (ii) following a breach of Section 4(v) above, Investor shall have the right to seek injunctive relief from a court or
arbitrator invalidating such lock-up; and (iii) if Company enters into a definitive agreement that contemplates a Fundamental Transaction
(as defined in the Notes), unless such agreement contains a closing condition that the Notes are repaid in full and that the Preferred
Shares are redeemed in full upon consummation of the transaction or Investor has provided its written consent in writing to such Fundamental
Transaction, Investor shall have the right to seek injunctive relief from a court or arbitrator preventing the consummation of such transaction.
Company specifically acknowledges that Investor&rsquo;s right to obtain specific performance constitutes bargained for leverage and that
the loss of such leverage would result in irreparable harm to Investor. For the avoidance of doubt, in the event Investor seeks to obtain
an injunction from a court or an arbitrator against the parties may be entitled under the Transaction Documents, at law or in equity.
For the avoidance of doubt, in the event either party seeks to obtain an injunction from a court or an arbitrator against the other party
or specific performance of any provision of any Transaction Document, such action shall not be a waiver of any right of such party under
any Transaction Document, at law, or in equity, including without limitation its rights to arbitrate any Claim pursuant to the terms of
the Transaction Documents, nor shall either party&rsquo;s pursuit of an injunction prevent such party, under the doctrines of claim preclusion,
issues preclusion, res judicata or other similar legal doctrines, from pursuing other Claims in the future in a separate arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.4. <U>Counterparts</U>. This Agreement
may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Counterparts may be delivered via exchange of electronic signatures (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered
shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.5. <U>Headings</U>. The headings
of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.6. <U>Severability</U>. In the
event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform to such statute or rule
of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of
any other provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.7. <U>Entire Agreement</U>. This
Agreement, together with the other Transaction Documents, contains the entire understanding of the parties with respect to the matters
covered herein and therein and, except as specifically set forth herein or therein, neither Company nor Investor makes any representation,
warranty, covenant or undertaking with respect to such matters. For the avoidance of doubt, all prior term sheets or other documents between
Company and Investor, or any affiliate thereof, related to the transactions contemplated by the Transaction Documents (collectively, &ldquo;<B>Prior
Agreements</B>&rdquo;), that may have been entered into between Company and Investor, or any affiliate thereof, are hereby null and void
and deemed to be replaced in their entirety by the Transaction Documents. To the extent there is a conflict between any term set forth
in any Prior Agreement and the term(s) of the Transaction Documents, the Transaction Documents shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.8. <U>Amendments</U>. No provision
of this Agreement may be waived or amended other than by an instrument in writing signed by both parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.9. <U>Notices</U>. Any notice
required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively given on
the earliest of: (i) the date delivered, if delivered by personal delivery as against written receipt therefor or by email to an executive
officer, or by facsimile (with successful transmission confirmation), (ii) the earlier of the date delivered or the third business day
after deposit, postage prepaid, in the United States Postal Service by certified mail, or (iii) the earlier of the date delivered or the
third business day after mailing by express courier, with delivery costs and fees prepaid, in each case, addressed to each of the other
parties thereunto entitled at the following addresses (or at such other addresses as such party may designate by five (5) calendar days&rsquo;
advance written notice similarly given to each of the other parties hereto):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in">If to Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Imunon, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: Stacy R. Lindborg</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">997 Lenox Drive, Suite 100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Lawrenceville, New Jersey 08648</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in">With a copy to (which copy shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 57pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Covington &amp; Burling LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: Michael J. Riella</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">850 10th St NW</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Washington, DC 20001</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in">If to Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 121pt 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Streeterville Capital, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: John Fife</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">297 Auto Mall Drive, Suite #4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">St. George, Utah 84770</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 57pt; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in">With a copy to (which copy shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 57pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Hansen Black Anderson Ashcraft PLLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: Jonathan Hansen</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">3051 West Maple Loop Drive, Suite 325</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Lehi, Utah 84048</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: [***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 63pt 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.10. <U>Successors and Assigns</U>.
This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by Investor hereunder may be
assigned by Investor to a third party, including its affiliates, in whole or in part, without the need to obtain Company&rsquo;s consent
thereto, provided that such third party agrees in writing to be bound, with respect to the transferred Securities, rights or obligations,
by the provisions of the Transaction Documents that apply to Investor. Company may not assign its rights or obligations under this Agreement
or delegate its duties hereunder without the prior written consent of Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.11. <U>Survival</U>. The representations
and warranties of Company and Investor and the agreements and covenants set forth in this Agreement shall survive the Closing hereunder
notwithstanding any due diligence investigation conducted by or on behalf of Investor or Company, as applicable. Company agrees to indemnify
and hold harmless Investor and all its officers, directors, employees, attorneys, and agents for loss or damage arising as a result of
or related to any breach or alleged breach by Company of any of its representations, warranties and covenants set forth in this Agreement
or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred. Investor agrees
to indemnify and hold harmless Company and all its officers, directors, employees, attorneys, and agents for loss or damage arising as
a result of or related to any breach or alleged breach by Investor of any of its representations, warranties and covenants set forth in
this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.12. <U>Further Assurances</U>.
Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all
such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.13. <U>Rights and Remedies Cumulative</U>.
All rights, remedies, and powers conferred in this Agreement and the Transaction Documents are cumulative and not exclusive of any other
rights or remedies, and shall be in addition to every other right, power, and remedy that each party may have, whether specifically granted
in this Agreement or any other Transaction Document, or existing at law, in equity, or by statute, and any and all such rights and remedies
may be exercised from time to time and as often and in such order as such party may deem expedient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.14. <U>Attorneys&rsquo; Fees and
Cost of Collection</U>. In the event any suit, action or arbitration is filed by either party against the other to interpret or enforce
any of the Transaction Documents, the unsuccessful party to such action agrees to pay to the prevailing party all costs and expenses,
including reasonable attorneys&rsquo; fees incurred therein, including the same with respect to an appeal. The &ldquo;prevailing party&rdquo;
shall be the party in whose favor a judgment is entered, regardless of whether judgment is entered on all claims asserted by such party
and regardless of the amount of the judgment; or where, due to the assertion of counterclaims, judgments are entered in favor of and against
both parties, then the arbitrator shall determine the &ldquo;prevailing party&rdquo; by taking into account the relative dollar amounts
of the judgments or, if the judgments involve nonmonetary relief, the relative importance and value of such relief. Nothing herein shall
restrict or impair an arbitrator&rsquo;s or a court&rsquo;s power to award fees and expenses for frivolous or bad faith pleading. If (i)
any Note is placed in the hands of an attorney for collection or enforcement prior to commencing arbitration or legal proceedings, or
is collected or enforced through any arbitration or legal proceeding, or Investor otherwise takes action to collect amounts due under
the Notes or to enforce the provisions of the Notes, or (ii) there occurs any bankruptcy, reorganization, receivership of Company or other
proceedings affecting Company&rsquo;s creditors&rsquo; rights and involving a claim under the Notes; then Company shall pay the reasonable
and documented costs incurred by Investor for such collection, enforcement or action or in connection with such bankruptcy, reorganization,
receivership or other proceeding, including, without limitation, reasonable attorneys&rsquo; fees, expenses, deposition costs, and disbursements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.15. <U>Waiver</U>. No waiver of
any provision of this Agreement shall be effective unless it is in the form of a writing signed by the party granting the waiver. No waiver
of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to any other prohibited
action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a party to provide a waiver
or consent in the future except to the extent specifically set forth in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.16. <U>Waiver of Jury Trial</U>.
EACH PARTY TO THIS AGREEMENT IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH PARTY MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM
ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT, OR THE RELATIONSHIPS OF THE PARTIES HERETO BE
TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE,
LAW, RULE OR REGULATION. FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT SUCH PARTY IS KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTY&rsquo;S
RIGHT TO DEMAND TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.17. <U>Time is of the Essence</U>.
Time is expressly made of the essence with respect to each and every provision of this Agreement and the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.18. <U>Voluntary Agreement</U>.
Company and Investor each has carefully read this Agreement and each of the other Transaction Documents and has asked any questions needed
for such party to understand the terms, consequences and binding effect of this Agreement and each of the other Transaction Documents
and fully understand them. Company and Investor each has had the opportunity to seek the advice of an attorney of such party&rsquo;s choosing,
or has waived the right to do so, and is executing this Agreement and each of the other Transaction Documents voluntarily and without
any duress or undue influence by any person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">7.19. <U>Third-Party Beneficiaries</U>.
This Agreement and each of the other Transaction Documents is intended for the benefit of the parties hereto and thereto and their respective
permitted successors and assigns. There are no third-party beneficiaries of this Agreement or any other Transaction Document. Nothing
in this Agreement or any other Transaction Document, express or implied, is intended to confer upon any other person any rights, remedies,
obligations or liabilities of any nature whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Remainder of page intentionally left blank; signature
page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
Investor and Company have caused this Agreement to be duly executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Streeterville Capital, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ John Fife</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">John Fife, President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">COMPANY:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Imunon, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Stacy R. Lindborg </I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Stacy R. Lindborg, Chief Executive Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ATTACHED EXHIBITS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-size: 10pt">Exhibit A</FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">A-1 Note</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exhibit B</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">B Note</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exhibit C</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Designation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exhibit D</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">DACA</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exhibit E</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Guaranty</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exhibit F</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Security Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exhibit G</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Officer&rsquo;s Certificate</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Exhibit H</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Arbitration Provisions</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: center; text-indent: -1in"><I>[Signature Page to Securities
Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Exhibit
H</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARBITRATION PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. <U>Dispute Resolution</U>. For purposes of these
arbitration provisions (the &ldquo;<B>Arbitration Provisions</B>&rdquo;), the term &ldquo;<B>Claims</B>&rdquo; means any disputes, claims,
demands, causes of action, requests for injunctive relief, requests for specific performance, liabilities, damages, losses, or controversies
whatsoever arising from, related to, or connected with the transactions contemplated in the Transaction Documents and any communications
between the parties related thereto, including without limitation any claims of mutual mistake, mistake, fraud, misrepresentation, failure
of formation, failure of consideration, promissory estoppel, unconscionability, failure of condition precedent, rescission, and any statutory
claims, tort claims, contract claims, or claims to void, invalidate or terminate the Agreement (or these Arbitration Provisions (defined
below)) or any of the other Transaction Documents. For the avoidance of doubt, Investor&rsquo;s pursuit of an injunction or other Claim
pursuant to these Arbitration Provisions or with a court will not later prevent Investor under the doctrines of claim preclusion, issue
preclusion, res judicata or other similar legal doctrines from pursuing other Claims in a separate arbitration in the future. The parties
to the Agreement (the &ldquo;<B>parties</B>&rdquo;) hereby agree that the Claims may be arbitrated in one or more arbitrations pursuant
to these Arbitration Provisions (one for an injunction or injunctions and a separate one for all other Claims). The parties to the Agreement
hereby agree that these Arbitration Provisions are binding on each of them. As a result, any attempt to rescind the Agreement (or these
Arbitration Provisions) or any other Transaction Document) or declare the Agreement (or these Arbitration Provisions) or any other Transaction
Document invalid or unenforceable pursuant to Section 29 of the 1934 Act or for any other reason is subject to these Arbitration Provisions.
Any capitalized term not defined in these Arbitration Provisions shall have the meaning set forth in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. <U>Arbitration</U>. Except as otherwise provided
herein, all Claims must be submitted to arbitration (&ldquo;<B>Arbitration</B>&rdquo;) to be conducted exclusively in Salt Lake County,
Utah and pursuant to the terms set forth in these Arbitration Provisions. Subject to the arbitration appeal right provided for in Paragraph
5 below (the &ldquo;<B>Appeal Right</B>&rdquo;), the parties agree that the award of the arbitrator rendered pursuant to Paragraph 4 below
(the &ldquo;<B>Arbitration Award</B>&rdquo;) shall be (a) final and binding upon the parties, (b) the sole and exclusive remedy between
them regarding any Claims, counterclaims, issues, or accountings presented or pleaded to the arbitrator, and (c) promptly payable in United
States dollars free of any tax, deduction or offset (with respect to monetary awards). Subject to the Appeal Right, any costs or fees,
including without limitation reasonable attorneys&rsquo; fees, incurred in connection with or incident to enforcing the Arbitration Award
shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Arbitration Award shall include
default interest (as defined or otherwise provided for in the Note, &ldquo;<B>Default Interest</B>&rdquo;) (with respect to monetary awards)
at the rate specified in the Note for Default Interest both before and after the Arbitration Award. Judgment upon the Arbitration Award
will be entered and enforced by any state or federal court sitting in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. <U>The Arbitration Act</U>. The parties hereby
incorporate herein the provisions and procedures set forth in the Utah Uniform Arbitration Act, U.C.A. &sect; 78B-11-101 <I>et seq.</I>
(as amended or superseded from time to time, the &ldquo;<B>Arbitration Act</B>&rdquo;). Notwithstanding the foregoing, pursuant to, and
to the maximum extent permitted by, Section 105 of the Arbitration Act, in the event of conflict or variation between the terms of these
Arbitration Provisions and the provisions of the Arbitration Act, the terms of these Arbitration Provisions shall control and the parties
hereby waive or otherwise agree to vary the effect of all requirements of the Arbitration Act that may conflict with or vary from these
Arbitration Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. <U>Arbitration Proceedings</U>. Arbitration between
the parties will be subject to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.1 <I>Initiation of Arbitration</I>.
Pursuant to Section 110 of the Arbitration Act, the parties agree that a party may initiate Arbitration by giving written notice to the
other party (&ldquo;<B>Arbitration Notice</B>&rdquo;) in the same manner that notice is permitted under Section 7.9 of the Agreement (the
&ldquo;<B>Notice Provision</B>&rdquo;); <I>provided, however</I>, that the Arbitration Notice may not be given by email or fax. Arbitration
will be deemed initiated as of the date that the Arbitration Notice is deemed delivered to such other party under the Notice Provision
(the &ldquo;<B>Service Date</B>&rdquo;). After the Service Date, information may be delivered, and notices may be given, by email or fax
pursuant to the Notice Provision or any other method permitted thereunder. The Arbitration Notice must describe the nature of the controversy,
the remedies sought, and the election to commence Arbitration proceedings. All Claims in the Arbitration Notice must be pleaded consistent
with the Utah Rules of Civil Procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><I>Arbitration Provisions,</I> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.2 <I>Selection and Payment
of Arbitrator</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) Within ten (10) calendar
days after the Service Date, Investor shall select and submit to Company the names of three (3) arbitrators that are designated as &ldquo;neutrals&rdquo;
or qualified arbitrators by Utah ADR Services (<U>http://www.utahadrservices.com</U>) (such three (3) designated persons hereunder are
referred to herein as the &ldquo;<B>Proposed Arbitrators</B>&rdquo;). For the avoidance of doubt, each Proposed Arbitrator must be qualified
as a &ldquo;neutral&rdquo; with Utah ADR Services. Within five (5) calendar days after Investor has submitted to Company the names of
the Proposed Arbitrators, Company must select, by written notice to Investor, one (1) of the Proposed Arbitrators to act as the arbitrator
for the parties under these Arbitration Provisions. If Company fails to select one of the Proposed Arbitrators in writing within such
5-day period, then Investor may select the arbitrator from the Proposed Arbitrators by providing written notice of such selection to
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) If Investor fails to submit
to Company the Proposed Arbitrators within ten (10) calendar days after the Service Date pursuant to subparagraph (a) above, then Company
may at any time prior to Investor so designating the Proposed Arbitrators, identify the names of three (3) arbitrators that are designated
as &ldquo;neutrals&rdquo; or qualified arbitrators by Utah ADR Service by written notice to Investor. Investor may then, within five (5)
calendar days after Company has submitted notice of its Proposed Arbitrators to Investor, select, by written notice to Company, one (1)
of the Proposed Arbitrators to act as the arbitrator for the parties under these Arbitration Provisions. If Investor fails to select in
writing and within such 5-day period one (1) of the three (3) Proposed Arbitrators selected by Company, then Company may select the arbitrator
from its three (3) previously selected Proposed Arbitrators by providing written notice of such selection to Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) If a Proposed Arbitrator
chosen to serve as arbitrator declines or is otherwise unable to serve as arbitrator, then the party that selected such Proposed Arbitrator
may select one (1) of the other two (2) Proposed Arbitrators within three (3) calendar days of the date the chosen Proposed Arbitrator
declines or notifies the parties he or she is unable to serve as arbitrator. If all three (3) Proposed Arbitrators decline or are otherwise
unable to serve as arbitrator, then the arbitrator selection process shall begin again in accordance with this Paragraph 4.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) The date that the Proposed
Arbitrator selected pursuant to this Paragraph 4.2 agrees in writing (including via email) delivered to both parties to serve as the arbitrator
hereunder is referred to herein as the &ldquo;<B>Arbitration Commencement Date</B>&rdquo;. If an arbitrator resigns or is unable to act
during the Arbitration, a replacement arbitrator shall be chosen in accordance with this Paragraph 4.2 to continue the Arbitration. If
Utah ADR Services ceases to exist or to provide a list of neutrals and there is no successor thereto, then the arbitrator shall be selected
under the then prevailing rules of the American Arbitration Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e) Subject to Paragraph 4.10
below, the cost of the arbitrator must be paid equally by both parties. Subject to Paragraph 4.10 below, if one party refuses or fails
to pay its portion of the arbitrator fee, then the other party can advance such unpaid amount (subject to the accrual of Default Interest
thereupon), with such amount being added to or subtracted from, as applicable, the Arbitration Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.3 <I>Applicability of Certain
Utah Rules</I>. The parties agree that the Arbitration shall be conducted generally in accordance with the Utah Rules of Civil Procedure
and the Utah Rules of Evidence. More specifically, the Utah Rules of Civil Procedure shall apply, without limitation, to the filing of
any pleadings, motions or memoranda, the conducting of discovery, and the taking of any depositions. The Utah Rules of Evidence shall
apply to any hearings, whether telephonic or in person, held by the arbitrator. Notwithstanding the foregoing, it is the parties&rsquo;
intent that the incorporation of such rules will in no event supersede these Arbitration Provisions. In the event of any conflict between
the Utah Rules of Civil Procedure or the Utah Rules of Evidence and these Arbitration Provisions, these Arbitration Provisions shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.4 <I>Answer and Default</I>.
An answer and any counterclaims to the Arbitration Notice shall be required to be delivered to the party initiating the Arbitration within
twenty (20) calendar days after the Arbitration Commencement Date. If an answer is not delivered by the required deadline, the arbitrator
must provide written notice to the defaulting party stating that the arbitrator will enter a default award against such party if such
party does not file an answer within five (5) calendar days of receipt of such notice. If an answer is not filed within the five (5) day
extension period, the arbitrator must render a default award, consistent with the relief requested in the Arbitration Notice, against
a party that fails to submit an answer within such time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><I>Arbitration Provisions,</I> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.5 <I>Related Litigation</I>.
The party that delivers the Arbitration Notice to the other party shall have the option to also commence concurrent legal proceedings
with any state or federal court sitting in Salt Lake County, Utah (&ldquo;<B>Litigation Proceedings</B>&rdquo;), subject to the following:
(a) the complaint in the Litigation Proceedings is to be substantially similar to the claims set forth in the Arbitration Notice, provided
that an additional cause of action to compel arbitration will also be included therein, (b) so long as the other party files an answer
to the complaint in the Litigation Proceedings and an answer to the Arbitration Notice, the Litigation Proceedings will be stayed pending
an Arbitration Award (or Appeal Panel Award (defined below), as applicable) hereunder, (c) if the other party fails to file an answer
in the Litigation Proceedings or an answer in the Arbitration proceedings, then the party initiating Arbitration shall be entitled to
a default judgment consistent with the relief requested, to be entered in the Litigation Proceedings, and (d) any legal or procedural
issue arising under the Arbitration Act that requires a decision of a court of competent jurisdiction may be determined in the Litigation
Proceedings. Any award of the arbitrator (or of the Appeal Panel (defined below)) may be entered in such Litigation Proceedings pursuant
to the Arbitration Act. In the event either party successfully petitions a court to compel arbitration, the losing party in such action
shall be required to pay the prevailing party&rsquo;s reasonable attorneys&rsquo; fees and costs incurred in connection with such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.6 <I>Discovery</I>. Pursuant
to Section 118(8) of the Arbitration Act, the parties agree that discovery shall be conducted as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) Written discovery will only
be allowed if the likely benefits of the proposed written discovery outweigh the burden or expense thereof, and the written discovery
sought is likely to reveal information that will satisfy a specific element of a claim or defense already pleaded in the Arbitration.
The party seeking written discovery shall always have the burden of showing that all of the standards and limitations set forth in these
Arbitration Provisions are satisfied. The scope of discovery in the Arbitration proceedings shall also be limited as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) To facts directly
connected with the transactions contemplated by the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) To facts and information
that cannot be obtained from another source or in another manner that is more convenient, less burdensome or less expensive than in the
manner requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) No party shall be allowed
(i) more than fifteen (15) interrogatories (including discrete subparts), (ii) more than fifteen (15) requests for admission (including
discrete subparts), (iii) more than ten (10) document requests (including discrete subparts), or (iv) more than three (3) depositions
(excluding expert depositions) for a maximum of seven (7) hours per deposition. The costs associated with depositions will be borne by
the party taking the deposition. The party defending the deposition will submit a notice to the party taking the deposition of the estimated
reasonable attorneys&rsquo; fees that such party expects to incur in connection with defending the deposition. If the party defending
the deposition fails to submit an estimate of reasonable attorneys&rsquo; fees within five (5) calendar days of its receipt of a deposition
notice, then such party shall be deemed to have waived its right to the estimated reasonable attorneys&rsquo; fees. The party taking the
deposition must pay the party defending the deposition the estimated reasonable attorneys&rsquo; fees prior to taking the deposition,
unless such obligation is deemed to be waived as set forth in the immediately preceding sentence. If the party taking the deposition believes
that the estimated reasonable attorneys&rsquo; fees are unreasonable, such party may submit the issue to the arbitrator for a decision.
All depositions will be taken in Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) All discovery requests (including
document production requests included in deposition notices) must be submitted in writing to the arbitrator and the other party. The party
submitting the written discovery requests must include with such discovery requests a detailed explanation of how the proposed discovery
requests satisfy the requirements of these Arbitration Provisions and the Utah Rules of Civil Procedure. The receiving party will then
be allowed, within five (5) calendar days of receiving the proposed discovery requests, to submit to the arbitrator an estimate of the
reasonable attorneys&rsquo; fees and costs associated with responding to such written discovery requests and a written challenge to each
applicable discovery request. After receipt of an estimate of reasonable attorneys&rsquo; fees and costs and/or challenge(s) to one or
more discovery requests, consistent with subparagraph (c) above, the arbitrator will within three (3) calendar days make a finding as
to the likely reasonable attorneys&rsquo; fees and costs associated with responding to the discovery requests and issue an order that
(i) requires the requesting party to prepay the reasonable attorneys&rsquo; fees and costs associated with responding to the discovery
requests, and (ii) requires the responding party to respond to the discovery requests as limited by the arbitrator within twenty-five
(25) calendar days of the arbitrator&rsquo;s finding with respect to such discovery requests. If a party entitled to submit an estimate
of reasonable attorneys&rsquo; fees and costs and/or a challenge to discovery requests fails to do so within such 5-day period, the arbitrator
will make a finding that (A) there are no reasonable attorneys&rsquo; fees or costs associated with responding to such discovery requests,
and (B) the responding party must respond to such discovery requests (as may be limited by the arbitrator) within twenty-five (25) calendar
days of the arbitrator&rsquo;s finding with respect to such discovery requests. Any party submitting any written discovery requests, including
without limitation interrogatories, requests for production subpoenas to a party or a third party, or requests for admissions, must prepay
the estimated reasonable attorneys&rsquo; fees and costs, before the responding party has any obligation to produce or respond to the
same, unless such obligation is deemed waived as set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><I>Arbitration Provisions,</I> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) In order to allow a written
discovery request, the arbitrator must find that the discovery request satisfies the standards set forth in these Arbitration Provisions
and the Utah Rules of Civil Procedure. The arbitrator must strictly enforce these standards. If a discovery request does not satisfy any
of the standards set forth in these Arbitration Provisions or the Utah Rules of Civil Procedure, the arbitrator may modify such discovery
request to satisfy the applicable standards, or strike such discovery request in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e) Each party may submit expert
reports (and rebuttals thereto), provided that such reports must be submitted within sixty (60) days of the Arbitration Commencement Date.
Each party will be allowed a maximum of two (2) experts. Expert reports must contain the following: (i) a complete statement of all opinions
the expert will offer at trial and the basis and reasons for them; (ii) the expert&rsquo;s name and qualifications, including a list of
all the expert&rsquo;s publications within the preceding ten (10) years, and a list of any other cases in which the expert has testified
at trial or in a deposition or prepared a report within the preceding ten (10) years; and (iii) the compensation to be paid for the expert&rsquo;s
report and testimony. The parties are entitled to depose any other party&rsquo;s expert witness one (1) time for no more than four (4)
hours. An expert may not testify in a party&rsquo;s case-in-chief concerning any matter not fairly disclosed in the expert report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.7 <I>Dispositive Motions</I>.
Each party shall have the right to submit dispositive motions pursuant Rule 12 or Rule 56 of the Utah Rules of Civil Procedure (a &ldquo;<B>Dispositive
Motion</B>&rdquo;). The party submitting the Dispositive Motion may, but is not required to, deliver to the arbitrator and to the other
party a memorandum in support (the &ldquo;<B>Memorandum in Support</B>&rdquo;) of the Dispositive Motion. Within seven (7) calendar days
of delivery of the Memorandum in Support, the other party shall deliver to the arbitrator and to the other party a memorandum in opposition
to the Memorandum in Support (the &ldquo;<B>Memorandum in Opposition</B>&rdquo;). Within seven (7) calendar days of delivery of the Memorandum
in Opposition, as applicable, the party that submitted the Memorandum in Support shall deliver to the arbitrator and to the other party
a reply memorandum to the Memorandum in Opposition (&ldquo;<B>Reply Memorandum</B>&rdquo;). If the applicable party shall fail to deliver
the Memorandum in Opposition as required above, or if the other party fails to deliver the Reply Memorandum as required above, then the
applicable party shall lose its right to so deliver the same, and the Dispositive Motion shall proceed regardless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.8 <I>Confidentiality</I>. All
information disclosed by either party (or such party&rsquo;s agents) during the Arbitration process (including without limitation information
disclosed during the discovery process or any Appeal (defined below)) shall be considered confidential in nature. Each party agrees not
to disclose any confidential information received from the other party (or its agents) during the Arbitration process (including without
limitation during the discovery process or any Appeal) unless (a) prior to or after the time of disclosure such information becomes public
knowledge or part of the public domain, not as a result of any inaction or action of the receiving party or its agents, (b) such information
is required by a court order, subpoena or similar legal duress to be disclosed if such receiving party has notified the other party thereof
in writing and given it a reasonable opportunity to obtain a protective order from a court of competent jurisdiction prior to disclosure,
or (c) such information is disclosed to the receiving party&rsquo;s agents, representatives and legal counsel on a need to know basis
who each agree in writing not to disclose such information to any third party. Pursuant to Section 118(5) of the Arbitration Act, the
arbitrator is hereby authorized and directed to issue a protective order to prevent the disclosure of privileged information and confidential
information upon the written request of either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.9 <I>Authorization; Timing;
Scheduling Order</I>. Subject to all other sections of these Arbitration Provisions, the parties hereby authorize and direct the arbitrator
to take such actions and make such rulings as may be necessary to carry out the parties&rsquo; intent for the Arbitration proceedings
to be efficient and expeditious. Pursuant to Section 120 of the Arbitration Act, the parties hereby agree that an Arbitration Award must
be made within one hundred twenty (120) calendar days after the Arbitration Commencement Date. The arbitrator is hereby authorized and
directed to hold a scheduling conference within ten (10) calendar days after the Arbitration Commencement Date in order to establish a
scheduling order with various binding deadlines for discovery, expert testimony, and the submission of documents by the parties to enable
the arbitrator to render a decision prior to the end of such 120-day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.10 <I>Relief</I>. The arbitrator
shall have the right to award or include in the Arbitration Award (or in a preliminary ruling) any relief which the arbitrator deems proper
under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the arbitrator may not
award exemplary or punitive damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.11 <I>Fees and Costs</I>. As
part of the Arbitration Award, the arbitrator is hereby directed to require the losing party (the party being awarded the least amount
of money by the arbitrator, which, for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees,
or other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of the Arbitration, and (b) reimburse the
prevailing party for all reasonable attorneys&rsquo; fees, arbitrator costs and fees, deposition costs, other discovery costs, and other
expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><I>Arbitration Provisions,</I> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">4.12 <I>Motion to Vacate</I>.
Following the entry of the Arbitration Award, if either party desires to file a Motion to Vacate the Arbitration Award with a court in
Salt Lake County, Utah, it must do so within the earlier of: (a) thirty (30) days of entry of the Arbitration Award; and (b) in response
to the prevailing party&rsquo;s Motion to Confirm the Arbitration Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. <U>Arbitration Appeal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5.1 <I>Initiation of Appeal.
</I>Following the entry of the Arbitration Award, either party (the &ldquo;<B>Appellant</B>&rdquo;) shall have a period of thirty (30)
calendar days in which to notify the other party (the &ldquo;<B>Appellee</B>&rdquo;), in writing, that the Appellant elects to appeal
(the &ldquo;<B>Appeal</B>&rdquo;) the Arbitration Award (such notice, an &ldquo;<B>Appeal Notice</B>&rdquo;) to a panel of arbitrators
as provided in Paragraph 5.2 below. The date the Appellant delivers an Appeal Notice to the Appellee is referred to herein as the &ldquo;<B>Appeal
Date</B>&rdquo;. The Appeal Notice must be delivered to the Appellee in accordance with the provisions of Paragraph 4.1 above with respect
to delivery of an Arbitration Notice. In addition, together with delivery of the Appeal Notice to the Appellee, the Appellant must also
pay for (and provide proof of such payment to the Appellee together with delivery of the Appeal Notice) a bond in the amount of 110% of
the sum the Appellant owes to the Appellee as a result of the Arbitration Award the Appellant is appealing. In the event an Appellant
delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of
this Paragraph 5.1, the Appeal will occur as a matter of right and, except as specifically set forth herein, will not be further conditioned.
In the event a party does not deliver an Appeal Notice (along with proof of payment of the applicable bond) to the other party within
the deadline prescribed in this Paragraph 5.1, such party shall lose its right to appeal the Arbitration Award. The Arbitration Award
will be considered final until the Appeal Notice has been properly delivered and the applicable appeal bond has been posted (along with
proof of payment of the applicable bond). The parties acknowledge and agree that any Appeal shall be deemed part of the parties&rsquo;
agreement to arbitrate for purposes of these Arbitration Provisions and the Arbitration Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5.2 <I>Selection and Payment
of Appeal Panel. </I>In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable
bond) in compliance with the provisions of Paragraph 5.1 above, the Appeal will be heard by a three (3) person arbitration panel (the
&ldquo;<B>Appeal Panel</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) Within ten (10) calendar
days after the Appeal Date, the Appellee shall select and submit to the Appellant the names of five (5) arbitrators that are designated
as &ldquo;neutrals&rdquo; or qualified arbitrators by Utah ADR Services (<U>http://www.utahadrservices.com</U>) (such five (5) designated
persons hereunder are referred to herein as the &ldquo;<B>Proposed Appeal Arbitrators</B>&rdquo;). For the avoidance of doubt, each Proposed
Appeal Arbitrator must be qualified as a &ldquo;neutral&rdquo; with Utah ADR Services, and shall not be the arbitrator who rendered the
Arbitration Award being appealed (the &ldquo;<B>Original Arbitrator</B>&rdquo;). Within five (5) calendar days after the Appellee has
submitted to the Appellant the names of the Proposed Appeal Arbitrators, the Appellant must select, by written notice to the Appellee,
three (3) of the Proposed Appeal Arbitrators to act as the members of the Appeal Panel. If the Appellant fails to select three (3) of
the Proposed Appeal Arbitrators in writing within such 5-day period, then the Appellee may select such three (3) arbitrators from the
Proposed Appeal Arbitrators by providing written notice of such selection to the Appellant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) If the Appellee fails to
submit to the Appellant the names of the Proposed Appeal Arbitrators within ten (10) calendar days after the Appeal Date pursuant to subparagraph
(a) above, then the Appellant may at any time prior to the Appellee so designating the Proposed Appeal Arbitrators, identify the names
of five (5) arbitrators that are designated as &ldquo;neutrals&rdquo; or qualified arbitrators by Utah ADR Service (none of whom may be
the Original Arbitrator) by written notice to the Appellee. The Appellee may then, within five (5) calendar days after the Appellant has
submitted notice of its selected arbitrators to the Appellee, select, by written notice to the Appellant, three (3) of such selected arbitrators
to serve on the Appeal Panel. If the Appellee fails to select in writing within such 5-day period three (3) of the arbitrators selected
by the Appellant to serve as the members of the Appeal Panel, then the Appellant may select the three (3) members of the Appeal Panel
from the Appellant&rsquo;s list of five (5) arbitrators by providing written notice of such selection to the Appellee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) If a selected Proposed Appeal
Arbitrator declines or is otherwise unable to serve, then the party that selected such Proposed Appeal Arbitrator may select one (1) of
the other five (5) designated Proposed Appeal Arbitrators within three (3) calendar days of the date a chosen Proposed Appeal Arbitrator
declines or notifies the parties he or she is unable to serve as an arbitrator. If at least three (3) of the five (5) designated Proposed
Appeal Arbitrators decline or are otherwise unable to serve, then the Proposed Appeal Arbitrator selection process shall begin again in
accordance with this Paragraph 5.2; <I>provided, however</I>, that any Proposed Appeal Arbitrators who have already agreed to serve shall
remain on the Appeal Panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><I>Arbitration Provisions,</I> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) The date that all three (3)
Proposed Appeal Arbitrators selected pursuant to this Paragraph 5.2 agree in writing (including via email) delivered to both the Appellant
and the Appellee to serve as members of the Appeal Panel hereunder is referred to herein as the &ldquo;<B>Appeal Commencement Date</B>&rdquo;.
No later than five (5) calendar days after the Appeal Commencement Date, the Appellee shall designate in writing (including via email)
to the Appellant and the Appeal Panel the name of one (1) of the three (3) members of the Appeal Panel to serve as the lead arbitrator
in the Appeal proceedings. Each member of the Appeal Panel shall be deemed an arbitrator for purposes of these Arbitration Provisions
and the Arbitration Act, provided that, in conducting the Appeal, the Appeal Panel may only act or make determinations upon the approval
or vote of no less than the majority vote of its members, as announced or communicated by the lead arbitrator on the Appeal Panel. <FONT STYLE="background-color: white">If
an arbitrator on the Appeal Panel ceases or is unable to act during the Appeal proceedings, a replacement arbitrator shall be chosen in
accordance with Paragraph 5.2 above to continue the Appeal as a member of the Appeal Panel. </FONT>If Utah ADR Services ceases to exist
or to provide a list of neutrals, then the arbitrators for the Appeal Panel shall be selected under the then prevailing rules of the American
Arbitration Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) Subject to Paragraph 5.7
below, the cost of the Appeal Panel must be paid entirely by the Appellant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5.3 <I>Appeal Procedure. </I>The Appeal will be deemed
an appeal of the entire Arbitration Award. In conducting the Appeal, the Appeal Panel shall conduct a de novo review of all Claims described
or otherwise set forth in the Arbitration Notice. Subject to the foregoing and all other provisions of this Paragraph 5, the Appeal Panel
shall conduct the Appeal in a manner the Appeal Panel considers appropriate for a fair and expeditious disposition of the Appeal, may
hold one or more hearings and permit oral argument, and may review all previous evidence and discovery, together with all briefs, pleadings
and other documents filed with the Original Arbitrator (as well as any documents filed with the Appeal Panel pursuant to Paragraph 5.4(a)
below). Notwithstanding the foregoing, in connection with the Appeal, the Appeal Panel shall not permit the parties to conduct any additional
discovery or raise any new Claims to be arbitrated, shall not permit new witnesses or affidavits, and shall not base any of its findings
or determinations on the Original Arbitrator&rsquo;s findings or the Arbitration Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5.4 <I>Timing. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) Within seven (7) calendar days
of the Appeal Commencement Date, the Appellant (i) shall deliver or cause to be delivered to the Appeal Panel copies of the Appeal Notice,
all discovery conducted in connection with the Arbitration, and all briefs, pleadings and other documents filed with the Original Arbitrator
(which material Appellee shall have the right to review and supplement if necessary), and (ii) may, but is not required to, deliver to
the Appeal Panel and to the Appellee a Memorandum in Support of the Appellant&rsquo;s arguments concerning or position with respect to
all Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration. Within seven (7) calendar days of the Appellant&rsquo;s
delivery of the Memorandum in Support, as applicable, the Appellee shall deliver to the Appeal Panel and to the Appellant a Memorandum
in Opposition to the Memorandum in Support. Within seven (7) calendar days of the Appellee&rsquo;s delivery of the Memorandum in Opposition,
as applicable, the Appellant shall deliver to the Appeal Panel and to the Appellee a Reply Memorandum to the Memorandum in Opposition.
If the Appellant shall fail to substantially comply with the requirements of clause (i) of this subparagraph (a), the Appellant shall
lose its right to appeal the Arbitration Award, and the Arbitration Award shall be final. If the Appellee shall fail to deliver the Memorandum
in Opposition as required above, or if the Appellant shall fail to deliver the Reply Memorandum as required above, then the Appellee or
the Appellant, as the case may be, shall lose its right to so deliver the same, and the Appeal shall proceed regardless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) Subject to subparagraph (a)
above, the parties hereby agree that the Appeal must be heard by the Appeal Panel within thirty (30) calendar days of the Appeal Commencement
Date, and that the Appeal Panel must render its decision within thirty (30) calendar days after the Appeal is heard (and in no event later
than sixty (60) calendar days after the Appeal Commencement Date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5.5 <I>Appeal Panel Award. </I>The Appeal Panel shall
issue its decision (the &ldquo;<B>Appeal Panel Award</B>&rdquo;) through the lead arbitrator on the Appeal Panel. Notwithstanding any
other provision contained herein, the Appeal Panel Award shall (a) supersede in its entirety and make of no further force or effect the
Arbitration Award (provided that any protective orders issued by the Original Arbitrator shall remain in full force and effect), (b) be
final and binding upon the parties, with no further rights of appeal, (c) be the sole and exclusive remedy between the parties regarding
any Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration, and (d) be promptly payable in United States
dollars free of any tax, deduction or offset (with respect to monetary awards). Any costs or fees, including without limitation reasonable
attorneys&rsquo; fees, incurred in connection with or incident to enforcing the Appeal Panel Award shall, to the maximum extent permitted
by law, be charged against the party resisting such enforcement. The Appeal Panel Award shall include Default Interest (with respect to
monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration Award. Judgment upon the
Appeal Panel Award will be entered and enforced by a state or federal court sitting in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><I>Arbitration Provisions,</I> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5.6 <I>Relief. </I>The Appeal Panel shall have the
right to award or include in the Appeal Panel Award any relief which the Appeal Panel deems proper under the circumstances, including,
without limitation, specific performance and injunctive relief, provided that the Appeal Panel may not award exemplary or punitive damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">5.7 <I>Fees and Costs. </I>As part of the Appeal Panel
Award, the Appeal Panel is hereby directed to require the losing party (the party being awarded the least amount of money by the arbitrator,
which, for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees, or other charges awarded
to any party) to (a) pay the full amount of any unpaid costs and fees of the Arbitration and the Appeal Panel, and (b) reimburse the prevailing
party (the party being awarded the most amount of money by the Appeal Panel, which, for the avoidance of doubt, shall be determined without
regard to any statutory fines, penalties, fees, or other charges awarded to any party) the reasonable attorneys&rsquo; fees, arbitrator
and Appeal Panel costs and fees, deposition costs, other discovery costs, and other expenses, costs or fees paid or otherwise incurred
by the prevailing party in connection with the Arbitration (including without limitation in connection with the Appeal).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">6. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">6.1 <I>Severability. </I>If any
part of these Arbitration Provisions is found to violate or be illegal under applicable law, then such provision shall be modified to
the minimum extent necessary to make such provision enforceable under applicable law, and the remainder of the Arbitration Provisions
shall remain unaffected and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">6.2 <I>Governing Law</I>. These
Arbitration Provisions shall be governed by the laws of the State of Utah without regard to the conflict of laws principles therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">6.3 <I>Interpretation</I>. The
headings of these Arbitration Provisions are for convenience of reference only and shall not form part of, or affect the interpretation
of, these Arbitration Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">6.4 <I>Waiver</I>. No waiver
of any provision of these Arbitration Provisions shall be effective unless it is in the form of a writing signed by the party granting
the waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">6.5 <I>Time is of the Essence</I>.
Time is expressly made of the essence with respect to each and every provision of these Arbitration Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Remainder of page intentionally left blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><I>Arbitration Provisions,</I> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ex10-2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.2</B></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURED
PROMISSORY NOTE A-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective Date:
  June <R>2,</R> 2026</FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> U.S. $2,720,000.00</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, <FONT STYLE="font-variant: small-caps">Imunon, Inc.</FONT>, a Delaware corporation (&ldquo;<B>Borrower</B>&rdquo;), promises
to pay to <FONT STYLE="font-variant: small-caps">Streeterville Capital, LLC</FONT>, a Utah limited liability company, or its successors
or assigns (&ldquo;<B>Lender</B>&rdquo;), $2,720,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date
that is eighteen (18) months after the Purchase Price Date (the &ldquo;<B>Maturity Date</B>&rdquo;) in accordance with the terms set
forth herein and to pay interest on the Outstanding Balance at the rate of eight percent (8%) per annum from the Purchase Price Date
until the same is paid in full. All interest calculations hereunder shall be computed on the basis of a 360-day year comprised of twelve
(12) thirty (30) day months, shall compound daily and shall be payable in accordance with the terms of this Note. This Secured Promissory
Note A-1 (this &ldquo;<B>Note</B>&rdquo;) is issued and made effective as of June <R>2,</R> 2026 (the &ldquo;<B>Effective Date</B>&rdquo;).
This Note is issued pursuant to that certain Securities Purchase Agreement dated June <R>2,</R> 2026, as the same may be amended from
time to time, by and between Borrower and Lender (the &ldquo;<B>Purchase Agreement</B>&rdquo;). Certain capitalized terms used herein
are defined in <U>Attachment 1</U> attached hereto and incorporated herein by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Note carries an original issue discount of $200,000.00 (the &ldquo;<B>OID</B>&rdquo;). In addition, Borrower agrees to pay $20,000.00
to Lender to cover Lender&rsquo;s legal, accounting and due diligence expenses incurred in connection with the purchase and sale of this
Note (the &ldquo;<B>Transaction Expense Amount</B>&rdquo;). The OID and the Transaction Expense Amount are included in the initial principal
balance of this Note and are deemed to be fully earned and non-refundable as of the Purchase Price Date. The purchase price for this
Note shall be $2,500,000.00 (the &ldquo;<B>Purchase Price</B>&rdquo;), computed as follows: $2,720,000.00 original principal balance,
less the OID and the Transaction Expense Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Payment;
Prepayment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1. <U>Payment</U>.
All payments owing hereunder shall be in lawful money of the United States of America and delivered to Lender at the address or bank
account furnished by Lender to Borrower for that purpose. All payments shall be applied first to (a) Lender&rsquo;s reasonable costs
of collection, if any, then to (b) fees and charges, if any, then to (c) accrued and unpaid interest, and thereafter, to (d) principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2. <U>Prepayment</U>.
Borrower may pay all or any portion of the Outstanding Balance earlier than it is due. If Borrower exercises its right to prepay this
Note, Borrower shall make payment to Lender of an amount in cash equal to 110% multiplied by the portion of the Outstanding Balance Borrower
elects to prepay. Early payments of less than all principal, fees and interest outstanding will not, unless agreed to by Lender in writing,
relieve Borrower of Borrower&rsquo;s remaining obligations hereunder. For the avoidance of doubt, any payments made pursuant to Sections
3.1 or 3.2 hereof shall not be considered prepayments by the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Security</U>.
Borrower&rsquo;s obligations under this Note are secured by the DACA and the Collateral Agreements (as defined in the Purchase Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <U>Redemptions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1. <U>Monthly
Redemptions</U>. Beginning on the six (6) month anniversary of the Purchase Price Date, Lender shall have the right, exercisable at any
time in its sole and absolute discretion, to redeem up to the Maximum Monthly Redemption Amount (such amount, the &ldquo;<B>Redemption
Amount</B>&rdquo;) per calendar month by providing written notice to Borrower (each, a &ldquo;<B>Redemption Notice</B>&rdquo;). The Maximum
Monthly Redemption Amount will be aggregated with redemptions submitted by Lender under all other A Notes (as defined in the Purchase
Agreement). For the avoidance of doubt, Lender may submit to Borrower one (1) or more Redemption Notices in any given calendar month.
Upon receipt of a Redemption Notice, Borrower shall pay the applicable Redemption Amount to Lender within two (2) Trading Days (the &ldquo;<B>Redemption
Amount Due Date</B>&rdquo;). If Borrower fails to pay the Redemption Amount on or before the Redemption Amount Due Date, the Outstanding
Balance shall automatically and without further action by any party be increased on a one-time basis by an amount equal to twenty percent
(20%) of the Redemption Amount (the &ldquo;<B>Redemption Failure Balance Increase Amount</B>&rdquo;). For the avoidance of doubt, the
failure by Borrower to pay the Redemption Amount on or before the Redemption Amount Due Date shall not be considered a Trigger Event
(as defined below). Upon such failure to pay the Redemption Amount by the Redemption Amount Due Date, Borrower shall then pay the Redemption
Amount plus the Redemption Failure Balance Increase Amount, within three (3) Trading Days of the date of the Redemption Failure Balance
Increase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2. <U>Limited
Redemptions</U>. Beginning on the six (6) month anniversary of the Purchase Price Date, if at any time thereafter a Limited Redemption
Event occurs, Lender shall have the right to submit a Redemption Notice in an amount up to the Maximum Limited Redemption Amount at any
time during the applicable Limited Redemption Window (&ldquo;<B>Limited Redemptions</B>&rdquo;). The Maximum Limited Redemption Amount
will be aggregated with Limited Redemptions made under all outstanding Notes (as defined in the Purchase Agreement). Borrower must pay
the applicable Limited Redemption amount to Lender within two (2) Trading Days of delivery of the applicable Redemption Notice. For the
avoidance of doubt, Limited Redemptions will not count toward the Maximum Monthly Redemption Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <U>Trigger
Events; Defaults; Remedies</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1. <U>Trigger
Events</U>. The following are trigger events under this Note (each, a &ldquo;<B>Trigger Event</B>&rdquo;): (a) Borrower fails to pay
any principal, interest, fees, charges, or any other amount hereunder when due and payable hereunder; (b) a receiver, trustee or other
similar official shall be appointed over Borrower or a material part of its assets and such appointment shall remain uncontested for
thirty (30) days or shall not be dismissed or discharged within sixty (60) days; (c) Borrower becomes insolvent or generally fails to
pay, or admits in writing its inability to pay, its debts as they become due, subject to applicable grace periods, if any; (d) Borrower
makes a general assignment for the benefit of creditors; (e) Borrower files a petition for relief under any bankruptcy, insolvency or
similar law (domestic or foreign); (f) an involuntary bankruptcy proceeding is commenced or filed against Borrower and such involuntary
bankruptcy proceeding shall remain uncontested for thirty (30) days or shall not be dismissed or discharged within sixty (60) days; (g)
Borrower fails to observe or perform any covenant set forth in Section 4 of the Purchase Agreement; (h) the occurrence of a Fundamental
Transaction without Lender&rsquo;s prior written consent; (i) Borrower defaults or otherwise fails to observe or perform any covenant,
obligation, condition or agreement contained herein or in any other Transaction Document (as defined in the Purchase Agreement), other
than those specifically set forth in this Section 4.1 and Section 4 of the Purchase Agreement and such default or failure continues uncured
for five (5) days; (j) any representation, warranty or other statement made or furnished by or on behalf of Borrower to Lender herein,
in any Transaction Document, or otherwise in connection with the issuance of this Note is false, incorrect, incomplete or misleading
in any material respect when made or furnished; (k) any money judgment, writ or similar process is entered or filed against Borrower
or any subsidiary of Borrower or any of its property or other assets for more than $250,000.00, and shall remain unvacated, unbonded
or unstayed for a period of thirty (30) calendar days unless otherwise consented to by Lender; (l) Borrower breaches any covenant or
other term or condition contained in any Other Agreements; and (m) Borrower receives a delisting determination notice from the Nasdaq
Listing Qualifications Department and such delisting notice is not stayed or otherwise resolved for a period of thirty (30) calendar
days;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2. <U>Trigger
Event Remedies</U>. At any time following the occurrence of any Trigger Event, Lender may, at its option, increase the Outstanding Balance
by applying the Trigger Effect (subject to the limitation set forth below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3. <U>Defaults</U>.
At any time following the occurrence of a Trigger Event, Lender may, at its option, send written notice to Borrower demanding that Borrower
cure such Trigger Event within five (5) Trading Days. If Borrower fails to cure the Trigger Event within the required five (5) Trading
Day cure period, the Trigger Event will automatically become an event of default hereunder (an &ldquo;<B>Event of Default</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4. <U>Default
Remedies</U>. At any time and from time to time following the occurrence of any Event of Default, Lender may accelerate this Note by
written notice to Borrower, with the Outstanding Balance becoming immediately due and payable in cash at the Mandatory Default Amount.
Notwithstanding the foregoing, upon the occurrence of any Trigger Event described in clauses 4.1(b) - 4.1(f), an Event of Default will
be deemed to have occurred and the Outstanding Balance as of the date of the occurrence of such Trigger Event shall become immediately
and automatically due and payable in cash at the Mandatory Default Amount, without any written notice required by Lender for the Trigger
Event to become an Event of Default. At any time following the occurrence of any Event of Default, upon written notice given by Lender
to Borrower, interest shall accrue on the Outstanding Balance beginning on the date the applicable Event of Default occurred at an interest
rate equal to the lesser of fifteen percent (15%) per annum or the maximum rate permitted under applicable law (&ldquo;<B>Default Interest</B>&rdquo;).
In connection with acceleration described herein, Lender need not provide, and Borrower hereby waives, any presentment, demand, protest
or other notice of any kind, and Lender may immediately and without expiration of any grace period enforce any and all of its rights
and remedies hereunder and all other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by
Lender at any time prior to payment hereunder and Lender shall have all rights as a holder of the Note until such time, if any, as Lender
receives full payment pursuant to this Section 4.4. No such rescission or annulment shall affect any subsequent Trigger Event or Event
of Default or impair any right consequent thereon. Nothing herein shall limit Lender&rsquo;s right to pursue any other remedies available
to it at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <U>Unconditional
Obligation; No Offset</U>. Borrower acknowledges that this Note is an unconditional, valid, binding and enforceable obligation of Borrower
not subject to offset, deduction or counterclaim of any kind. Borrower hereby waives any rights of offset it now has or may have hereafter
against Lender, its successors and assigns, and agrees to make the payments called for herein in accordance with the terms of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <U>Waiver</U>.
No waiver of any provision of this Note shall be effective unless it is in the form of a writing signed by the party granting the waiver.
No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to any other
prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a party to
provide a waiver or consent in the future except to the extent specifically set forth in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <U>Opinion
of Counsel</U>. In the event that an opinion of counsel is needed for any matter related to this Note, Lender has the right to have any
such opinion provided by its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. <U>Governing
Law; Venue</U>. This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity,
interpretation and performance of this Note shall be governed by, the internal laws of the State of Utah, without giving effect to any
choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdiction) that would cause the application
of the laws of any jurisdiction other than the State of Utah. The provisions set forth in the Purchase Agreement to determine the proper
venue for any disputes are incorporated herein by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <U>Arbitration
of Disputes</U>. By its issuance or acceptance of this Note, each party agrees to be bound by the Arbitration Provisions (as defined
in the Purchase Agreement) set forth as an exhibit to the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <U>Cancellation</U>.
After repayment of the entire Outstanding Balance, this Note shall be deemed paid in full, shall automatically be deemed canceled, and
shall not be reissued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <U>Amendments</U>.
The prior written consent of both parties hereto shall be required for any change or amendment to this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. <U>Assignments</U>.
Borrower may not assign this Note without the prior written consent of Lender. This Note may be offered, sold, assigned or transferred
by Lender to any of its affiliates or any other person without the consent of Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. <U>Notices</U>.
Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with
the subsection of the Purchase Agreement titled &ldquo;Notices.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. <U>Liquidated
Damages</U>. Lender and Borrower agree that in the event Borrower fails to comply with any of the terms or provisions of this Note, Lender&rsquo;s
damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties&rsquo; inability to predict
future interest rates, future share prices, future trading volumes and other relevant factors. Accordingly, Lender and Borrower agree
that any fees, balance adjustments, Default Interest or other charges assessed under this Note are not penalties but instead are intended
by the parties to be, and shall be deemed, liquidated damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. <U>Severability</U>.
If any part of this Note is construed to be in violation of any law, such part shall be modified to achieve the objective of Borrower
and Lender to the fullest extent permitted by law and the balance of this Note shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Remainder
of page intentionally left blank; signature page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, Borrower has caused this Note to be duly executed as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BORROWER:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Imunon,
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Stacy R. Lindborg</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stacy
    R. Lindborg, Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ACKNOWLEDGED,
    ACCEPTED AND AGREED:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LENDER:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Streeterville
    Capital, LLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John Fife</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Fife, President</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Secured Promissory Note A-1]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATTACHMENT
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Note, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A1. &ldquo;<B>Common
Shares</B>&rdquo; means shares of Borrower&rsquo;s common stock, par value $0.01 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A2. &ldquo;<B>Fundamental
Transaction</B>&rdquo; means that (a) (i) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions,
consolidate or merge with or into (whether or not Borrower or any of its subsidiaries is the surviving corporation) any other person
or entity, (ii) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, sell, lease,
license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective properties or assets to any other
person or entity, (iii) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, allow
any other person or entity to make a purchase, tender or exchange offer that is accepted by the holders of more than fifty percent (50%)
of the outstanding shares of voting stock of Borrower (not including any shares of voting stock of Borrower held by the person or persons
making or party to, or associated or affiliated with the persons or entities making or party to, such purchase, tender or exchange offer),
(iv) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, consummate a stock or share
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme
of arrangement) with any other person or entity whereby such other person or entity acquires more than fifty percent (50%) of the outstanding
shares of voting stock of Borrower (not including any shares of voting stock of Borrower held by the other persons or entities making
or party to, or associated or affiliated with the other persons or entities making or party to, such stock or share purchase agreement
or other business combination), (v) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions,
reorganize, recapitalize or reclassify the Common Shares or preferred stock, other than an increase in the number of authorized Common
Shares, (vi) Borrower transfers any material asset to any subsidiary, affiliate, person or entity under common ownership or control with
Borrower, or (vii) Borrower pays or makes any monetary or non-monetary dividend or distribution to its shareholders; or (b) any &ldquo;person&rdquo;
or &ldquo;group&rdquo; (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act (as defined in the Purchase
Agreement) and the rules and regulations promulgated thereunder) is or shall become the &ldquo;beneficial owner&rdquo; (as defined in
Rule 13d-3 under the 1934 Act), directly or indirectly, of more than fifty percent (50%) of the aggregate ordinary voting power represented
by issued and outstanding voting stock of Borrower. For the avoidance of doubt, Borrower or any of its subsidiaries entering into a definitive
agreement that contemplates a Fundamental Transaction will be deemed to be a Fundamental Transaction unless such agreement contains a
closing condition that this Note is repaid in full upon consummation of the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A3. &ldquo;<B>Limited
Redemption Event</B>&rdquo; means that on any given Trading Day the Common Shares trade at a price that is at least fifteen percent (15%)
greater than the Nasdaq Minimum Price for such Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A4. &ldquo;<B>Limited
Redemption Window</B>&rdquo; means the period beginning on the date a Limited Redemption Event occurs and ending on the date that is
five (5) Trading Days after the date the Limited Redemption Event occurs. For the avoidance of doubt, more than one (1) Limited Redemption
Window may be open at the same time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A5. &ldquo;<B>Major
Trigger Event</B>&rdquo; means any Trigger Event occurring under Sections 4.1(a) - 4.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A6. &ldquo;<B>Mandatory
Default Amount</B>&rdquo; means the Outstanding Balance following the application of the Trigger Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A7. &ldquo;<B>Maximum
Limited Redemption Amount</B>&rdquo; means five percent (5%) of the cumulative daily dollar trading volume on the Trading Day that a
Limited Redemption Event occurs; measured as the cumulative dollar trading volume on all exchanges beginning at 4:01 PM Eastern Time
on the Trading Day before the occurrence of the Limited Redemption Event and ending at 4:00 PM Eastern Time on the Trading Day during
which the Limited Redemption Event occurs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A8. &ldquo;<B>Maximum
Monthly Redemption Amount</B>&rdquo; means $250,000.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A9. &ldquo;<B>Minor
Trigger Event</B>&rdquo; means any Trigger Event that is not a Major Trigger Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A10. &ldquo;<B>Nasdaq
Minimum Price</B>&rdquo; means the Minimum Price as defined under Nasdaq Rule 5635(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A11. &ldquo;<B>Other
Agreements</B>&rdquo; means, collectively, (a) all existing and future agreements and instruments between, among or by Borrower (or an
affiliate), on the one hand, and Lender (or an affiliate), on the other hand, and (b) any financing agreement or a material agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A12. &ldquo;<B>Outstanding
Balance</B>&rdquo; means as of any date of determination, the Purchase Price, as reduced or increased, as the case may be, pursuant to
the terms hereof for payment, offset, or otherwise, plus the OID, the Transaction Expense Amount, accrued but unpaid interest (including
Default Interest), collection and enforcements costs (including attorneys&rsquo; fees) incurred by Lender, transfer, stamp, issuance
and similar taxes and fees incurred under this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A13. &ldquo;<B>Purchase
Price Date</B>&rdquo; means the date the Purchase Price is delivered by Lender to Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A14. &ldquo;<B>Trading
Day</B>&rdquo; means any day on which Borrower&rsquo;s principal trading market (or such other principal market for the Common Shares)
is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A15. &ldquo;<B>Trigger
Effect</B>&rdquo; means multiplying the Outstanding Balance as of the date the applicable Trigger Event occurred by (a) fifteen percent
(15%) for each occurrence of any Major Trigger Event, or (b) five percent (5%) for each occurrence of any Minor Trigger Event, and then
adding the resulting product to the Outstanding Balance as of the date the applicable Trigger Event occurred, with the sum of the foregoing
then becoming the Outstanding Balance under this Note as of the date the applicable Trigger Event occurred; provided that the Trigger
Effect may only be applied three (3) times hereunder with respect to Major Trigger Events and three (3) times hereunder with respect
to Minor Trigger Events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>ex10-3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURED
PROMISSORY NOTE B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    Date: June <R>2,</R> 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    $5,000,000.00</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, <FONT STYLE="font-variant: small-caps">Imunon, Inc.</FONT>, a Delaware corporation (&ldquo;<B>Borrower</B>&rdquo;), promises
to pay to <FONT STYLE="font-variant: small-caps">Streeterville Capital, LLC</FONT>, a Utah limited liability company, or its successors
or assigns (&ldquo;<B>Lender</B>&rdquo;), $5,000,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date
that is eighteen (18) months after the Purchase Price Date (the &ldquo;<B>Maturity Date</B>&rdquo;) in accordance with the terms set
forth herein and to pay interest on the Outstanding Balance at the rate of five percent (5%) per annum from the Purchase Price Date until
the same is paid in full. All interest calculations hereunder shall be computed on the basis of a 360-day year comprised of twelve (12)&nbsp;thirty
(30)&nbsp;day months, shall compound daily and shall be payable in accordance with the terms of this Note. This Secured Promissory Note
B (this &ldquo;<B>Note</B>&rdquo;) is issued and made effective as of June <R>2,</R> 2026 (the &ldquo;<B>Effective Date</B>&rdquo;).
This Note is issued pursuant to that certain Securities Purchase Agreement dated June <R>2,</R> 2026, as the same may be amended from
time to time, by and between Borrower and Lender (the &ldquo;<B>Purchase Agreement</B>&rdquo;). Certain capitalized terms used herein
are defined in <U>Attachment 1</U> attached hereto and incorporated herein by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Payment; Prepayment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.
<U>Payment</U>. All payments owing hereunder shall be in lawful money of the United States of America and delivered to Lender at the
address or bank account furnished by Lender to Borrower for that purpose. All payments shall be applied first to (a) Lender&rsquo;s reasonable
costs of collection, if any, then to (b) fees and charges, if any, then to (c) accrued and unpaid interest, and thereafter, to (d) principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.
<U>Prepayment</U>. Borrower may pay all or any portion of the Outstanding Balance earlier than it is due. If Borrower exercises its right
to prepay this Note, Borrower shall make payment to Lender of an amount in cash equal to 110% multiplied by the portion of the Outstanding
Balance Borrower elects to prepay. Early payments of less than all principal, fees and interest outstanding will not, unless agreed to
by Lender in writing, relieve Borrower of Borrower&rsquo;s remaining obligations hereunder. For the avoidance of doubt, any payments
made pursuant to Section 2 hereof shall not be considered prepayments by the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Security</U>. Borrower&rsquo;s obligations under this Note are secured by the Collateral Agreements (as defined in the Purchase Agreement)
and the DACA (as defined in the Purchase Agreement). Borrower acknowledges and agrees that Lender is authorized to send a Lender Instruction
Notice (as defined in the DACA) to the Bank (as defined in the DACA) directing the disposition of the funds held in the Deposit Account
(as defined in the DACA): (a) upon the occurrence of a Trigger Event (as defined below); or (b) upon Lender&rsquo;s receipt of a notice
from Borrower pursuant to Section 4(vii) of the Purchase Agreement or otherwise becoming aware of the event necessitating the notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Limited Redemptions</U>. Beginning on six (6) month anniversary of the Purchase Price Date, if at any time thereafter a Limited Redemption
Event occurs, Lender shall have the right to submit a Redemption Notice in an amount up to the Maximum Limited Redemption Amount at any
time during the applicable Limited Redemption Window (&ldquo;<B>Limited Redemptions</B>&rdquo;). The Maximum Limited Redemption Amount
will be aggregated with Limited Redemptions made under any other outstanding Notes (as defined in the Purchase Agreement). Borrower must
pay the applicable Limited Redemption amount to Lender within two (2) Trading Days of delivery of the applicable Redemption Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Trigger Events; Defaults; Remedies</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.
<U>Trigger Events</U>. The following are trigger events under this Note (each, a &ldquo;<B>Trigger Event</B>&rdquo;): (a) Borrower fails
to pay any principal, interest, fees, charges, or any other amount when due and payable hereunder; (b) a receiver, trustee or other similar
official shall be appointed over Borrower or a material part of its assets and such appointment shall remain uncontested for thirty (30)
days or shall not be dismissed or discharged within sixty (60) days; (c) Borrower becomes insolvent or generally fails to pay, or admits
in writing its inability to pay, its debts as they become due, subject to applicable grace periods, if any; (d) Borrower makes a general
assignment for the benefit of creditors; (e) Borrower files a petition for relief under any bankruptcy, insolvency or similar law (domestic
or foreign); (f) an involuntary bankruptcy proceeding is commenced or filed against Borrower and such involuntary bankruptcy proceeding
shall remain uncontested for thirty (30) days or shall not be dismissed or discharged within sixty (60) days; (g) Borrower fails to observe
or perform any covenant set forth in Section 4 of the Purchase Agreement; (h) the occurrence of a Fundamental Transaction without Lender&rsquo;s
prior written consent; (i) Borrower defaults or otherwise fails to observe or perform any covenant, obligation, condition or agreement
contained herein or in any other Transaction Document (as defined in the Purchase Agreement), in any material respect, other than those
specifically set forth in this Section 4.1 and Section 4 of the Purchase Agreement and such default or failure continues uncured for
five (5) days; (j) any representation, warranty or other statement made or furnished by or on behalf of Borrower to Lender herein, in
any Transaction Document, or otherwise in connection with the issuance of this Note is false, incorrect, incomplete or misleading in
any material respect when made or furnished; (k) any money judgment, writ or similar process is entered or filed against Borrower or
any subsidiary of Borrower or any of its property or other assets for more than $250,000.00, and shall remain unvacated, unbonded or
unstayed for a period of thirty (30) calendar days unless otherwise consented to by Lender; (l) Borrower breaches any covenant or other
term or condition contained in any Other Agreements; and (m) Borrower receives a delisting determination notice from the Nasdaq Listing
Qualifications Department and such delisting notice is not stayed or otherwise resolved for a period of thirty (30) calendar days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.
<U>Trigger Event Remedies</U>. At any time following the occurrence of any Trigger Event, Lender may, at its option, increase the Outstanding
Balance by applying the Trigger Effect (subject to the limitation set forth below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.
<U>Defaults</U>. At any time following the occurrence of a Trigger Event, Lender may, at its option, send written notice to Borrower
demanding that Borrower cure such Trigger Event within five (5) Trading Days. If Borrower fails to cure the Trigger Event within the
required five (5) Trading Day cure period, the Trigger Event will automatically become an event of default hereunder (an &ldquo;<B>Event
of Default</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.
<U>Default Remedies</U>. At any time and from time to time following the occurrence of any Event of Default, Lender may accelerate this
Note by written notice to Borrower, with the Outstanding Balance becoming immediately due and payable in cash at the Mandatory Default
Amount. Notwithstanding the foregoing, upon the occurrence of any Trigger Event described in clauses 4.1(b) - 4.1(f), an Event of Default
will be deemed to have occurred and the Outstanding Balance as of the date of the occurrence of such Trigger Event shall become immediately
and automatically due and payable in cash at the Mandatory Default Amount, without any written notice required by Lender for the Trigger
Event to become an Event of Default. At any time following the occurrence of any Event of Default, upon written notice given by Lender
to Borrower, interest shall accrue on the Outstanding Balance beginning on the date the applicable Event of Default occurred at an interest
rate equal to the lesser of fifteen percent (15%) per annum or the maximum rate permitted under applicable law (&ldquo;<B>Default Interest</B>&rdquo;).
In connection with acceleration described herein, Lender need not provide, and Borrower hereby waives, any presentment, demand, protest
or other notice of any kind, and Lender may immediately and without expiration of any grace period enforce any and all of its rights
and remedies hereunder and all other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by
Lender at any time prior to payment hereunder and Lender shall have all rights as a holder of the Note until such time, if any, as Lender
receives full payment pursuant to this Section 4.4. No such rescission or annulment shall affect any subsequent Trigger Event or Event
of Default or impair any right consequent thereon. Nothing herein shall limit Lender&rsquo;s right to pursue any other remedies available
to it at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Unconditional Obligation; No Offset</U>. Borrower acknowledges that this Note is an unconditional, valid, binding and enforceable
obligation of Borrower not subject to offset, deduction or counterclaim of any kind. Borrower hereby waives any rights of offset it now
has or may have hereafter against Lender, its successors and assigns, and agrees to make the payments called for herein in accordance
with the terms of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Waiver</U>. No waiver of any provision of this Note shall be effective unless it is in the form of a writing signed by the party granting
the waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent
to any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit
a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Opinion of Counsel</U>. In the event that an opinion of counsel is needed for any matter related to this Note, Lender has the right
to have any such opinion provided by its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Governing Law; Venue</U>. This Note shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of Utah, without giving effect
to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdiction) that would cause the
application of the laws of any jurisdiction other than the State of Utah. The provisions set forth in the Purchase Agreement to determine
the proper venue for any disputes are incorporated herein by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Arbitration of Disputes</U>. By its issuance or acceptance of this Note, each party agrees to be bound by the Arbitration Provisions
(as defined in the Purchase Agreement) set forth as an exhibit to the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Cancellation</U>. After repayment of the entire Outstanding Balance, this Note shall be deemed paid in full, shall automatically be
deemed canceled, and shall not be reissued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Amendments</U>. The prior written consent of both parties hereto shall be required for any change or amendment to this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Assignments</U>. Borrower may not assign this Note without the prior written consent of Lender. This Note may be offered, sold, assigned
or transferred by Lender to any of its affiliates or any other person without the consent of Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Notices</U>. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given
in accordance with the subsection of the Purchase Agreement titled &ldquo;Notices.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Liquidated Damages</U>. Lender and Borrower agree that in the event Borrower fails to comply with any of the terms or provisions of
this Note, Lender&rsquo;s damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties&rsquo;
inability to predict future interest rates, future share prices, future trading volumes and other relevant factors. Accordingly, Lender
and Borrower agree that any fees, balance adjustments, Default Interest or other charges assessed under this Note are not penalties but
instead are intended by the parties to be, and shall be deemed, liquidated damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Severability</U>. If any part of this Note is construed to be in violation of any law, such part shall be modified to achieve the
objective of Borrower and Lender to the fullest extent permitted by law and the balance of this Note shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Remainder
of page intentionally left blank; signature page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, Borrower has caused this Note to be duly executed as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BORROWER:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Imunon,
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Stacy R. Lindborg </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stacy
    R. Lindborg, Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ACKNOWLEDGED,
ACCEPTED AND AGREED:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LENDER:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Streeterville
    Capital, LLC</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John Fife </I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Fife, President</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Secured Promissory Note B]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATTACHMENT
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Note, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A1.
&ldquo;<B>Common Shares</B>&rdquo; means shares of Borrower&rsquo;s common stock, par value $0.01 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A2.
&ldquo;<B>Fundamental Transaction</B>&rdquo; means that (a) (i)&nbsp;Borrower or any of its subsidiaries shall, directly or indirectly,
in one or more related transactions, consolidate or merge with or into (whether or not Borrower or any of its subsidiaries is the surviving
corporation) any other person or entity, (ii)&nbsp;Borrower or any of its subsidiaries shall, directly or indirectly, in one or more
related transactions, sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective
properties or assets to any other person or entity, (iii)&nbsp;Borrower or any of its subsidiaries shall, directly or indirectly, in
one or more related transactions, allow any other person or entity to make a purchase, tender or exchange offer that is accepted by the
holders of more than fifty percent (50%) of the outstanding shares of voting stock of Borrower (not including any shares of voting stock
of Borrower held by the person or persons making or party to, or associated or affiliated with the persons or entities making or party
to, such purchase, tender or exchange offer), (iv)&nbsp;Borrower or any of its subsidiaries shall, directly or indirectly, in one or
more related transactions, consummate a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with any other person or entity whereby such other person or entity
acquires more than fifty percent (50%) of the outstanding shares of voting stock of Borrower (not including any shares of voting stock
of Borrower held by the other persons or entities making or party to, or associated or affiliated with the other persons or entities
making or party to, such stock or share purchase agreement or other business combination), (v)&nbsp;Borrower or any of its subsidiaries
shall, directly or indirectly, in one or more related transactions, reorganize, recapitalize or reclassify the Common Shares or preferred
stock, other than an increase in the number of authorized Common Shares, (vi) Borrower transfers any material asset to any subsidiary,
affiliate, person or entity under common ownership or control with Borrower, or (vii) Borrower pays or makes any monetary or non-monetary
dividend or distribution to its shareholders; or (b)&nbsp;any &ldquo;person&rdquo; or &ldquo;group&rdquo; (as these terms are used for
purposes of Sections 13(d) and 14(d) of the 1934 Act (as defined in the Purchase Agreement) and the rules and regulations promulgated
thereunder) is or shall become the &ldquo;beneficial owner&rdquo; (as defined in Rule&nbsp;13d-3 under the 1934 Act), directly or indirectly,
of more than fifty percent (50%) of the aggregate ordinary voting power represented by issued and outstanding voting stock of Borrower.
For the avoidance of doubt, Borrower or any of its subsidiaries entering into a definitive agreement that contemplates a Fundamental
Transaction will be deemed to be a Fundamental Transaction unless such agreement contains a closing condition that this Note is repaid
in full upon consummation of the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A3.
&ldquo;<B>Limited Redemption Event</B>&rdquo; means that on any given Trading Day the Common Shares trade at a price that is at least
fifteen percent (15%) greater than the Nasdaq Minimum Price for such Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A4.
&ldquo;<B>Limited Redemption Window</B>&rdquo; means the period beginning on the date a Limited Redemption Event occurs and ending on
the date that is five (5) Trading Days after the date the Limited Redemption Event occurs. For the avoidance of doubt, more than one
(1) Limited Redemption Window may be open at the same time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A5.
&ldquo;<B>Major Trigger Event</B>&rdquo; means any Trigger Event occurring under Sections 4.1(a) - 4.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A6.
&ldquo;<B>Mandatory Default Amount</B>&rdquo; means the Outstanding Balance following the application of the Trigger Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A7.
&ldquo;<B>Maximum Limited Redemption Amount</B>&rdquo; means five percent (5%) of the cumulative daily dollar trading volume on the Trading
Day that a Limited Redemption Event occurs; measured as the cumulative dollar trading volume on all exchanges beginning at 4:01 PM Eastern
Time on the Trading Day before the occurrence of the Limited Redemption Event and ending at 4:00 PM Eastern Time on the Trading Day during
which the Limited Redemption Event occurs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A8.
&ldquo;<B>Minor Trigger Event</B>&rdquo; means any Trigger Event that is not a Major Trigger Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A9.
&ldquo;<B>Nasdaq Minimum Price</B>&rdquo; means the Minimum Price as defined under Nasdaq Rule 5635(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A10.
&ldquo;<B>Other Agreements</B>&rdquo; means, collectively, (a) all existing and future agreements and instruments between, among or by
Borrower (or an affiliate), on the one hand, and Lender (or an affiliate), on the other hand, and (b) any financing agreement or a material
agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A11.
&ldquo;<B>Outstanding Balance</B>&rdquo; means as of any date of determination, the Purchase Price, as reduced or increased, as the case
may be, pursuant to the terms hereof for payment, offset, or otherwise, plus the accrued but unpaid interest (including Default Interest),
collection and enforcements costs (including attorneys&rsquo; fees) incurred by Lender, transfer, stamp, issuance and similar taxes and
fees incurred under this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A12.
&ldquo;<B>Purchase Price</B>&rdquo; means $5,000,000.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A13.
&ldquo;<B>Purchase Price Date</B>&rdquo; means the date the Purchase Price is delivered by Lender to the Deposit Account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A14.
&ldquo;<B>Trading Day</B>&rdquo; means any day on which Borrower&rsquo;s principal trading market (or such other principal market for
the Common Shares) is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A15.
&ldquo;<B>Trigger Effect</B>&rdquo; means multiplying the Outstanding Balance as of the date the applicable Trigger Event occurred by
(a) fifteen percent (15%) for each occurrence of any Major Trigger Event, or (b) five percent (5%) for each occurrence of any Minor Trigger
Event, and then adding the resulting product to the Outstanding Balance as of the date the applicable Trigger Event occurred, with the
sum of the foregoing then becoming the Outstanding Balance under this Note as of the date the applicable Trigger Event occurred; provided
that the Trigger Effect may only be applied three (3) times hereunder with respect to Major Trigger Events and three (3) times hereunder
with respect to Minor Trigger Events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 58px; width: 186px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMUNON
Announces Up to $10 Million Cash Financing </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Includes
up-front issuance of preferred stock for $2.5 million and secured </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>promissory
notes for $7.72 million</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Uniquely
structured, flexible financing supports IMUNON&rsquo;s Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LAWRENCEVILLE,
N.J., June <R>4,</R> 2026 (GLOBE NEWSWIRE) &ndash; <U>IMUNON</U>, Inc. (Nasdaq: IMNN)</B>, a clinical-stage company in Phase 3 development
with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate
gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible preferred
stock for $2.5 million and two secured promissory notes in the principal amounts of $2.72 million and $5.0 million. The promissory notes
accumulate interest at a rate of 8% and 5%, respectively, per annum and mature 18 months after the issuance date. Interest will be partially
offset with interest earned via bank deposit. IMUNON intends to use the net proceeds to support continued enrollment of the pivotal Phase
3 OVATION 3 clinical trial in patients newly diagnosed with advanced ovarian cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMUNON
recently reported updated Phase 2 clinical data showing continued improvement in median overall survival (OS) in women with newly diagnosed
advanced ovarian cancer treated with its investigational therapy IMNN-001 in combination with standard of care (SoC) chemotherapy. The
increase in median OS rose from the previously reported 11.1 months to 14.7 months following final data analysis. Patients treated with
PARP inhibitors in addition to IMNN-001 and SoC chemotherapy demonstrated median increase in OS of 24.2 months compared to SoC chemotherapy
alone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
investor-friendly structured financing avoids the highly dilutive discounts and warrants common to straight equity financings and traditional
registered direct offerings. It provides IMUNON with company controlled access to capital needed to achieve our patient enrollment targets
in the Phase 3 OVATION 3 study, strengthens our balance sheet, and provides meaningful potential to minimize dilution for existing shareholders.
Unlike those conventional approaches, this creative structure does not include warrants and is designed to enhance shareholder value,&rdquo;
said Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. &ldquo;We believe this financing will improve our equity
profile, reduce potential market overhang and lower dilution pressure. This approach is fully consistent with our objective to be shareholder
friendly while advancing our Phase 3 trial goals.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Lindborg added &ldquo;The final clinical results from our Phase 2 OVATION 2 Study of IMNN-001, demonstrating a 14.7-month extension in
median overall survival in treated patients compared to standard of care chemotherapy alone, reinforce our confidence in IMNN-001&rsquo;s
potential to transform care for women with newly diagnosed advanced ovarian cancer. This represents a meaningful and sustained observed
clinical benefit with a highly favorable, well-tolerated safety profile in the frontline treatment setting &mdash; an area of medicine
that has seen very little progress in recent decades. The flexible, shareholder-friendly capital financing now positions us even better
to sustain this clinical momentum and complete enrollment in our pivotal Phase 3 OVATION 3 study.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Phase 3 OVATION 3 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OVATION
3 is an ongoing Phase 3 pivotal study to evaluate the dosing, safety, efficacy and biological activity of intraperitoneal administration
of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin in patients newly diagnosed
with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to activate
the patient&rsquo;s immune system to recognize and eliminate tumor cells, while also shrinking the tumor as much as possible for optimal
surgical removal after three cycles of chemotherapy. Following N/ACT, patients undergo interval debulking surgery, followed by three
additional cycles of adjuvant chemotherapy plus IMNN-001 to further stimulate anti-tumor immunity and treat any residual tumor. This
randomized controlled study will enroll 500 patients, who will be randomized 1:1 and evaluated for safety and efficacy to compare N/ACT
plus IMNN-001 versus standard-of-care N/ACT. In accordance with the study protocol, patients randomized to the IMNN-001 treatment arm
can receive up to 17 weekly doses of 100 mg/m<SUP>2</SUP> in addition to N/ACT. The primary endpoint of the trial is overall survival.
Additional endpoints include objective response rate, chemotherapy response score, surgical response and time to second line therapy.
The trial includes two interim analyses for assessment of efficacy, and which could potentially serve as opportunities for early registration.
OVATION 3 is currently enrolling at multiple sites throughout the US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Phase 2 OVATION 2 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OVATION
2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant
and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian, fallopian
tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal
surgical removal after three cycles of chemotherapy. Following N/ACT, patients undergo interval debulking surgery, followed by three
additional cycles of adjuvant chemotherapy to treat any residual tumor. This open-label study enrolled 112 patients who were randomized
1:1 and evaluated for safety and efficacy to compare N/ACT plus IMNN-001 versus standard-of-care N/ACT. In accordance with the study
protocol, patients randomized to the IMNN-001 treatment arm could receive up to 17 weekly doses of 100 mg/m<SUP>2</SUP> in addition to
N/ACT. As a Phase 2 study, OVATION 2 was not powered for statistical significance. Additional endpoints included objective response rate,
chemotherapy response score and surgical response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
IMNN-001 Immunotherapy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
using IMUNON&rsquo;s proprietary TheraPlas&reg; platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle
delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most
active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell
proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or
as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase
1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with
newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which
assessed IMNN-001 (100 mg/m<SUP>2</SUP> administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of
paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Epithelial Ovarian Cancer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epithelial
ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every
year and approximately 70% are diagnosed in advanced stage III/IV. Epithelial ovarian cancer is characterized by dissemination of tumors
in the peritoneal cavity with a high risk of recurrence (75%, stage III/IV) after surgery and chemotherapy. Since the five-year survival
rates of patients with stage III/IV disease at diagnosis are poor (41% and 20%, respectively), there remains a need for a therapy that
not only reduces the recurrence rate but also improves overall survival. The peritoneal cavity of advanced ovarian cancer patients contains
the primary tumor environment and is an attractive target for a regional approach to immune modulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
IMUNON</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMUNON
is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body&rsquo;s natural
mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach
from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas&reg;,
is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological
approach is deemed promising. The second modality, PlaCCine&reg;, is developed for the gene delivery of viral antigens that can elicit
a strong immunological response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer
that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical
trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such
as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of
its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through
partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information,
please visit <B><U>www.imunon.com</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IMUNON
wishes to inform readers that forward-looking statements in this release are made pursuant to the &ldquo;safe harbor&rdquo; provisions
of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not
limited to, statements regarding expectations regarding the use of proceeds from the financing, the timing and enrollment of the Company&rsquo;s
clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the
Company&rsquo;s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company&rsquo;s plans
and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking
statements by using words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;intend&rdquo; and similar expressions (as well as other words or expressions referencing future events,
conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without
limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials,
including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing
interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate
its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed
from time to time in IMUNON&rsquo;s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the
extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information
or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 49%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts:</B></FONT></TD><TD STYLE="text-align: left; width: 2%"></TD><TD STYLE="text-align: left; width: 49%"></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors</B></FONT></FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jenna Urban</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Peter
                                            Vozzo</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CG life</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">ICR
                                            Healthcare</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212-253-8881</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">443-213-0505</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>jurban@cglife.com</U></B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>peter.vozzo@icrhealthcare.com</U></B></FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #5 JH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y7Q9XP70"EM!&);IQD GA1
M[U$YQA'FD;T,/4Q$U3IJ[9U5%><V6O>(S VH.R/$.3&1Q78:!KL.NV)GC&QT
M.V1#V-9TZ\9NR-\1@:M!.3LTM';HS6HHHK<X0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK'\1Z_#H&
MG&=\-*W$:9ZFIE)15V:4J<JLU""NV7K[4;/38#->3I$@[L:YVV\37VOS&/1;
M/9"IP]Q/]W'M[UPVGI?^-O$*BZE8QYW/CHB^U>NV5E;Z?:I;6T:QQ(,  5RT
MZDZSNM(_BSUL3AJ. BHS]ZH_N7^;'6T4D,0629I6[DU-1178M#QF[N[#(HJI
MJ%C]N@*+/) _:2,\BN*U-/&7AOS+FUNO[5M%YV2CYU'O6D(<VE]02N>@5XCX
MR$B^++TRY_UF1GTP.E=+HWQ7MY6\G5K8V\F<;D^Z/KFMW7?#]AXPLTO;*X3S
M0N$D7D'V-<N-PM1PM8]C*<5#"5[U=FK7['G\>O20Z:;=6X(QBMWX9B=M5O),
M-Y!3GTW9JO%\--4:8+)-"J9Y;.>*]$T/1+;0; 6ML">[N>K&O/PU"ISJ4]$C
MU<QQN$CAY4Z+4G/L:=%%%>L?(A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;(ZQQL[
MD!5&233JX[XDZR=*\,O$F?,NCY0([>]7"+G)10TKNQ0\.:E+XH\;WFH;<V-F
MGEP?[V>OUKT"O._A"H'AZ\/\1N.3^%>B5I7TFXKH.>]@HHHK D**** "BBB@
M#B?&WA'^TX6U"Q3_ $I!ET'_ "T'^->4.C1N58$,#@@]J^C:XGQ?X*35-U]I
MZJET.73H'_\ KUYV*PO-[\-SZC*,W]G:A7>G1]O)^1Y-5FRD:.4,C%6'0@]*
MCN+>6UF:&9&1U."K#I3K7[YKRH_$?6U6G3=CTWPUXU5BEGJ;@,>$F/\ 6M7Q
M9XHBT6Q*0,'NI!\@!SM]S7DLY(7(INFR?VCJL-E=W7EI*VWS9#]VOJL)!32<
MC\_Q>&C&;E$ET3P[>>*]=();RMV^>4_RKW2PLX+"RBM;90L42[0!7'PW<%B\
M?AWPQ&)9S@W%R.D8[DGUKL;*V%G:I#O+E1RS=2:VQ$W*W8\Z;N6****Y3,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\C^+U
MXQU.QL?X?+,GXYKURO)OC#8%)K#4P"5YA8]AWKIPMO:JY=/XBK\*M:%IJDVF
M2R!8YQNC![O7L=?+T,TD$R30N4D0[E8=J]8\+_$ZVGC2TUG]S*!CS_X3]:Z,
M50;?/$N<'NCTFBJMIJ-G?PB6UN8Y4/=6JUUKSVK&(4444@"BBF/-'&NYW51[
MF@!]%9UQK5I"/E;S#_LUD76OSR96+$8]1UJU!L=F'BS0=+U2W,DS+#=*/D=>
MI]C7E,EC-8W312K]#V->A.&D<M<2[!C/S'D_2L_4YK&6U-O';[V/21OO ^U8
M5L#&I[T?B/:P.9U,.O93UA^7I_D<7/\ <KGKXD'(.#74:E97%F0D\3(2,C(Z
MBN7O^]=V 36C-:\E+5;'L?PHNK2Y\-,L42K<QOMF;^)SV)KOJ\6^#$SC6;^'
M)\LQ!L=LYKVFEBH\M5GAU%:3"BBBN8S"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHI"ZCJP'U- "T4WS$_OK^=.!!Z4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VNZ/;Z]I%QI]
MS]R5<!@.5/J*T:*:;3N@/F/6-)O/#>I26%_&PVGY),<,/456&&&>"*^D-=\/
M:?XBL6M;^$./X7Q\R'U!KR#7?A5K.FR/)I3&[@S\JC[X_"O6I8F$U:6C.F,T
M]SF[&^N+20>5-(GT8UUEAXLU>)0%OWQZ'FN$N(-1L93#<V<D<B]0RFD359H>
M#&./6MY4U(IQN>N6WC'4F #3!O?%7E\37\@XFQ]*\AB\331_\L5-6X_%M\!E
M+0-^!KG>&\B/9GJAUB\E^_<,:B-R[\L['ZFO/[77_$6H,(K32F=STVH?ZUJ6
MWAGQ[J3_ +PO9J3T<@8J'24=VD+EMN=2UPJC)91]36=<:]80'#72[_[J\D_E
M4MK\*+FZ0-K.MS._=8>GZUV6E^#=!T<H]M81^:HQYC_,3[\UC*=./6Y+<4<M
MI=EJ&MG>MK);P9_ULW1A[5U^GZ)IM@=^5EE_ON0:TKB+S;5X48(67 ([5S_]
M@7G_ #W3_OJL7/FZV)O<SOB+:03:5'=(%,L;;20?X:\6O^IKUSQ=I\UAHC/-
M*K!FV@ UY6UI-?WT=K A>65]JJ*WPUE(]"B_W6IZ'\&])9(+W4W!&\B)?<=<
MUZM65X<T>/0M"M;"/DQI\Q/4GO6K7/6GSU'(\^<N:385Q_Q%\07GAWP^ES9.
M%F>4(":["O)_C1J06WL=-'4DS'^5/#QYJB3""O(Y#_A:/B;_ )^Q_P!\UTG@
M?QGXC\0>)[:UFN-]N,M* /X:\GKTWX,0L=?O)L?*L&W/XUZE>G3C3;21O**4
M7H>W4C':I/H,TM5-3NDLM,N;E_NQQEC7BI7=CE/$M:^)FOP:U=Q6UR%A20J@
MQT JA_PM'Q-G_C['_?-<C=2>;=RR9SO<M^9J&O?5"FE\*.SE78^G/!VO_P#"
M1>';>]<CS\;90.S5OUXC\(-?^R:M+I,TH6&X&Z,'NXKVZO&Q%/V=1KH<TXV8
M4445@0%%%%  2 ,GI7D/C?XG75KJQL=$E41P\22XSN;T%;OQ,\9_V)IYTVRD
MQ?7"\L#_ *M?\:\&9B[%F.23DDUZ6$PZ?OS1O3AU9V?_  M'Q-_S]C_OFNQ^
M'/B_6_$>OR07MQO@CB+D8[]J\:KUSX+6F6U"[QTPF?UKHQ%.G&DVD7-)1V/7
MZP?&6K3:+X6O;VW8+.B?NR>QK>KSWXOW?D>%(X0?FFF Q[8KRJ,>:HD<\5=I
M'G7_  M'Q,./M8_[YK4\.?$#Q)JWB&QL6N@5FE"L-O:O-Z[?X66@N?&4#8SY
M2EZ]BK2IQ@WRHZ91BE>Q]!C( SUI:**\(Y HHHH I:O>_P!G:1=7F<>3&6KP
M=_BCXD\QMMV-N3CY>U>L_$>[^R^";\9YE3R_SKYP/6O3P=*,HMR5S>E%-79W
M5I\2O$]S=PPB[!+N%^[[U[[ S-;Q,_WB@)^N*^9O!=H;WQ?IL.,@S GV%?3@
M   '05GC8QBTHJPJJ2>@$X!->%Z_\2]=M]=O(K.Y"P)(508]*]KU*Y%GIES<
M'I'&6_2OE2[D\V[FD_O.S?F:>"IQDVY*X4HIWN==_P +1\39_P"/L?\ ?->T
M^#_$">(_#\%YN'G ;95'9J^8J] ^%7B0Z5KW]GS2D6MWQ@] _8UT8G#Q<+Q6
MJ+G!6T/>Z***\<Y@HHHH H:W?'3=$O+T'!AB+BO"&^*/B7>VV[&,\#;7J_Q+
MO39^"KP X\X>7^=?.9ZUZF#I1E!N2N;THIJ[.\L/B1XGN[^"W%V#YCA<;?>O
M?(2Q@C+_ 'BHS]<5\S^"+1KSQAIL84E?.#-[ 5]-@8&*RQL8QDE%6)JI)Z!1
M15+5=6L]&L9+R^F6*)!W/7V%<*3;LC(N,ZHI9V"J.22< 5P_B'XHZ-HSO!;$
MWEP ?]7]T'T)KS7QE\1;_P 0S/;VCM;6 R BG!<>IKB"23DFO2HX+K4^XWC2
M[G<ZI\5O$-^,02)9C_ID.?UKFI_$NLW+EI=1N&)_VZRJ,&N^-*$=D;**6QH#
M7-44Y%_<9_WS6K8>/?$>GLOEZE*R \H_(-<U@^E%-PB]T%D>P:!\8U=_*UJU
M"@X"RP_U%>HZ?J5GJEJMS97"31-T937R=6]X9\5ZAX9ODFM928L_O(2?E<5Q
MUL'%J\-&92I)['T[167H&O6GB'2X[ZT<$,/G7NI]#6I7DM-.S.?8*J:I=?8=
M+NKK./*C+9JW7+_$*^%CX+OSG!E3RQ^-5"/-)(:5V>12?%'Q)YK[;L;=QQ\O
M:I+7XJ>(8[N)Y[@/$K NF.HKA3UHKW?84_Y4=?+'L?6.G7T.I:?!>0,&CE0,
M"*M5Y1\(/$AE@ET2YERR?/;@]E[BO5Z\2M3=.;B<LE9V"BBBLB0KE_'VNS^'
M_#,EY;,%F+A$)]3745Y;\9[[R],LK+M(_F?E6U"/-4294%>2.*_X6CXF_P"?
ML?\ ?-;_ (-\<^(M;\36EG-<AH6.7&.U>65Z'\'[5IO%C3%24BA;GW.,5ZU:
MG3C3;LCHE%)-V/>****\,Y0HHHH **** (GMH)#EX8V)_O*#65=>$]!O&+3Z
M9 Y)R?EQ6U15*36S'<YY? WAI&#+I, (]C6K;Z3I]I$(X+.!$'8(*N44.<GN
MPNQB0Q1G*1HOT4"GT45(@K#U:VOY;@& LT>. O:MRBFG9W&CD_L.J?W9/SH^
MPZI_=D_.M;5Y-021!9AMF.2H[URFL>)=0L,VPG87+#IC[M7*HHQYI6-Z-*=:
M2A!:F!XKO9I)OL;.2(CR,Y^:M[P!X1^RD:Q>I^]8?N4(^Z/7ZTOAGPE)=3KJ
M6IJ2N=RHW5CZFO0  H    Z 5$:DG'U-\3.,%[*'3<6BBBD< 5X/\8+E9_%,
M<:G)BA"GVYKW@G S7S1X\N_MOC/490<KYFU?H!7=@8WJ7[&M):G-U[9\&+,)
MHU[=%?F>4*#[8KQ,=:^B?AC:_9_!-H^.9LO^M=F-=J5NYK5?NG95S?CZ<0>"
M-48M@F(J*Z2O.OC%=M!X9@@1L>=-AAZ@"O*HQYJD4<\5>2/"3UHHHKZ$["WI
ME])INI6]Y$</"X<5]1Z3J$>JZ5;7L1RDR!A7RC7M?P>UXW.G3Z1-+EX#OB4]
ME[_K7!C:?-#F70RJJZN>H4445Y!S!6'XK\1V_AG19;R4@RD;8D_O-6K>7D%A
M:2W5U*L<,:[F9N@%?-_C3Q3-XGUIYR2+:,E84SP!ZUU8:A[66NR-(1YF8VIZ
MC<:KJ$UY=2%Y96+$DU4HHKVTK:(Z@KWSX1V'V3PHT^.;F3?GZ<5X(.37TKX!
MM7L_!6FQ2##^7DCZFN+'.U.WF957[ITM>/?&JY87.G6V?E*%\?CBO8:^?OBM
MJ;7WB^2W/W;5?+'\ZX\'&]6_8RI+WCA:]5^"^GE]0O=0(^5$\H?4\UY57N7P
M:MFB\.W<K# EF!'T KT,7*U)FU1^Z>DT445X9RA1110!YO\ &.[6/PW;VP;#
MRS X]@*\,KU/XU3$ZKIT.>!"6Q^->65[F$C:DCJIKW3OOA);K/XP#,,^7$SB
MO?:\A^"VFJQO]2/WE(A'XC->O5YV,E>J_(QJOWCGO'%VMGX-U.1FP3"57W)K
MYF/4U[O\89VB\)Q1JV/,G /N,5X/7;@8VIW[FM)>Z%/AE>&5)(V*NI!!'8TR
MBNXU/IOP9KR^(/#=M=$KYRKLE4'H1705X-\*?$?]EZ]_9TS'R+P[1Z!^U>\U
MX.(I>SJ-=#DG&S"BBBN<@\U^,E\D?A^VLMW[R64/CV%>'5Z?\:9M^N6$0/W(
M#D?C7F%>YA(VI(ZZ:]T]!^$$"S>+F9ESY<#,/8U[U7DGP6T]3'J&H$?,K"(?
M3&:];KSL9*]5F%1^\07EW!86<MU<R!(8E+,Q[ 5\Z>-?%]QXHU0MN*6D9(BC
M!XQZGWKK/BWXJ,]RNA6K_NX_FG(/5NPKRJNS"4.5<\MV:4X65V%6;&PNM2ND
MMK.!YIG. J#)J?1=&N]=U.*QLTW22'&>RCU-?1'A3P?8>%[%8XD62Y8?O)B.
M2?:MJ^(5)>9<YJ)Y]H/P=EF1)M8N3$",^5&,D>QKMX/AKX7A0!M.64@=78\U
MUM%>3/$5)/5G.YR9RS?#KPJRX_LF)?<$_P"-<OK_ ,'[2='ET><PR]HGY7\Z
M]1HI1KU(NZ8E.2ZGRAJ>EWFCWTEG>PM%,AY##K[BJ=?1WCSPC;^)='D=(P+^
M%=T4@')]C7SI+&T4KQL,,I((]Z]BA656-^ITPES(['X<^*9- UU()'/V.Y8)
M(I/ /9J^AE8,H93D$9!KY&4D$$'!KZ6\":M_;'A.SG>0/,B[)/4$<5QXZE:T
MT9U8]3I*\\^,%RL?A2.#< \DZX'L*]#KQCXU7+'4].MPWR")F(]\US86/-51
MG35Y'E=%%%>Z=9HZ'JLVBZQ;7\)^:)P2/4=Q7T_IM_#JFG07D#J\<J!@5_45
M\GU['\'_ !'YD,NASMRG[R'/IW%<&-I<T>==#*K&ZN>L4445Y!S!7B7QFOHY
M];LK5#EH(CO'H2:]MKYO^(\WG>.-08'(#!1^ KMP4;U+]C6DO>.4KV7X*0#[
M%J4Y7YO,50?;%>-5]!_"JP2U\&Q3C[UPY<_@<"NW&2M2MW-:C]T[BBBBO%.4
M**** "BBB@ HHHH **** "BBB@ HJM>ZA;:?"9;F4(O3W)]*P;C^V/$.8H0^
MG6)^\[?ZQQ[>U1*:6BU9T4J#G[S=H]W_ %K\AFO>*_(F_L[2(_M>H-\N$Y"?
M6H?#_@\PW!U+6'^T7C_-M/(4UOZ5H=CH\)2UB 9N7D;EF/KFM&LE2<GS5/NZ
M(Z9XN-.#I8=63W?5_P"2\@  &!P****Z#S@HHHH CG8);R.QP I)/X5\IZG,
M;C5+J4_QRL?UKZ4\8W367A'4YT.&6$XKYA8EF)/4FO4P$=)2.BBMV+&NZ15]
M3BOJ;P]9K8>'[&V7HD*_XU\RZ-9OJ&L6EJGWI90HKZI@3RK>./\ NJ%_(4L>
M_A0JSV1)7CWQIO#]HT^S!XV&0_GBO8:^?OBM>M=>,98B>($""L,'&]6_8BDO
M>.%J['I=S-I<NH(FZ")PCD=N*I5[)\.?#J:EX!U*WN1A+UOE(ZC KU*U3V<>
M8Z)2Y5<\;K?\':VV@^);2[R?*WA9 .ZFLF_M)+"_GM95*O$Y4@U7!P<BM&E*
M-NC'NCZXC<2QK(OW6 (_&G$@#)Z5QGPTUW^V?"T4<DA>XM?W;DGD^E4?B7XT
M&B6!TRS?_39UY8'_ %:_XUX*HR=3V:W.3E=['(_%#QI_:5T='L)#]EB.)F!X
M=O3Z5YG2LQ=BS$DDY)-3V-E/J%[%:VR%Y96"JH[FO<IPC3CRHZTE%6+.E:/<
M:J\QB&(H$,DK]E6L]@ Q .1GK7MFJ:!!X.^%]];*%^U7,8$T@ZL?2O$CU-32
MJ^TNUL*,N8FM(S+>0QC^)P/UKZNLD$5C;HHP%C48_"OFCP=:?;O%VFVY&0TP
MS]*^G5 50HZ 8KAQ[UBC*L]D!. 3Z5\Q^,[M;WQ;J,Z'*M*?TXKZ3U*X%IIM
MS.?X(R?TKY4NG\R[E?\ O.3^M& CJY!16[(1UKZ4^'MJ+7P3IR[0&9-S>Y)K
MYNB4O,B@9)( %?56C6HL]&LX%& D2_RK3'OW4AU7H7J***\DYPHHI&.%)]!0
M!\\_%"^:[\:749/RP8C7^=<76QXHN_MWB6_G'\4Q_3BL@#)Q7T5)<L$CMBK)
M'O/PALVMO"LDS#B>7</PXKT&N>\#VILO!NG0GJ(\G\3FNAKPJTN:HV<DG=L\
M@^-.H,)=/T\'Y2IE/USBO(Z[WXM78N/%QBSGR(PM<%7LX:-J2.F"M%'3^'/"
MKZ_HNJ74>[S+1-Z ?Q''2N992K%2,$<$5[G\'K'R/#5S.X!^T2Y'T Q7G7Q%
M\.G0/$LGEC%O<YEC]O4?G4TZUZLH/Y"4KR:.3BE>&59(V*NIR"#T-?2_@S7T
M\0^'+>Y!'FH DH]&%?,M=_\ "OQ)_9&O?8)Y"+6[.W'8/V-+%TN>%UN@J1NC
MWRBBD8X4GT%>(<I\[?$V]:[\:WBELI"0B_E7'5J^([O[;XAOI\YW3-^G%98&
M2!7T=-<L$CM2LCWSX269M_"1F(QY\A;\N*ZS7]531=#N[]^?)C) ]35+P59_
M8/"&G08P1'D_CS7)?&/5/L^BVVGJ2&G?<<=U%>-;VM>W=G-;FF>+WER]Y>37
M$C%GD<L23ZFH0"2 .II*Z/P-HPUOQ3:6SJ#$K;Y!_LBO:DU&-^QTMV1Z]\-/
M"BZ%HJWES$1?70W'<.47L*[JD10B*BC"J, 4M?/3FYR<F<;=W<****@04444
M %?.GQ*TO^S?&%SLB$<,W[Q,=#ZU]%UXU\;(Q_:&ER<9\IE_6NS!2M5MW-:3
M]X\IKV;X*3DV&I0%NDBL!^%>,UZG\%W8:E>IGY2@)%>CBE>DS:I\)[17S[\5
M;XW7C*:'^&W4(/YU]!'@5\O>+;O[;XHOYLYS*1^7%<.!C>;9E26IBUU;>%&E
M\"KKT2L620JZ@?P^M<H.M?2'A#1D_P"%?VVG7*_+-$=X]=U=V)J^S2:[FLY<
MI\WUH:)J<FCZQ;7\><PN&(!ZCN*D\1:1)H>N75A(/]4YVGU':LNM])1\F5NC
MZQTV_BU/3H+R%@8Y4##%6J\G^$'B7S(9=#N)"67YX,],=Q7K%>!6ING-Q.22
ML[#9'$<;.QP%!)KY6URZ:]UN\G<Y+3-^6:^F/$4_V7P[J$^<;(&.?PKY:E??
M*SGJQ)KNP$?B9K16[&CDU]/>$+3[%X5T^'&,1 _GS7S7IEK]MU.VMO\ GK(%
M_,U]56D7DV<$7]R-5_(4\?+11'5>R)J***\LYPHHHH **** "BBB@ HHHH *
MCF$C +&0N>I[@>U244#3L4H=+MTD,L@\Z4]7?G]*NT44DDMARG*6["BBBF2%
M%%% !1110!Q'Q4U 67@V6+O<L(A_.OGNO9?C1=@6=A:9Y+E_TQ7C5>U@XVI7
M[G527NG6?#BW,_C?3SC(C?>:^CZ\.^#=IYOB&YN&7*Q0X!]R:]QKBQLKU+=C
M*J_>$)"J2>@&:^8_&=^NI^+=1ND.5:4@?AQ7TK?RK!I]Q*QP%C8Y_"OE*Z;=
M=RMZN3^M:X".LF516[(1UKZ3^'D)A\#Z:",$QY/YU\XVZ&6XCC R68"OJO2[
M9+/2K6WC&%2)0!^%7CY>ZD.J]+'CGQ>\/&TU6/5X4 BN1MD/^W_^JO,J^GO&
M&AQZ_P"&[JT9 TNPM$?[K#O7S)-$T,SQ.,,C%2#V-:X.IST[/=%4Y71TW@OQ
M>_A.YNI1&95EBVA,\;NQK!U/4;C5=0FO+J0O+*Q8D_RJI172H14G+JR[*]Q0
M"Q  R37N?PQ\%_V39+J]]'B[F7,:,.8U_P :Y3X8^"3JEXNKW\9%I"<Q*1_K
M&_PKW$    8 Z"O/QE?_ )=Q^9C4GT1YQ\8[L1>&[>V#8:6;)'L!7AE>J_&J
M<_VEIT /'E%B/QQ7E5=.$C:DBZ:]T[OX3VHN/&".1GRHRXKZ KQ[X+Z:&GOM
M2/\ "!$/QYKV&O/QDKU?0QJOWCGO'-V+/P;J<A.&,)5?K7S,>IKWCXPS-'X3
MB13CS)P#[C%>#5V8&-J=^YK27NFOX7MUN_$VG0,,AYU!%?4:*$15'0#%?//P
MOTS^T/&5O)QBV!F/X5]#US8Z5YI$57J%%%%<!B%4=9NOL.C7ES_SSB9JO5S/
MC^]2R\%ZB6.&DB*)]35P5Y)#6K/FZX?S;B23^\Q/ZTMK$TUU%$@RSL% J(]:
MWO!<(N/&&EQD9!G&17T,GRQ;.QZ(^E-.A%OIMM$!C9$H_2K!. 3Z4H&!@=*A
MNIDM[2:60X1$))_"OG-V<1\T^-+X:CXMU"X'0RD#\.*P!UJQ?R>;J%Q)G.Z1
MC^M10KOF1?5@*^CBN6*1VK1'T;\.+<V_@>P#+M9P6(_&F?$7P]_;WAF7RD!N
M;?\ >1G')QU%='I<"6^E6D4:A56)>!]*M$!@01D'J*\!U&JG.NYR7]ZY\C,I
M5BI&"#@BG12O#*LD;%74Y!'8UU_Q'\.'0?$DCQ1A+2YS)%CMZC\ZXVO>A)3B
MI+J=:=U<^F?!/B!/$/ANWN=ZF=%"3*/X6%:.O79L-!OKH=8X6:O$_A7XB.D^
M(18ROBWO#M(/0/V->J?$._CL?!6H;S@S)Y:_4UX]6CR5E%;,YI1M*Q\XS2&6
M=Y#_ !,3^9IUK"\]U%%&,N[!0/K4)ZUT'@B$3^,M+1AE?/!(KV9/EBV=+T1]
M):?%Y.G6T6,;8E'Z5XW\:+E9=;L(%/,4)W?4FO;:\#^+G_(V_P#;,5X^#UJW
M.>G\1P%>K_!?35>[OM2.,Q@1#\>:\HKVGX*8_LK4O7SE_E7H8MVI,VJ?">I4
M445X9R!1110 4444 %>)_&BZCEUJP@1LM%"VX>A)KVLD $GH*^:?'>IQ:MXO
MOKF%]T6_8I^G%=N"C>I?L:TE[QS=>L?!:W+75_<<X4!:\GKW+X.:=+;:!=7<
MBX6XE!C/J ,5WXMVI,UJ/W3OM4NQ8:7<W3=(HRU?*MW+Y]W-+_?=F_,YKZ3\
M<W*6O@S4V8X+0E5^IKYF/6L, O=;)I+1L?$C22JB@EF. !7U;I47DZ39Q]-L
M*#]*^:_!UNMUXNTR%URC3KN'M7T\ %  & .!48^6L8BK/9'F/Q>\.?:]/BUF
M!/WEO\LH ZJ>]>)U]:7MI#?V<UK.@>*52K*>X-?,/B31IM!URYL)@/D8E2.A
M4]*TP56\>1]!TI75B'1-5FT;5[>_A)#1.&QZCN*^H-,U"'5--@O;=U>.5 P*
M^O>OD^O8O@_XC+QRZ'<2?=^>#/IW%/&TN:/.N@ZL;JYU'Q-U V'@NY _Y;D1
M?G7SJ>M>X?&6]C30;6S)_>22[P/85X?58*-J5^X4E[IT'@FU>[\8::B+D"8,
MWL!7TW7A'P>@$GBN25ER(X&Q[$U[O7)CI7J)=C.J]0HHHKA,@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#PKXQ7JW'B6"!3_J(=I'N3FO
M.:ZKXBS";QSJ1#957"C\JY6OH*"M3BCLBK11[/\ !:W']FZA<8Y\T)G\,UZI
M7&_#"QCM/!5K*H^:XS(U=E7C8B7-5DSFF[R9SGCR\^Q>"]2D!PYB*K]37S03
MDFO>OB[<^1X26,'F68+C\*\$KT<#&U-OS-J2]TU_#%K]M\3:?;XSOF48KZB1
M=D:KZ "OGSX6V(N_&=O(?^6 ,@_"OH6N;'2O-(BJ];!7S_\ %+0!I'B4W40_
M<WF9  .%/0BOH"N2^(F@_P!N>%IQ&FZXM_WL>!R2.U8X:I[.HNS(A*S/G&NE
M\&>%)_%&L)" 5M8SNFD]!Z?6LC2]*N=6U2&PMT)FD?:!Z?6OI+PMX;M?#.CQ
MV<"@R$9ED[NU>EB:_LXV6[-YSY4:=C96^G645I:QB.&)=JJ*L44C':I/H,UX
MFYRGSS\4-0>\\9W43'Y;?$:_SKBZV?%=X+_Q/J%PIR&F/Z<5CCK7T5)<L$CM
MBK)'NOP=M7@\,3RL.)IMP_ 8KT6N<\!VOV3P7IL6/F\O)]R371UX5:7-4DSD
MD[MGCWQIU!Q<6%@/N;#*?KG%>2UZ7\9\_P#"16>>GV?C\Z\TKV<*K4HG3#X4
M>G?!B$G7+V;' AVY_&O;:\2^#$^W7+R M@-#N ]>:]MKS,9_%9A4^(****Y#
M,*\S^,UXB:#:6F_$CS;]OJ *]+9@JEF(  R2:^<_B)XA&O\ B:5HFW6]O^ZC
M/\_UKKPD'*HGV-*:O(Y&N]^$M@MYXN$K=+>,R#ZUP5>S_!K2&BLKO4Y%(,C!
M(SZCO^M>GB9<M)F\W:)ZI7.^.[@V_@K5'5L,82 ?>NBK@OBW>&V\(B-3S/*$
MQ[8KQJ*YJD5YG-%7:/ CU-:GAJR_M'Q'86A&1),HK*KL_AA:?:?&EJV,^5E_
MRKW:DN6#9UR=DSZ&C01Q(@Z*H%.HHKYTXCDOB'X<_M_PU-Y49:ZMQYD04<GV
MKYS=61V5@0P."#VKZY/(Q7SO\2?#G]A>))'B3%M<YD3T![BO3P-7>FS>E+H<
M?%(T4JR(2&4Y!'8UZ;XQ\3)K_P .M-?<HG$H$J ]"!BO+Z=YC^7LW'9G.,\5
MWSIJ34NQLU=IC:[WX2V2W?B\2-T@B+CZ]JX*O6_@M:;I-0N\?=PGZ9K/$RM2
M9,W:+/8*\2^-%LL>N6,Z_P#+6$[OJ#7MM>;?&'2?M6AP:@BDO;OM;V4UY6%E
MRU484W:1X;7J7P9U3RM2N]-;I,OF ^XXKRVM;PWK,F@Z[;7Z9Q&XWCU7N*]B
MM#GIN)T25U8^I:*K:??0:E8PW=M(LD4JA@RGBK-?/-6.,**** "BBJ.KZO::
M)ITE[>RA(D&?<GT%-)MV0&'X_P#$:>'_  W,RL/M,X\N)<\Y/>OG!V+NS,<D
MG)-;WB[Q1<>*-8>ZD)6%?EAC_NK7/U[F&H^RAKNSKA'E1);P27-PD,2EG=@J
M@=R:^HO#6EC1_#UE8C_EG&,_4\FO'?A3X9.IZS_:=Q'FVM3E2>[]J]WKBQU2
M[4%T,JLM;'G?QAN/+\+0P@X,DXS] *\(KUOXU7F)].LP>"C2$?CBO)*Z\(K4
MD:4U[IV_PLL1>^,H6(XA0R?E7T)7C7P7M U]?7>.44)^=>RUP8R5ZMNQC5?O
M!7F7Q<\-&\TZ/6+:(M+;\2[1_!ZGZ5Z;4-W:Q7UG-:SKNBE4HP]0:YZ51TYJ
M2)B[.Y\E5?T;5)=&U>VOX>7A<-C/7VJQXFT630=>N;&0<(Q*'U4]*R*^@5I1
M\F=>Z/0OBGK$.LW.E7%NX9#;$G!Z$D$UY[3F=F4!F) Z GI3:5."A%10)65C
MV#X*V0,6HWI'(98Q^5>MUPGPFM!!X068#F:0G\J[NO$Q,KU9'+-WDPHHHKG(
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CN'\NVE?^ZA/Z5)6
M1XHO/L'AC4;K./+A)_I3BKM(:/F74YWN=2N9I#EGD8D_C5=%W.%]3BB1M\C,
M>YS5O2+?[5J]I !G?*H_6OI-D=I]+>%;$Z=X7T^U;JD0S^/-;%1P+LMXU]%
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MT_\ LSPG86W<1[C^/-;U5[&,Q:?;1GJL2@_D*L5\W)WDV<3U84445(@HHHH
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MBBBO-, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>imnn-20260601.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWayAKbP9z5Z8CekhvWB9bTkKjycq6/y/ISWiyRa2YbMM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:IMNN="http://imunon.com/20260601" elementFormDefault="qualified" targetNamespace="http://imunon.com/20260601">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://imunon.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="imnn-20260601_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="imnn-20260601_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>imnn-20260601_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>imnn-20260601_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="imnn-20260601.xsd#Cover" roleURI="http://imunon.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://imunon.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 01, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  01,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Imunon,
Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000749647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-1256615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">997
    Lenox Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lawrenceville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08648-2311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(609)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">896-9100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMNN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imunon.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>imnn-20260601.xsd</File>
    <File>imnn-20260601_lab.xml</File>
    <File>imnn-20260601_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "IMNN",
   "nsuri": "http://imunon.com/20260601",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "imnn-20260601.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imnn-20260601_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imnn-20260601_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://imunon.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-06-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-06-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://imunon.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-26-027201-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-027201-xbrl.zip
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M\^/]^RGR<08#C6$;M_"YL#/X=WSV%N[,L^VP&V-7YQ5\  [RW,M@W!/=._-
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M%8=4A/."Q@%-<.Y(3V#2!"6$_Q[TT!J$_CGHFS@GO&D6Z F3-$"S9EHENH3
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M<IZ9HQT7DT7&]L>6>Q#F2-$CFG N\S6)HZ3;<HC:G>7E JZB<P>V2[*U<V\
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M%AZFI0.(?5 I&*Q^0GG67*;G]TTLT+(.K6;],ZQSA383'5W QLM7%JI%L;U
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M\%*<*-!(B%/JVM_"&4N"262UC5Q6,Q6I-8'@+@?LTFG.D/>JH@3P*5QF40:
M*?XM1N%ZCYLN2#D##ZTZ<ND%@S1>J4N0%C$#GAT!L2,W/WQQQ"&#6W3^W, F
M9]B]W[DK>:BI^'[KIB?=QCMELWR,;2<(\0G4 WN@MI=_(I$OY!.Z>C1+8L(I
MVZ)(D;J/&-:HK2!"GH=NC)4VYPRC6/\^;K6TLN)K<%'0? 4^?ZL5'X-C46%.
M,U5KQKD+TJ$1<Q$&J4&WEI&&CKMF208.Q:R'E#XL,>M6 [IT2=;#7YG_KN;@
MNX\.OETA"*5QD]_>5=@G4Z0+N?/)P1>E*[02PBP5@ZSSJ7(GKL"L#TZ4ZPJ^
M-9$#!G?L/K:/,@V&V4Y>8S:+!5A.UX\J\Z2NF?VXYAJQ92'F0;D%\Q^H/RL]
M_MS,S<H*IIGI@:6E\WM8(8%MX*J+$**19@N2WA50T1G*;\E"M=V![_1)!IW+
M*IZ.8F(W()+GIV61C[0E*OGA4GATZH&_K;JV)B6# <6-+BCY7IBL0KD8G@U"
M\HI(">[=0.N@F&*.EHJD8/B,DG6V72MO@U/6)"\A"KVOWF\Q*Y>05C9FZ3S2
M*Z1KW"(1\H!$2%%C#PTDH<AL"?3O8M3 _XTWSF15^I3$;KS1"Q%)5QDKSIE5
M'(.U)1'JODQ"MI& 0<YAZA=@2ZWP1JW4%[V2R"LB=:DQ$QIJGP>9\!CD!-HW
M:4>/I7M;=;+>U(1$<@U#TQ[,H./E91V7)QTM"LJ!AJ=9BIRCJVF0!J$WGXA_
ME7\<EXY7@EV,S/K.5SJYX>A0WXAYXX\Y+Z"?2MPAR9NK+@P+HVUN4$X7A=&-
MM[>CZ7!V<7N)J8E%APN%R\FTFBPD1G99+0V==3)KN[?<GEW*<-R#O(XTZ9L^
M]6L"W-\P-6\\EGWO6RS[INZIAWA/'4JIY:M<FUC+/75\&KGM1*;7RRXGD='6
MRFD5YI1S=;Z"C6V2<$!447(\B*I.YR9)I/DCZ=(VB2TL,DY>M"4>2W,3,?UW
M()HL5KSFH<=)_[BD(9:2[XB*)%S'U.A$"@/E"W+O=^N5>L1R*.CA<$MH!XD$
MH9ZIOJY8,IWF;AK5QM#%2#M _20IC]^TK,-(%_QM6G+?[_:>XJ55![GO,Y$O
M2Q+6>?366*KKI*O&\%FD379!$772T-$2Z:E7P$(Y*>]XEQ5 "_FUUBAP96O+
M#!Z$\'Q*)2KYI$L)O0MC'4$0P9=.GJL?51/H[G34MJSE/S<:7:]QB<&Z9DIZ
M(%[<JA+X)G^740I285G3<F_Y:J2&9SR@$\JGMZQ\)GXVQ:YK]2+T* _^L-[T
M:M$3:])G1KXEAM;P4H(Z,#2MX)\+&'.<C^(\1FGOUS/OS8UW489?<;&T9&N+
M.PS2-"WKM)AFH)\UM"(%:,G6MPMEVS1HF751X\S0Y1+KI%R32ZVL4*;WJ/,A
MFE+WA= KTO3&-.TDK4FAW=FZ?1&E6GMM)TSN#!\U<%O6AHUG<M-ZXC7>NH_P
MUGVNW@_V(KVSG!&ROW_8^L%'OBZ; .[]*GT^IZQ6@/LOF&G_9_,H8VJ:V).!
M.'2'E,7T GW*&)@KSY%)F=;3_ ,6L$J'"N^EGVO [KPS7+D 4SH_89$Z7( &
MSXTKN<<?WZ[E)+BZ.B/ 4:2$9=09Y/-46GZ&TL=F;-,FT^QK^$4]N<!:>84$
M<5-I03'Q[1@I>CNA6613['USX?.5N[=/I/9AMQ<;3F]S5C8]1ZO7ZW>Z;#!]
M3TECDI20Z50)2,XT+-4C.@2W8E_9[_+*(G13TM)S-V;/(,QK[B*GXIJ;U:^
MM2":R==T/ P4^<,E@*M+#DL^2(Y!I0&I7 ,U*Q!%>$2NA (C/I_/7&[/_WOY
MY?RYJ&K)RFU3_8D657Z4%5*,4@XQU* UA5DA:")PSX^<.*_UE[;2!@0'87/
M7H#ZD!.^#/6^Y'-9ES/''6WK6N123@<W4W 1S+N@X;PN^-7LW!4S_=Z4D04;
M+@@P 6$GB<Q$N$D^:1RE\ST<< ET59Z@"HF7LHGRHURJ7.,D@Z^IP> @IE@R
M5 3XE(UGC!%D1MS<6#)D-*;/--2^NF'@-9.C?L-GT5@FF=D'9H >A"/ /<N
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M??4,#!?H@-^C3K1$CEWA$KVR&-O<N+P<BP^DK1:T<FSH"*Q:XL&F\PW!4T?
M?:QMM#OC6LI$R35_9=[Y<KT'A5S<>C!BAA7M!^/[%'_RO;!\%>\UM<*Z:@_"
M@"ELIM+;@_!2^F3H6<-T-*UK/K$3X>9&9ZAN1\+DR@T)V17)>RJW>\LSC=%^
M#BJQ>SD&G&)%2GS0-$&\?V)BO(6;E*Z^,/7>#,"5/1$C'CS%4N"H,>(*UL,?
M5NQ'K^*[LE=9I#:CPJ'":/W'I N,,LS,S88H@7M %'W27YA9NSF9_7"["63W
MR_V=$KOUJT5,:M-CJM6LTYY S9$B\,BE4[AR][%H_;=(4G,7Q6@?=/.5[_\8
MTU\^1![N@:4M%AGPMY7\:4_4LD:+\;VRJMEBSZGM]EPD#>BR%\WR9K=7:[FX
M54B+4I"3,\D&X</8(_8&ZP5*<#GXX]?T=6I<(R21[BTI&?=K]%VYLE@ZQ3Z!
M2\K!K*#\$B,'S5F.OT%^#>[251;KI)[A^]"1<:T82SH2V:XQ-)U2 +YP@EK]
MPU:(YZ6,;IHVAFFL&$CZ.48#>1>VUB'U,O4?D*;NQHNS;Z"?8T]G3/'Z&97J
MLAT<K]:SL:NY]75N9+'!/HT>??12\OP2W1RS;B_']GB?HZ6C[8C'A;:-9"9T
MCN>JQ?;HO<N[/Z[8I16;<;GVCV"9K.ZZ!\;Y$[3.U:F=(N(2V-V4S9@&W\G*
M;3P55#?%H"6OR3A05KHX5=@+L>B5H'_N"/^];Q'^FX[P/_P6X?_3-$V-.MVN
M-IXNTT;UH;91_90NJI$*$G 73"PG2/<5"HWQEEPI^+:ZR>KF!C OXB83 M<E
MU>"^07N]6?[>64NWT)/ :WV64)X(:I0@A9;V!E]%Q;8NBECD48IJ'LG^N>W9
M0*5//'COV&VW?=R]]BH>><,F[73S**,TE=PT;6P8II1VIX?*$4+.DZ>$E*4/
M(?U0BOE]A44VQP^A%@=/GI4,>U>4C-\LB+QH1OVSK+ X1Y] $TC(ST6C15$N
M@$_&C+,UFRT*! X(R78M^O<;+S^_>/OFV,M(N)1.*AAUC%=+6?V$\?[&???T
M@+I!KAE,N_'V]!".BLTZVW^E3L)=I:8E3"@NW;1["?-'.:JXE,TP_H#T@/7V
MN&=;S89I^YI5W89[>PG7H8ZBE\&]T+QB@^&6D_-6=A@>+^DP_'#[\=(&P_$Y
MCEH, _]4;NK3D+\.M][5@G?:,Y=(%*"+4)T[#L33>!<+9Q85_!<%T"92]L6B
M#RXO9'W347R:RD5 :IY1*XT<EBU0+WO<<VNL4?20PDWFUB5Z<45E7&3L:7-8
MCBO[PJXX*-A6;+HKT"(-78+Y.]5=>,S_MER5@'S-5\>\RC4,G1&(2+O0*@!@
MA*I6I>H,X?JH%(EA4AGU1+OJTDASO+7P&D.!69U014\JY6072FTN9H=_X_><
M;2MKZH;B("P)N"IW$TRTU[;"?!U+SKDO'PH--),E?DF"=3QW4Y;IV%1XV<L1
M*:TF:N7#@ZUL(")BL+Y#\)*D]=6,B[$J(:WU2O!-Q2R-C:M\TS>+:(98AUDN
M]=\%D'_/=Y0=ALL%#?C.M_!I0;WANSF;3/)Q=I8WW4A:I@ ZK&T(I&5-1ZBE
MS<C]W[,S;41,#R5VG7FL-R@RJ4<PUXFRH/R2JX1/Z4(_TX<^-4"_"@OFLM8-
M'DR$\HH!35"]I?Z'37]/Y):LG.>N;9](YT$&W;*5+=H]:WT92NIE?T>$)9\F
MP38WMCB;%D%3"7^K9>)U:_E4]E(*PWPN+:'R2:CE'1A8Y4OB"K$/-R*B 8P)
MZ8E+P&?*5LPWE.W+U5%;""PTU$)3C@@IEW>'!5L:=\Y.N1*>@0%1_<>,-.J[
MQX  ; .M:'YU"<2>WD7XS,EU,$8](#X=@SV"YUE-;S+2EX,&]</TR&2NMECG
M_(:M7JJ!+**,E_[EXL0_8;W$7QV@GC5@1)C V4XXB.&%XN:LE-=U8?MCQLT"
M@-=0RJ  4G4N1H;/!KU+W=RX6@)FVI\42&DIW@RDS,MN;+$7/JE%I3:SK(1/
M6D:Z3T50"E,MJR!9)-XJCB$$R).X<_II^$I1,N=-8BH]>!C[@J\_Z\+8*FUN
MA7,:4A.7XR@8@JK]ZQ,7.T?71^U"2=12Z=*Z[KE603<Q_K QOP4. )G! P*L
M_6K'BTK5R50#PN7CZ&#CC%)RR5)3G C2]*I>V6M,P_SL3'8UA?:A]0&$1LL=
M+X Q=K0Y<+2)O54\=L1614^%;3,O[\EL&VT,@!P;ZHH?"])"JP0Z3&@%,>JW
MH&F!Z>T8.0$7Q,X,!.E2A!7VWVJ- 0,W8X_0R402*_HR$+=B  ,J)F_A_-2L
M]_B3V&<'\T0ENHK9-EAZSE,@MP#-8<"X59CGPRG]^">%_?".:1$1G+AC5T1"
MF8YV)C8NIBA(XF5=3N53V"^N9HB&F1NC>&_.G8O&%B$M3;TOOHRZ%WI7#RES
M>S9'1.UY=D$>:6PS55 ;B".$"48=#X.GE!+HG);K-]E'5)*U80*UC9Z@\VBK
MW> !H0H:A)8@9(!ZP)T=HLIX"P'< SL7"O@1C+>W@G]5LV7&]J#D,@9:P=UO
M>=L[K)VJ=J4(S'#VJ<<4>0TTV6B:G:?L?4?P@S%G%M3!@8'N(&RE0\W),(%$
M8,NI.6C2D0WV:"D<R7-I97Y G;;K+H&QD4],X43N#JK&D"*@P AO2G&.=4:F
MF*$TG"!KKA=61X3;/[2UNAX/G]9AUZ*>3^T33N> :2")_X1%S8P )YK!RA"S
M4S!A46_OK4^^1N?(F@2(^]\2(&XZ >+1MP2(F])^'@7@I54:C_?6;&ZLAU[J
MRI%>>*7H.0NPE%P"7ZFO0= ?!5CJQ+P)7/-&$99ND#,>=[&4F$-VZZBL, X!
M&3"EB)Q?"DXI68&FA,"8UPFGY,&!VFA*E*/R1>"4>G-=EF LF1B[@JFO)/.L
M7$[E^'-_C,R8//EYZ-Q&K3I=W^<OC5)XD&XM?_L?Q9-*K@XGY1/A/P%/:BT$
M](K8WI>T^;]$+.=2\@R%V2-"7WD->T2N.E<NZB\,O-(WBQN2Y(\8BN4($Y]!
M_4)4<BE$GK 3P0CSY87>.2;V+-BQ?9:74]'ZX4"#B4 HQ5*/&8K8R;IJ0M-L
M[Z7PLH!Z*1'6LX1I0"Y8:RW"< U@KV$DL47H<_W?5_G('H2Q28Q:DCX7.1P6
M148.!C%]EOD?;DW&S",N=_\%11T%O%YEYQZOLV[Y@0SW^!T_H3=-$E]V[J^U
MHT9ZY%)N6O<.)GVP+":PO\2O].Z\0N? ?.JD_5/^UTX(N]IFW&>,);A0X:9@
M">]W8W/C5 .X:T$<*O8H ''/7)$[N;DI4YA_H-S/*)D"M6M5 U/)N] RJSR:
M$8;(TY43N$4[1MD3OV&#3H'4!@.8^G56E$D@7E*1;NOVS9\JED)HD4@O@IRB
MXKZ16$4=R#*?2(VYU0:UDE2+DRHC-R0+8I[3+=J8AY+60M53(I#VZQK97_#^
M](^@SV%3 VPL@QC<F@+(SW;ZXS(L/]X4VD+B<IO[%9&>74FD /[/H;V&T4DC
MZ.N4$@8D19]4,@0=[</_?B$U46=S)1_A@R?)VSEEAOT$5QZ81=\<A3?B*'S\
MJ8["/[_;KC/8]\_>/O_]*?[CY?'K5T__/U!+ P04    "  28,1<59 Q=6DB
M   .V   "@   &5X,3 M,BYH=&WM/6MSVT:2WUG%_S#G2E)B%23K83M92^LJ
M6J(3[<F23Y*3VKJZ#R P)"<& 08/R;Q??_V:P8 $:3EG)Y+,K4U"D<!,3T]/
MOZ?[Z)?KMV>ONIVC7P;]$_BOPO\=79]>GPU>'3WE_\*O3^7GH]<7)_]65]?_
M/AO\\\DH2\N7:F]W5JIK,]6%.M>WZC*;AFG 7P3J2N=F] 1>A%??V?=*_;'<
M#A,S3E^J2*>ES@_57<<Z5-,P'YMTN\QF+Q4\[KX89F693>F[)Z]^2(?%[/#H
MZ;N%J>\^C0]D;L:3\HXS'[U^-?@X,4-3PC0[^T=/7[]:!48Q#9-D.PIGQ6<L
MG*:I_VD"RM@$(-Y<G%_[DVV/PJE)YB\_-0<]6YC_U8PD6H[%)2X$QWWHZ[D:
M'+^_')QT.^\N+]Z>7EU=7/Y;G5]<#U1_>^\.J[RW2[/[U(3^NO_Z;*".!V=G
M[_HG)Z?G/__SR>X3^OOJ7?_8_OWZXO)D<$D?!91;$Y<3''KW^SM1_MV/,+*#
MH^M+.]&-SDL3A8E%#$SRA!C1T?5)&\?XO2I*,YH?*H'P^>[W7Q*+@]%(1Z6Y
MT>HD+/5+!.1?5:K5T>6K_>#HZ>4KM;^[_\)A^?ID':S".+X.I.K]SM6.^FX_
M^'%_-]C=W=W9W?7!@G]=$NLF"B!B^&K$+'OR]:GYJX(O7YHTUCCX[LYSDW[)
M);VYN.QV?NV?O1^HR\'QX/37P4F@EH>_"7,3-OGIDU>GTRK-8(K3--H1I 0J
M5"<Z"6_#7*LHRV=9'I8F2]76#TG\1Y4= J][G>5Y=JMSY&L_Y/1M+U"S/)N:
M0A?=3IFI63B',W=7.*[*7&M@7#<F2;0Z#F>F#)- G9T=>U"]+\.)2LS4E#J&
M_X9#DYAR#C!.9V$Z#U26*U,6JJBB2!=%E@,@\%58%+ ;A0_^F8:]6 "^0? J
M3&/X9ZX,<E-=E($::=R#: +;CA_P@01.,GVOPBC**P!J @]7.+8"?)43K6)X
M!- Q"4ME"J7QW&H-J-S[J:>F@(T)O#N"*>CA=U4.XQ?P(3<1,PJUA3_4D+\-
MRRK'1>./_@( 4H0BR^,PA7=O33FA,6'L*:!$E]W.*,OA2P01GP7X99?L&BW,
M%U59E/"[2<?J=9C0>  __I0C2-F(%Z)F.D=QH[9^^KZ'?\"@:355(R"#5>OI
M=JJT- G]7(13C5B9A29&\$=5DNRH?I+4$ '_CJJ$R*_PD%M,@'+44-/65T@-
M OHP+&!  #!4!R]VMV-8W5R'.3V7 VG&^%MYJY,;@&1K;[\';YD<T+EUL-M3
M^#AO2B!3X'L9S D_P=$DI+FY 77A$(AU+>)QN@F =)Z5>D==X\<K'54Y0/*.
M3@N0Z;S;P9]13\#MAD?J_<8?FMM<P/\+I#4$9AK&6FDG6D*:L$6N+))14QKY
M$^QT.]<68&^R6947%9Q:I!FBY@C$:PA+I]68TL A<-O='\-AGB)E(/G';0 %
M"*LC@BD@'C *'V%[8R(@.#3 ]6@Z^&^@AHS]H8;=@P-D&1!]R<=Y<8W+X#36
MJ8YE!1$S&V"HL6Q:5<A1-FFW@UPPUB.3:B+2H_>O^F491A-:'RAV[U_!X< O
MY!V &&$RJ66=;BQ< VUOKD?P!5#+SJ.20X]0M.)1D-,9A7F.5!ZF(&<,P!<F
M?#A4;(H(F$2)9^^[_5TG0Q;H\>+TI$F I\ XXM@@<PL\@D9J+2QO_LZ))!*J
M0NGP*<I P96_?\@+'+)0B1ZCU$1VA&P6^#>28DPP MZ0Y)3^.-,I"&FDT"K/
MF:JC+$V1(0 ;=0QL9L\/<;TPT9:9"4(6EG>=AVD1\A@#GD/UIPA'<]77*&%.
M3U@ P>?5[RD\>@!E4L4,)3YN4D 8H![8>1J969AT.T.143ZO90%.1Q>./HDZ
M8# H8>8*!$(J_!-TGVTXC<#AB96'PK!;11>#[K RHQ] IOHX<<(!M(GG*RFA
M.7A3#7$2#6 994F2W18O%W031WX.!TI0$'0["6@^+,7OA.,-![KG2]K;09'S
M+IRCO#GL=M[E>L9_H.C9;-^77=+>E]Z\QO;1CG4[J.'*'@*_N44VW:+: K\#
M&PPX%JJD>FX9T_N4K)^K$C@2<:O^%":/0N;T.@&=+F=^)[)"-'>0-#FR!N!7
MPS#] 'H-"PG@B7EJ"M1>0#VIY8N31\SA8!3@?+.LT*RA._@=O.%LEAA4WDQ>
MD)JX%?86Y5.NPR)+B=5&65&B?3:"3V#R12P%S4B1)0<0IS3&L"<&%JS.V5Y+
M3T4]9X'A@U4J)H6UW80/PO1H:P7T3MRK^>??>HR^,,T]PD.TSX>HR?FZ'4>B
M:#Z@LH24B 8_V.V@>9.TDU/39M*"&@ $2\2=*D/V.6A*H):-:N+7'\'$-:0M
M :V3VXTT,P+%$_R>_L8'8AI^T/:0>(<1+5/0^EB](=NCF"C]1P4B'![:V]O]
M7DVKI#1\E,A>T'=9BYV]V]%XEHH:R!TU@'7./88S4J(C("2)IT4$]5&K70+>
M9+<&GDXS.$]52D.0JLJZE6,=L*A;M ?3,2@C.? C?5.#AY/;SQY3F((9AA-D
M0R"K16-_1[W)V#T2WF0FMII>G%5#.MG>TL@:]BW5*^8KL$D'.WM(&@<[^S0R
M#,#[!,MA/T):F)@XY\R166$WP(*\81/W6GU@-B$.B?D"DW#DYA,9BUS/: "#
MH1#WC.S]2?^X[_3H8Q!5('=S.*[.J5" H"M\#T'#?'"/];X!50T6]1_;V^J-
MT4G\4KT+Q_H0!OBC0KL37E3;VQ()/CHY_=6"\:D8T O\;ICEL%/NN]=)&'U0
M>[#Z(DM,# N[6SA*II314/$(9P6 9C^YD J'IY:C?&O#2\V-2/2(WG !'&_H
M&G\VH&+#*4=/ 34M6!J"[O)A>ZA!&P-H9H1:'W,O5L:-WS41O13(;LSH;=]3
MW#_>LJ]&K(*C#5-;O:0#8FJ7.M;3&3&MC=EW[V7K@9A];S&6D,R[G<7M4Z\U
M ,HZ#PN,PGQ46R\D)H1Q%+3CBC"?KW%(!5;G8E5F$H*F14$:5%,#J[NR8ZM$
M34E\ZB;E,%F6B)ML"!^KDAV9N69+#+0GD((@NU0U8Z>_5F_#CV9:396L2]7+
MLAZ[K:**)J+?DGWF>;WJI\$$7G(,4OP(^"FL*,P%#2""9WEV8UC[!*%>@KT'
M&ALBP#=1MW0833! V#892O8%+QM[\F0UW<[JY9#&B[;M&,3XF%SYY![-Z_U4
M136<(F2^_<QZ!9DC:':J/JD7:S4%P$FM*JQ5>64.-'IX[@8NLE2KK;T>*KM3
MD!5J"1$%!:Q ;1X#B:4+* >%Z?T,'LUUI,VLY$C:TA!+U@X;0^(#B(CBEI%9
M6T&(0US^+9CA^SWT3M(.GX3S8M%5NDPTZJ1JB5HUK+91:!+G0<?QEH%!<RI7
M+$]7/&+G"1:M+E JQ>SBU8<5B-N0M &)$>("P7)"WPKMO[A>*8:%]@I&',G%
M$Z%'A,.7(6[=-AU0CF+2T]96=#9B>0L4,K>AUVYG:W_W^YYE$BT'<A4ZU1M
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M6YBJ.DQJ;!T-G_:1#9MR[5\+23*.LMB9@*C'#;GS<G]_U]JJ>$=UNPH0>(L
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M1C/Y*Z-W@,(6PSR2?@(_5(;=H :5%=.D\ V'/NJWOD+-<905NN1,S#'S!8S
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MRIV6I]"4;FM5[9>]?.8R]%\"J[V*0:]G7HO/I[PX#1JN/D$W^&10-_D=1I0
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M9FH :!JP5!^E&[!@N1 =L*Y6=LK[^B#3OZ8JW@S0BCPOB[>W4&_E+F^I"A&
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MRL5,#M$?S'E9I4>\"BK9("!$**,L,;"5]KS$G/DF[.]W5A<+)?I^BMC7WK]
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M5RV!2(<Y)%&S#<9TY":!>2I>B!SBX+<7+RDXA<7CJ%4P'GN*AV:!-+G,5UE
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MQLB4XO&BZ4B%>AOF6[#(XB60H[;%L72%G6)+N:UB!K\'YIN6H/Z9"I_"NM
MO0D,B/@K6N3L,=\M:@<NX!\$8!O->;.L@*4:8S^YG3DL?][OQ4:690YMSGM+
M0JRIO/NHEIC$HG-_;X5D25:Q_%G)MW\[:JRS@GRDM]ZB-S^KLG1.)0,)J!\&
MV =6JR.=\G2??4+'A-*B==*AAF&'V73$#;\M($.Q>\O=QG=.:A/:4A70ZA[#
M,DR_/5:[C-:5KPF6XC&;U*WSE3H*;>D9N0GA81,UTQ4/<NA:W;F)L;W?Z[MH
MAN71<'%!,=)C@>7&7/-[6!7A4W,S[+UKY<N0#BCHLVFL1IF!!]-^Q768F )K
MIC\\OE];?CQ+I0!P"UKT0Z[B*)L9^V]'D!V3&&PR'EQ$%%,6(IQ@U+EU[AOO
M:^?@Q8[/M5 /7L)?]V*O)7_1K:ZA!=Z>750LF=-0=0#8)VUSZXK<6R[<1$@@
MVCOVW!BL-IRG2Z /1N\_?6&59;)'LKLB2_@NQ=C,HK@"QGK%IG!#@!VF<0;G
MG+(-6BHG\T4YL'>(N\X)USGAOLX)=[4I3KC^O3*+CPN4M^5))W=6GBYK9;@N
M+$Z*;%H?4<*$\\\MG?HZ3^D'S3VZ'7SR:P<^>4CPR:\=^*0#GW3@DT+N339%
M[ITJ.-&!C21I)W58Z@7%4^Q>% G;QLD,_E3F E-O*T1<OW1N0$XFD:2";CK6
MH]7N>RO=+MJJ5#8;OLS 8.-/+BC?7\R7]*>K:W33-_0GQ3I@JYK+S*>65KPW
MB71("RQX^KNH168>77QV&8YK?M ?W+P!FJOKOEWE[2U;3(H%?2T[O0K$K9DW
M_$..@"!TY;C.5280R@,6#-BX49R0S\?%SI]JVG(^@@@?Z(LI,%R7C#!/F2IN
M2<H^:$HX[RR.SN+X.LZK-H7S7LAXBGT46QKSIW!P*J"_';'+7W/E+_%%<NN
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M'7VPO_UX^*<F"EYW0H\\@3<,#D][,!_GI_#&X]YI_[_TR^$)O%3_-KP\/!O
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MJ<H8.MH1R$$1RK%HF-_K>-P2'N\17ZH8XY+"\EI#F7%DM1.E7(]YJ\G-E2S
MQ*C*Q!2QOJ 82[3D\'PY=!/$"8$1#D'Z *U3VD!X9F*R5)5VT.U\+#)]3D&5
M_ 2CF2*X)SG%H\ 8Z=U!L8(V(:NG5J=(#0@!THB0J=$5D8I[0"ALS@M)%9/
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MK\M<\@L\<FZ8PF<?-]T$1Q>(#TY;D&Q&E>NX/3H7='M>2/N;)+OF]'HFYV]
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M,-DP&;#E#$F+6<X-CAJ^Q+$EFYG/I&U:B!<F!_#PF&W :'H.#&AO8'G49LZ
M6R/"J6?R]DA\J3YP6M %$41$RQ!?1/*+!E"/JU%[Y+]K.Q8TCM]AEH6)ZP&<
MK'#&R =F,Q<LRKH-WPYDZFDU6\A*<E>WYS,,RPCDTQT4140N6RB;]NSV6?V1
M)9Y(4VCHY)2A\]TU/1!R7)0:V"H&SI.M'?:K?6&U-TZ,_JS\V*>ER+8<QV+4
M%ANTQ^R@6%Y28M>0R5L;I=+.5%MH9O[/'*!,=4G0I\?Z1?HJ81VQ"G?BD5*A
M+%%'P$TD41WSTU?R&Z1VV""%8BX+!5>?QZ%_#3-C$3SG^6OPOV:8)UV[IF.9
M.LP$NW,,=@ 8 ]:4Z'>W6')JM/7MM8)=+#%NLE>+C71A?P2)/=6I29C+EV@F
M7X@@76P?3H!SI5Q6EEQ"W1+JWN8P3T+=F<O0^L&%-;'G$YT9][3=GA;/TK]^
M<_L;GW*-GZ_6PHNE:4[OWV*#'_0KHT<Z]B![+U\R,H65UNK#H%"678+A$@S?
MYC"'8%A+!L,ZYP/FW@N)9>=LT_IX?&M=S"I79^:0N'X')$[T\F\$QB++E%;T
MAP&C*IL,C,M5Q6>D/8Q8:#*.REQFQ$8WV)<OU)Z*J\*(+F9_WW#0U$_=?IE<
MGO699BB=XT&N?OH'HWJ7Z!;E?%[I$V\[SZHPVUZ=N]3P(P9\U&LYU@I?78[,
MDV;-YDQ[A><*Q"8-\S4PX/=-UX0G(<C/S5J=AD.SR&\*#<Z"'VB4"FR4+[0$
M:$S9 ]G0M[J?;\_-;Z67S2&))3:/TYZJH%6IMD=PS]&OTJ1/77)-K0$C_\YE
M<WG2Q\-4NXE[O%]_:MGS),&%0K*OA$1!5E.@5;*$U&Z;]?TF+?\^?6$)B:5R
MQPA/5?#4\.6XWS_NM3%P\#V1Z6?''.V//MA>N_G]O/"2'J@X%0)1.^E B,)6
M$GA$^X8J@!OT]Q09B:3@SR3E@_9-CUKDF+I7S%OZ<B^>@U.W#730F=8:$1WS
M<9".*]#\3&S9'DN6,3F!=L'#1U([I.,Z-UX7_?P^)M!03@S6-FUY4(]<Z\Z5
M??]O;*%;'L16)"O(OHT=N>"=*VNBM"G.^.GC&3^8SB6C!856II!06=+Q;F&M
M&#H(/XS4FUW0 5MH:3M0DJ.-2<[=A_;X7WT0']7D-\F87-TJ.;0Q<HH_.G.(
MZ!43=FDD$G=_,&\AAV^A9:_>UJ9C%^8C2R D<2 T)Q(&NP!SS&*Z!S!G.R+>
M->!,E((.J+1$O+?'%#$P><P_"IAHRQJA^-^8T#0*O@WDPQN779L<O@/PI+:.
MR^E4%S?A(*5X:9)!78/+A$1C6K"MN$*#8%L4%+,D$,:%'+B_ZA3Y2+@@\13Y
MR"GS44:]O5/D%T)\4G.K,,)YY/D.?/5[@*LK4+D8 &&73XK2U#L'QN1R74A,
M&,:.AJW'P]KQ%B;CT6-QZTF_)@P1W7NPE<7:XHOQ%%XY=_RQ]/T%WUE0-V%,
M\,1E]"K38@"^0$Q?\#$Z8=\N$Z(3=PYS=L;;-_P>C6_#>-3(/+9+$<R.X_,C
M!BK0=EI2TOE&V;03!W:6O*M[K)>X=^X)BB"?Q5N+(EO/4,3"CLU9SP/I!W@N
M)>[N<"9.O*'$SY\D^^ADFF)+;[7C,K'@G)W8U!N;&TM[YP[BU4.P@!E6GLO^
MR6:)A Z=VIHX^+J05IV:84 )G;BTILY%)G@N,EE! QAW'A: B[B!M:*\,G#&
MA%R+=_F=52)L#1&M #N:$AX&%<# !@,:S'KJ"UA"M9$@Q)DJKP4".=&8L/F;
M'KR&1L5Q&D1%P]+DZ*B64'_=OF;<<]SQJM+*$4#G /T*_-#DZ!#H0+!M:)Q:
MPH_!%S7?P8$7XD'0-57 ;R6-OL.*N4H*Y1Q15P9.TG0F+H)#IC75[5=CW50.
MB&HVV "*XX>1'Q*IX)[5BD2.)]<RR2'JP8#VP>46YTG_.Y]+@_^N!76G!>-H
M!T:K@TX?,%1G#%PL+%Q(EW.B_ [P QA"9;@)&CMS'3PBS@&0.G'@LVHFCZ$N
MD&7'-6&V81YT</  [:$'IVK<*(@:19^T6)^P#JQLO \[8L2 @#LIV'M0^V5L
M.V@_SM,]+:%U*2U.1T8!A>B*' Y%:YI,5(./)Z0A*^YB$-XPU646D(C"@!],
MT7]6(AC)*/$G4HCL9 5-+'1RKYDU2FCY/*Q^0AIURT&_&MQC@4#%-$' 2(((
M*(CS"<_IG^C%TG%^'8JDZFFZ'*=T%&2(RW0&TF'X\UQ(>AMFRAC 1>8!S JY
MNGTCHM9]J-4+-4&+VE=^"(8X-[8450J?@"B.,N*)Q@<M#B!,W=$8Z&$@7*>\
M*WT#3^P9]7%:3),D^</RM;!\53:>/*'"#:U<"W/G9-4(G%R!!=",1'K4]L!N
MLH PR_)II9PSCX]1GE8GM7I=*D_:QXVV8O(-!+0X *#>2'TK50JVUQE0#(T!
M@(IE!"A#37N*)B !VV"ZR^[X;).[>KF(J'FF!0,O*I DQ<<NP.M@E)5@J%:U
M""@ G98#;X*@6_"Q8#9(C\6HB+[Y=4T9#*DT.FH7L'_PJ]"H(#\HN.&A!J :
M&04HTY!'!@/H<OH"S9"F:X%U:1 2N1K&AGWHN.D-4.?B!S>.>X6UJ )Q-@F3
M1&Q][E.)GX"F,NT2WL'?/) V%4^T.QHE;294X48V]\X?FH[K<!ZR(YA&<=,!
M-0R@MJWBC($RB+!XB9"O!"'K;;F?/C!LG($GXL<H32UJ"1/13\A4RIPH80D_
MDF=T8+GHY^.F'ZX&PF\#74H,&#F!D0%@JYEM<'=!O 26A"\E<N/)GBZ&U7N
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M +O)-@5M34 D6(T!-!RTQ3.E7HB8B9&)XW1.8[+[A>S!=ADZMTP -MM0:**
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MAI[]%T6 XM#XH+Y1"(RA)$Q7[1-?]V:#?3=M_HW]9=^_:K;\#U!+ 0(4 Q0
M   ( !)@Q%RN!?R_(V0  -'S 0 *              "  0    !E>#$P+3$N
M:'1M4$L! A0#%     @ $F#$7%60,75I(@  #M@   H              ( !
M2V0  &5X,3 M,BYH=&U02P$"% ,4    "  28,1<SS:UWM8?  !MR0  "@
M            @ '<A@  97@Q,"TS+FAT;5!+ 0(4 Q0    ( !)@Q%S12P(I
MTC   %V8 0 )              "  =JF  !E>#,M,2YH=&U02P$"% ,4
M"  28,1<*U>^/[<6  "Y9P  "@              @ '3UP  97@Y.2TQ+FAT
M;5!+ 0(4 Q0    ( !)@Q%Q#$2,'N1\  +GY   +              "  ;+N
M  !F;W)M."UK+FAT;5!+ 0(4 Q0    ( !)@Q%R]IS7')P,  -P+   1
M          "  90. 0!I;6YN+3(P,C8P-C Q+GAS9%!+ 0(4 Q0    ( !)@
MQ%QATG?\_0H  '^&   5              "  >H1 0!I;6YN+3(P,C8P-C Q
M7VQA8BYX;6Q02P$"% ,4    "  28,1<B+4]"5@'  #05P  %0
M    @ $:'0$ :6UN;BTR,#(V,#8P,5]P<F4N>&UL4$L%!@     )  D %0(
' *4D 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imnn-20260601.xsd" xlink:type="simple"/>
    <context id="AsOf2026-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000749647</identifier>
        </entity>
        <period>
            <startDate>2026-06-01</startDate>
            <endDate>2026-06-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-06-01" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AsOf2026-06-01" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-06-01" id="Fact000005">0000749647</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-06-01" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-06-01" id="Fact000011">2026-06-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-06-01" id="Fact000012">Imunon, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-06-01" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-06-01" id="Fact000014">001-15911</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-06-01" id="Fact000015">52-1256615</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-06-01" id="Fact000016">997     Lenox Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-06-01" id="Fact000017">Suite     100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-06-01" id="Fact000018">Lawrenceville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-06-01" id="Fact000019">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-06-01" id="Fact000020">08648-2311</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-06-01" id="Fact000021">(609)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-06-01" id="Fact000022">896-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-06-01" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-06-01" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-06-01" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-06-01" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-06-01" id="Fact000027">Common     stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-06-01" id="Fact000028">IMNN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-06-01" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-06-01" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
